

CITATION REPORT

List of articles citing

A prediction rule to identify low-risk patients with community-acquired pneumonia

DOI: 10.1056/nejm199701233360402

New England Journal of Medicine, 1997, 336, 243-50.

Source: <https://exaly.com/paper-pdf/28257877/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2266	Community-Acquired Pneumonia. 169-174		
2265	Prognosis and decisions in pneumonia. <i>New England Journal of Medicine</i> , 1997 , 336, 288-9	59.2	21
2264	A prediction rule for community-acquired pneumonia. <i>New England Journal of Medicine</i> , 1997 , 336, 1913-4; author reply 1914-5	59.2	4
2263	Treatment of acute biliary pancreatitis. <i>New England Journal of Medicine</i> , 1997 , 336, 286-7	59.2	41
2262	Quality of Care, Process, and Outcomes in Elderly Patients With Pneumonia. 1997 , 278, 2080		471
2261	Grepafloxacin--focus on respiratory infections. 1997 , 40 Suppl A, 1-4		37
2260	Prospective evaluation of clinical criteria to select older persons with acute medical illness for care in a hypothetical home hospital. 1997 , 45, 1066-73		28
2259	The 67gallium-transferrin pulmonary leak index in pneumonia and associated adult respiratory distress syndrome. 1997 , 93, 463-70		3
2258	The potential for clinical guidelines to impact appropriate antimicrobial agent use. 1997 , 11, 803-12		19
2257	LOWER RESPIRATORY TRACT INFECTIONS IN ELDERLY PATIENTS WITH ASTHMA. 1997 , 17, 671-700		78
2256	Does This Patient Have Community-Acquired Pneumonia?. 1997 , 278, 1440		209
2255	Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia. 1997 , 19, 975-88		23
2254	Community-acquired pneumonia. Tailoring management of adult patients according to risk category. 1997 , 102, 45-7, 52, 55-62		5
2253	Community-acquired pneumonia due to <i>Escherichia coli</i> . 1998 , 4, 717-723		19
2252	Commentary to 'Community-acquired pneumonia due to <i>Escherichia coli</i> ' by Marrie TJ et al. 1998 , 4, 724-725		1
2251	Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection. 1998 , 4 Suppl 1, S25-S31		2
2250	Severe sepsis in the emergency department and its association with a complicated clinical course. 1998 , 5, 1169-76		16

2249	Strategies to rationalize sepsis management--a review of 4 years' experience in Dundee. 1998 , 37 Suppl 1, 10-7	6
2248	Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. 1998 , 31, 376-80	60
2247	Older persons' preferences for site of treatment in acute illness. 1998 , 13, 522-7	31
2246	Economic effects of community versus hospital-based faculty pneumonia care. 1998 , 13, 774-7	53
2245	The hospitalist movement and the future of academic general internal medicine. 1998 , 13, 783-5	18
2244	Assessment criteria in identifying the sick sepsis patient. 1998 , 37 Suppl 1, 24-9	50
2243	Prise en charge des pneumonies aiguës communautaires en médecine générale. Etude prospective menée avec un réseau de 95 médecins généralistes du Puy-de-Dôme. 1998 , 28, 638-646	
2242	Pneumopathies communautaires non tuberculeuses en pratique de ville: quand hospitaliser, quels examens complémentaires, quel traitement?. 1998 , 28, 599-603	
2241	Community-acquired pneumonia. 1998 , 352, 1295-302	126
2240	The cost of treating community-acquired pneumonia. 1998 , 20, 820-37	421
2239	[Toward a reflective and methodologic approach to community-acquired pneumonia]. 1998 , 5 Suppl 1, 3s-4s	
2238	[Severe community-acquired pneumonia in immunocompetent children]. 1998 , 5 Suppl 1, 49s-56s	
2237	Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. 1998 , 92, 1032-9	69
2236	Time course of symptom resolution in patients with community-acquired pneumonia. 1998 , 92, 1137-42	32
2235	Community-acquired pneumonia. 1998 , 44, 613-75	17
2234	Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. 1998 , 12, 741-59, x	27
2233	Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods. 1998 , 12, 613-30, viii	24
2232	Outpatient parenteral antibiotic therapy in the management of community-acquired lower respiratory infections. 1998 , 12, 921-33, vii	6

2231	Patient selection in outpatient parenteral antimicrobial therapy. 1998 , 12, 835-47, v-vi	18
2230	Model to evaluate the cost-effectiveness of different antibiotics in the management of community-acquired pneumonia in Germany. 1998 , 1, 247-261	3
2229	Practical considerations and guidelines for the management of community-acquired pneumonia. 1998 , 55, 31-45	45
2228	Value of noninvasive studies in community-acquired pneumonia. 1998 , 12, 689-99, ix	14
2227	Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. 1998 , 10, 35-46	10
2226	Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. 1998 , 158, 1350-6	148
2225	Severe community-acquired pneumonia. Assessment of severity criteria. 1998 , 158, 1102-8	792
2224	Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. 1998 , 279, 1452-7	318
2223	Comparative clinical study of cefonicid, chloramphenicol, and penicillin in community-acquired pneumonia. 1998 , 2, 343-8	2
2222	Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. 1998 , 114, 1588-93	150
2221	Cryptococcal pneumonia complicating pregnancy. 1998 , 77, 153-67	60
2220	The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy. 1998 , 113, 142-6	47
2219	Outpatient management of community-acquired pneumonia. 1998 , 33, 123-33	7
2218	Validation and application of the pneumonia prognosis index to nursing home residents with pneumonia. 1998 , 46, 1538-44	70
2217	Use of guidelines in treating community-acquired pneumonia. 1998 , 113, 1689-94	49
2216	Geriatric respiratory medicine. 1998 , 114, 1704-33	129
2215	Future Directions: Alternative Approaches to Traditional Hospital Care—Home Hospital. 1998 , 14, 851-862	3
2214	Breathing Easier in the Intensive Care Unit. 1999 , 11, 409-422	

2213	Treatment of community-acquired pneumonia--IDSA guidelines. Infectious Diseases Society of America. 1999 , 115, 9S-13S	66
2212	Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. 1999 , 116, 157-65	49
2211	Guidelines in pulmonary medicine: a 25-year profile. 1999 , 116, 1046-62	15
2210	Pneumonia acquired in the community through drug-resistant <i>Streptococcus pneumoniae</i> . 1999 , 159, 1835-42	147
2209	Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. 1999 , 159, 2449-54	158
2208	The Cost of Treating Patients with Community-Acquired Pneumonia. 1999 , 20, 189-197	73
2207	Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. 1999 , 159, 970-80	206
2206	Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. 1999 , 159, 2562-72	332
2205	Responding to patient requests for physician-assisted suicide. 1999 , 281, 227; author reply 228-9	5
2204	Providing better care for patients who may have pneumonia. 1999 , 54, 925-8	5
2203	Methodologic standards for the development of clinical decision rules in emergency medicine. 1999 , 33, 437-47	422
2202	Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia. 1999 , 39, 171-8	10
2201	Hospitalized low-risk community-acquired pneumonia: outcome and potential for cost-savings. 1999 , 4, 307-9	6
2200	Validation of the pneumonia severity index. Importance of study-specific recalibration. 1999 , 14, 333-40	35
2199	Change in physician knowledge and attitudes after implementation of a pneumonia practice guideline. 1999 , 14, 688-94	37
2198	Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. 1999 , 14, 555-8	205
2197	New concepts in antimicrobial therapy for emergency department infections. 1999 , 34, 503-16	8
2196	Treatment options for resistant pneumococcal infections. 1999 , 5 Suppl 4, S3-S11	5

2195	Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. 1999 , 6, 1243-8	81
2194	Influence of socioeconomic status on features and outcome of community-acquired pneumonia. 1999 , 18, 704-8	18
2193	Community-Acquired Pneumonia: An Overview. 1999 , 1, 49-56	1
2192	Treatment of Community-Acquired Pneumonia Requiring Admission to a Hospital Ward. 1999 , 1, 455-457	2
2191	Announcement. 1999 , 14, 558-558	
2190	Physicians and Managed Care: Challenges in the New Environment. 1999 , 14, 340-340	78
2189	Effectively treating common infections in residents of long-term care facilities. 1999 , 19, 1026-35	2
2188	Management of Community-Acquired Pneumonia. 1999 , 6, 225-239	4
2187	Treatment of Pneumonias in a Managed-Care Organisation. 1999 , 6, 159-173	4
2186	Management of Community-Acquired Pneumonia. 1999 , 5, 41-54	5
2185	A Critical Pathway for the Treatment of Community-Acquired Pneumonia. 1999 , 58, 273-275	3
2184	Infections respiratoires basses de l'adulte: pneumonie communautaire et bronchite aiguë. 1999 , 29, 237-257	9
2183	Treatment cost of acute exacerbations of chronic bronchitis. 1999 , 21, 576-91	123
2182	Nonresolving or slowly resolving pneumonia. 1999 , 20, 623-51	54
2181	Strategies for early discharge of the hospitalized patient with community-acquired pneumonia. 1999 , 20, 599-605	23
2180	Use of prognostic scoring and outcome assessment tools in the admission decision for community-acquired pneumonia. 1999 , 20, 521-9, viii	17
2179	Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. 1999 , 160, 397-405	457
2178	A prognostic rule for elderly patients admitted with community-acquired pneumonia. 1999 , 106, 20-8	128

2177	Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes?. 1999 , 107, 5-12	84
2176	Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. 1999 , 14, 370-375	1
2175	The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. 1999 , 116, 1278-81	64
2174	Commentary on the 1993 American Thoracic Society guidelines for the treatment of community-acquired pneumonia. 1999 , 115, 14S-18S	22
2173	Managing community-acquired pneumonia. Factors to consider in outpatient care. 1999 , 105, 106-14	7
2172	[What is the cost of inappropriate admission of pneumonia patients?]. 1999 , 35, 312-6	11
2171	Drug Usage Evaluation of Antimicrobial Therapy for Community-Acquired Pneumonia. 1999 , 29, 317-320	6
2170	Basing empiric treatment choices for respiratory tract infection on the results of the Alexander Project. 1999 , 11 Suppl 1, 51-5	7
2169	Recent changes: pulmonary medicine. 1999 , 318, 171-6	3
2168	Severe pneumonia. When and why to hospitalize. 1999 , 105, 117-24	2
2167	A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. 1999 , 116, 974-83	31
2166	Community-acquired pneumonia at the end of the 20th century. 1999 , 105, 101-102	
2165	Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. 2000 , 118, 1339-43	71
2164	Implementation of admission decision support for community-acquired pneumonia. 2000 , 117, 1368-77	59
2163	Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia. 2000 , 117, 1090-3	4
2162	Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home-acquired pneumonia. 2000 , 117, 1378-85	56
2161	Severity assessment in community-acquired pneumonia. 2000 , 16, 1193-201	34
2160	Care-seeking pattern and outcome of hospitalized pneumonia patients who are socioeconomically disadvantaged. 97-120	

2159	Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. 2000 , 118, 1839-40	73
2158	Outcome of nursing home-acquired pneumonia: derivation and application of a practical model to predict 30 day mortality. 2000 , 48, 1292-9	57
2157	Don't let perfection be the enemy of the good: it's time for optimism over the role of severity scoring systems in intensive care unit performance measurement. 2000 , 6, 153-154	2
2156	The "new" scores: what problems have been fixed, and what remain?. 2000 , 6, 158-165	14
2155	An appraisal of treatment guidelines for antepartum community-acquired pneumonia. 2000 , 183, 131-135	43
2154	Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. 2000 , 79, 210-21	153
2153	Prognosis - what does the clinician associate with this notion?. 2000 , 19, 425-30	30
2152	Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. 2000 , 15, 638-46	61
2151	Vascular Brachytherapy for In-Stent Restenosis. 2000 , 13, 417-423	1
2150	An appraisal of treatment guidelines for antepartum community-acquired pneumonia. 2000 , 183, 131-5	35
2149	Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. 2000 , 20, 461-9	5
2148	Management strategies for community acquired pneumonia. 2000 , 24, 279-88	1
2147	Ongoing issues in pneumonia care: when to admit, how to treat and the role of oral therapy. 2000 , 24, 297-306	1
2146	National data sources on the care and outcomes of patients with community acquired pneumonia. 2000 , 24, 267-77	2
2145	[Community-acquired infections of the respiratory tract and lung parenchyma. Clinical and experimental aspects]. 2000 , 41, 1158, 1161-9	1
2144	[Therapy of community-acquired pneumonia]. 2000 , 95, 169-70	
2143	Update in hospital medicine. 2000 , 132, 384-90	1
2142	Care Plan for Community-Acquired Pneumonia. 2000 , 11, 22D-26D	1

2141	Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. 2000 , 7, 371-82	37
2140	Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. 2000 , 11, 237-48	18
2139	Treatment of Respiratory Infections with Quinolones. 2000 , 255-284	1
2138	Development of a best-practice model at a university hospital to increase efficiency in the management of patients with community-acquired pneumonia. 2000 , 57 Suppl 3, S6-9	5
2137	Update in infectious diseases. 2000 , 133, 285-92	3
2136	Levofloxacin use at an academic teaching institution. 2000 , 57, 1791-3	5
2135	Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. 2000 , 31, 869-74	153
2134	Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. 2000 , 30, 520-8	221
2133	Severity prediction rules in community acquired pneumonia: a validation study. 2000 , 55, 219-23	122
2132	Slowly resolving and nonresolving pneumonia. Questions to ask when response is delayed. 2000 , 108, 115-22; quiz 13	15
2131	Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. 2000 , 118, 1344-54	130
2130	Survival in end-stage dementia following acute illness. 2000 , 284, 47-52	278
2129	Understanding physician adherence with a pneumonia practice guideline: effects of patient, system, and physician factors. 2000 , 160, 98-104	126
2128	Predictors of symptom resolution in patients with community-acquired pneumonia. 2000 , 31, 1362-7	33
2127	Guidelines for community-acquired pneumonia: a tale of 2 countries. 2000 , 31, 422-5	16
2126	A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. 2000 , 283, 749-55	451
2125	Practice guideline for evaluation of fever and infection in long-term care facilities. 2000 , 31, 640-53	99
2124	Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. 2000 , 31, 347-82	1226

2123	Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. 2000 , 44, 1796-802	54
2122	Respiratory antibiotic use and clostridium difficile infection: is it the drugs or is it the doctors?. 2000 , 55, 633-4	13
2121	Assessing the quality of clinical data in a computer-based record for calculating the pneumonia severity index. 2000 , 7, 55-65	63
2120	Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. 2000 , 30, 461-5	30
2119	Treatment of community-acquired pneumonia. 2000 , 46 Suppl 1, 24-31	16
2118	Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. 2000 , 109, 378-85	155
2117	How long a stay in the hospital is needed for patients with community-acquired pneumonia?. 2000 , 109, 434-6	9
2116	A prognostic rule for elderly patients admitted with community-acquired pneumonia. 2000 , 108, 438	0
2115	Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. 2000 , 22, 872-8	44
2114	Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. 2000 , 22, 250-64	41
2113	Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group. 2000 , 94, 97-105	38
2112	Management of patients with community-acquired pneumonia in a primary care hospital: a critical evaluation. 2000 , 94, 556-63	17
2111	Clinical use of the fluoroquinolones. 2000 , 84, 1447-69	88
2110	Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. 2000 , 162, 2063-8	59
2109	Community-acquired pneumonia in the elderly: a practical guide to treatment. 2000 , 17, 93-105	16
2108	Community-acquired pneumonia in the elderly. 2000 , 31, 1066-78	219
2107	Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. 2000 , 284, 79-84	663
2106	What's new? Using prior models as a measure of novelty in knowledge discovery.	

2105	Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. 2000 , 31, 383-421	527
2104	A. Ruiz. 2000 , 114, 77-78	1
2103	52-year-old man with shortness of breath. 2000 , 75, 417-20	
2102	[Reduction of hospitalization in community-acquired pneumonia by the use of therapeutic strategy based on short-term mortality]. 2000 , 114, 77-8	
2101	[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]. 2000 , 115, 561-3	10
2100	New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?. 2000 , 16, 263-72	14
2099	Treatment of community-acquired pneumonia in hospitalised patients. 2001 , 18 Suppl 1, S63-70	2
2098	Pneumonies extrahospitalières: épidémiologie et prise en charge en réanimationCommunity-acquired pneumonia of critically ill patients: epidemiology and treatment.. 2001 , 10, 302-310	1
2097	Recomendaciones ALAT sobre la neumonía adquirida en la comunidad. 2001 , 37, 340-348	10
2096	Community-Acquired Pneumonia and its Management. 2001 , 9, 43-64	4
2095	Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. 2001 , 163, 1730-54	1706
2094	Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. 2001 , 110, 306-9	52
2093	The benefits of, controversies surrounding, and professional recommendations for routine PSA testing: what do men believe?. 2001 , 110, 309-13	2
2092	A statewide initiative to improve the care of hospitalized pneumonia patients: The Connecticut Pneumonia Pathway Project. 2001 , 111, 203-10	82
2091	Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. 2001 , 111, 367-74	77
2090	Critical evaluation of guidelines for the treatment of lower respiratory tract bacterial infections. 2001 , 95, 95-108	4
2089	The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. 2001 , 95, 78-82	136
2088	[Thoracic empyema in very old patients: two types of clinical presentation]. 2001 , 22, 1124-7	3

2087	Traitement antibiotique des pneumonies communautaires de l'adulte à l'appport des nouvelles molécules ; place des traitements de durée abrégée ; données pharmaco-économiques. 2001 , 31, 174-180	1
2086	Pneumonie communautaire, facteurs de risques et signes de gravité. 2001 , 31, 240-249	6
2085	Révision de la IV ^e Conférence de consensus en thérapeutique anti-infectieuse de la Société de pathologie infectieuse de langue française (SPILF). 2001 , 31, 268-301	2
2084	Nosologie des infections des voies aériennes basses. 2001 , 31, 609-613	
2083	Pneumonia in the elderly. 2001 , 85, 1441-59	39
2082	Defining severe community-acquired pneumonia. 2001 , 85, 1413-25	14
2081	[Community-acquired pneumonia requiring hospital admission. A comparison of the clinical management, resource use and prognosis by different medical specialties]. 2001 , 201, 65-8	2
2080	Practice Guideline for Evaluation of Fever and Infection in Long-Term Care Facilities. 2001 , 2, 246-258	3
2079	Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues. 2001 , 85, 1493-509	32
2078	Achieving a safe and early discharge for patients with community-acquired pneumonia. 2001 , 85, 1427-40	12
2077	Indications et modalités de l'antibiothérapie en urgence au service des urgences. 2001 , 10, 673-678	5
2076	[Prospective study of 221 community acquired pneumonias followed up in an outpatient clinic. Etiology and clinical-radiological progression]. 2001 , 116, 161-6	6
2075	How should we make the admission decision in community-acquired pneumonia?. 2001 , 85, 1397-411	14
2074	[Etiology of community-acquired pneumonia in ambulatory patients. Usefulness of a diagnostic investigation protocol using detection of Streptococcus pneumoniae and Legionella pneumophila antigens in urine samples]. 2001 , 117, 657-9	4
2073	Neumonía en el anciano. 2001 , 117, 454-456	4
2072	Management of patients with infectious diseases in an emergency department observation unit. 2001 , 19, 187-207	16
2071	[Community-acquired pneumonia: influence of the duration of intravenous antibiotic therapy on hospital stay and the cost-benefit ratio]. 2001 , 37, 366-70	9
2070	Current treatment considerations in community-acquired pneumonia in older patients. 2001 , 17, 5-8	

2069	Pre- and in-hospital management of community-acquired pneumonia in southern France, 1998-99. 2001 , 20, 770-8	9
2068	[Ambulatory acquired pneumonia--risk assessment, empirical and targeted therapy]. 2001 , 58, 582-7	
2067	Estudo de casos hospitalizados por pneumonia comunitária no período de um ano. 2001 , 27, 243-248	2
2066	Community-acquired pneumonia. A prospective outpatient study. 2001 , 80, 75-87	79
2065	Community-acquired pneumonia--implementation of a prediction rule to guide selection of patients for outpatient treatment. 2001 , 8, 279-86	13
2064	Severe community-acquired pneumonia: current outcomes, epidemiology, etiology, and therapy. 2001 , 14, 703-9	27
2063	Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states : 1993, 1995, and 1997. 2001 , 119, 1420-6	137
2062	Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. 2001 , 161, 2099-104	73
2061	Top Ten List in Pneumonia. 2001 , 119, 1563-1564	0
2060	Initial risk class and length of hospital stay in community-acquired pneumonia. 2001 , 18, 151-6	37
2059	A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. 2001 , 18, 362-8	101
2058	Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged > or = 75 yrs. 2001 , 17, 200-5	51
2057	Using clinical practice analysis to improve care. 2001 , 27, 291-301	17
2056	Evaluating quality indicators for patients with community-acquired pneumonia. 2001 , 27, 575-90	17
2055	Optimal treatment strategies for community-acquired pneumonia: high-risk patients (geriatric and with comorbidity). 2001 , 47 Suppl 4, 19-25; discussion 26-7	7
2054	Appropriate microbiological testing in community-acquired pneumonia. 2001 , 119, 5-7	9
2053	Community acquired pneumonia (CAP): an update. 2001 , 13 Suppl 1, 23-7	1
2052	A pneumonia adquirida na comunidade. O internamento hospitalar: quem, quando e onde?. 2001 , 7, 378-388	

2051	Factors Influencing the Hospital Admission Decision of Low-Risk Patients with Community Acquired Pneumonia: Evaluating the Usefulness of a Prediction Rule. 2001 , 8, 67-72	1
2050	Community-acquired pneumonia: the evolving challenge. 2001 , 7, 30-38	11
2049	Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. 2001 , 161, 1866-72	57
2048	Utility of prognostic stratification in adults with community-acquired bacterial meningitis. 2001 , 27, 72-7	5
2047	Hospitalization decision for ambulatory patients with community-acquired pneumonia: a prospective study with general practitioners in France. 2001 , 29, 320-5	8
2046	Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. 2001 , 20, 14-9	44
2045	Arterial blood gas and pulse oximetry in initial management of patients with community-acquired pneumonia. 2001 , 16, 590-8	44
2044	What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?. 2001 , 16, 599-605	41
2043	Practice guideline for evaluation of fever and infection in long-term care facilities. 2001 , 49, 210-22	38
2042	Clinical policy for the management and risk stratification of community-acquired pneumonia in adults in the emergency department. 2001 , 38, 107-13	25
2041	An emergency department-based randomized trial of nonbronchoscopic bronchoalveolar lavage for early pathogen identification in severe community-acquired pneumonia. 2001 , 38, 357-63	14
2040	A comprehensive set of coded chief complaints for the emergency department. 2001 , 8, 980-9	47
2039	Outcome of Older Patients with Severe Pneumonia Predicted by Recursive Partitioning. 2001 , 49, 1614-1621	21
2038	Infectious cost of leisure (Keynote lecture). 2001 , 7, 1-357	
2037	Introduction. Designing a transition therapy program. 2001 , 21, 77S-78S	
2036	Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience. 2001 , 21, 83S-88S	4
2035	A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. 2001 , 21, 89S-94S	10
2034	New directions in anti-infective therapy for community-acquired pneumonia in the emergency department. 2001 , 21, 95S-99S	4

2033	Telithromycin: an oral ketolide for respiratory infections. 2001 , 21, 1204-22	21
2032	Community-acquired pneumonia: the evolving challenge. 2001 , 7, 30-38	21
2031	Management of Antimicrobials in Infectious Diseases. 2001 ,	3
2030	Diabetes and the risk of infection-related mortality in the U.S. 2001 , 24, 1044-9	181
2029	Evaluation of a computerized diagnostic decision support system for patients with pneumonia: study design considerations. 2001 , 8, 473-85	26
2028	Severity assessment of lower respiratory tract infection in elderly patients in primary care. 2001 , 161, 2709-13	33
2027	Factors Influencing Length of Stay, Time to Resolution of Morbidity, and Cost of Patient Care: A Comparative Retrospective Study of Short-Stay and Long-Stay Patients Hospitalized for Simple Pneumonia (DRG 89 and 90). 2001 , 10, 375-383	5
2026	Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired <i>Streptococcus pneumoniae</i> pneumonia. 2001 , 161, 848-50	86
2025	Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. 2001 , 119, 181-4	87
2024	Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. 2001 , 119, 1439-48	75
2023	Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. 2001 , 120, 185-92	33
2022	Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections. 2001 , 10, 353-67	36
2021	Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. 2001 , 56, 121-5	35
2020	Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial. 2001 , 48, 527-34	6
2019	Predicting mortality in nursing home residents with lower respiratory tract infection: The Missouri LRI Study. 2001 , 286, 2427-36	90
2018	What white blood cell count should prompt antibiotic treatment in a febrile child? Tutorial on the importance of disease likelihood to the interpretation of diagnostic tests. 2001 , 21, 479-89	7
2017	Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. 2001 , 35, 1180-5	37
2016	Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. 2001 , 161, 1837-42	276

2015	Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. 2001 , 33, 158-65	664
2014	Clinical epidemiology of acute lung injury. 2001 , 22, 237-46	10
2013	Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. 2001 , 163, 1599-604	193
2012	Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant <i>Streptococcus pneumoniae</i> : a randomized study of amoxicillin-clavulanate and ceftriaxone. 2001 , 7, 85-96	47
2011	In vivo veritas: in vitro macrolide resistance in systemic <i>Streptococcus pneumoniae</i> infections does result in clinical failure. 2002 , 35, 565-9	48
2010	Treatment of community-acquired lower respiratory tract infections in adults. 2002 , 36, 40s-53s	19
2009	Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. 2002 , 162, 682-8	167
2008	Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. 2002 , 162, 1059-64	245
2007	Quantifying Risk in Sepsis: A Review of Illness Severity and Organ Dysfunction Scoring. 2002 , 81-96	
2006	Patient and hospital characteristics associated with recommended processes of care for elderly patients hospitalized with pneumonia: results from the medicare quality indicator system pneumonia module. 2002 , 162, 827-33	56
2005	PREDICTORS OF LENGTH OF HOSPITAL STAY IN COMMUNITY-ACQUIRED PNEUMONIA. 2002 , 11, 46-51	3
2004	Use of ??-Lactam/??-Lactamase Inhibitor Combinations to Treat Community-Acquired Respiratory Tract Infections. 2002 , 11, S20-S26	
2003	Clinical Experience With Newer Quinolones for Community-Acquired Pneumonia. 2002 , 527-533	
2002	Does acute organ dysfunction predict patient-centered outcomes?. 2002 , 121, 1963-71	48
2001	Influence of deviation from guidelines on the outcome of community-acquired pneumonia. 2002 , 122, 612-7	81
2000	Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. 2002 , 14, 609-17	24
1999	Treatment of Community-Acquired Pneumonia. 2002 , 163-178	
1998	Pathophysiology of Pneumonia and the Clinical Consequences. 2002 , 179-192	0

1997	Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. 2002 , 162, 1278-84	133
1996	The hospitalist movement 5 years later. 2002 , 287, 487-94	259
1995	Management of patients with community-acquired pneumonia treated in hospital in Sweden. 2002 , 34, 887-92	24
1994	Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant <i>Streptococcus pneumoniae</i> . 2002 , 34 Suppl 1, S17-26	68
1993	Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model. 2002 , 14, 591-6	3
1992	Tumor necrosis factor-alpha-converting enzyme: its role in community-acquired pneumonia. 2002 , 186, 1790-6	20
1991	Nursing home-acquired pneumonia. 2002 , 35, 1205-11	107
1990	Health-related quality of life and posttraumatic stress disorder among survivors of an outbreak of Legionnaires disease. 2002 , 35, 11-7	53
1989	Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. 2002 , 20, 990-5	143
1988	Epidemiology of Community-Acquired Pneumonia. 2002 , 13-27	
1987	Community-acquired pneumonia: process of care studies. 2002 , 15, 169-74	9
1986	International Respiratory Tract Infection Guidelines. 2002 , 11, S3-S11	
1985	Severe community-acquired pneumonia. 2002 , 8, 453-60	10
1984	Putting outcomes into practice in physician offices. 2002 , 17, 51-62; quiz 90	4
1983	An open, comparative pilot study of thiamphenicol glycinate hydrochloride vs clarithromycin in the treatment of acute lower respiratory tract infections due to <i>Chlamydia pneumoniae</i> . 2002 , 14, 265-71	5
1982	The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia. 2002 , 122, 920-9	113
1981	Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. 2002 , 121, 1486-92	94
1980	Nursing Home-Acquired Pneumonia. 2002 , 143-162	

1979	Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur). 2002 , 14 Suppl 4, 1-22	9
1978	An intervention to improve antibiotic delivery and sputum procurement in patients hospitalized with community-acquired pneumonia. 2002 , 122, 913-9	17
1977	A Critical Pathway for the Treatment of Community-Acquired Pneumonia. 2002 , 273-281	
1976	Guidelines for managing community acquired pneumonia in adults. 2002 , 324, 436-7	11
1975	Comparaç� prospectiva entre pneumonia adquirida em lar de idosos e pneumonia adquirida na comunidade. 2002 , 8, 178-180	
1974	Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. 2002 , 122, 1271-9	31
1973	Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. 2002 , 166, 717-23	249
1972	A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. 2002 , 34, 1076-83	64
1971	Improving the quality of pneumonia care that patients experience. 2002 , 113, 379-83	13
1970	Clinical practice. Management of community-acquired pneumonia. <i>New England Journal of Medicine</i> , 2002 , 347, 2039-45	59.2 126
1969	Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. 2002 , 19, 61-6	14
1968	The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. 2002 , 20, 119-29	23
1967	Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region. 2002 , 20 Suppl 1, S1-12	92
1966	Influenza vaccinations: who needs them and when?. 2002 , 62, 2413-20	16
1965	Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. 2002 , 165, 766-72	441
1964	Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. 2002 , 20, 513-28	19
1963	Infection with non-B subtype HIV type 1 complicates management of established infection in adult patients and diagnosis of infection in newborn infants. 2002 , 34, 417-8	38
1962	Algorithm-based management of pneumonia in HIV-1-infected patients. 2002 , 359, 359-60	4

1961	Respiratory rate measurement in adults--how reliable is it?. 2002 , 96, 31-3	42
1960	Cephalosporin-resistant pneumococcal pneumonia: does it, affect outcome?. 2002 , 96, 805-11	9
1959	Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. 2002 , 44, 85-91	14
1958	Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. 2002 , 44, 117-25	12
1957	Treatment of drug-resistant pneumococcal pneumonia. 2002 , 2, 404-15	65
1956	The Pneumonia Severity Index as a decision-making tool to guide patient disposition. 2002 , 20, 387-8	2
1955	Insertion of IVs by residents: does it save time?. 2002 , 20, 385-7	1
1954	Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections. 2002 , 24, 838-50; discussion 837	11
1953	A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. 2002 , 24, 1770-85	57
1952	Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. 2002 , 24, 1915-36	55
1951	A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. 2002 , 24, 736-51	39
1950	Intérêt d'un score de gravité des pneumonies communautaires : application du score de Fine aux pneumonies admises au centre hospitalier d'Annecy. 2002 , 32, 19-27	
1949	Efficacité comparée de la ceftriaxone dans un traitement de dix jours versus un traitement raccourci de cinq jours des pneumonies aiguës communautaires de l'adulte hospitalisé avec facteur de risque. 2002 , 32, 369-381	19
1948	Protocolo diagnóstico-terapéutico de la neumonía adquirida en la comunidad. 2002 , 8, 3325-3329	
1947	Neumonía comunitaria grave. Nuevas recomendaciones y viejas cuestiones. 2002 , 26, 448-451	1
1946	Comparison of processes and outcomes of pneumonia care between hospitalists and community-based primary care physicians. 2002 , 77, 1053-8	48
1945	Antibióticos en las infecciones respiratorias. 2002 , 9, 119-135	
1944	[Community-acquired pneumonia: usefulness of clinical presentation in the selection of antibiotic treatment]. 2002 , 119, 641-3	5

1943	[When to admit a patient with community-acquired pneumonia]. 2002 , 38, 549-51	2
1942	Quels scores pronostiques dans le sepsis?What severity scores in sepsis?.. 2002 , 11, 178-185	
1941	[Diagnostic methods and treatment of community-acquired pneumonia in Spain: NACE study]. 2002 , 119, 321-6	5
1940	Neumonías adquiridas en la comunidad en pacientes mayores de 60 años. 2002 , 118, 398-399	
1939	[Community-acquired pneumonia associated with influenza virus]. 2002 , 118, 622-6	1
1938	Clinical Pharmacist Interventions Associated with Appropriateness and Length of Inpatient Antimicrobial Therapy for Pneumonia. 2002 , 8, 406-406	1
1937	Clinical Features and Outcomes of Community-Acquired Pneumonia. 2002 , 29-34	
1936	Possible interaction between gatifloxacin and warfarin. 2002 , 59, 1205-6	9
1935	Student conduct at the personnel placement service. 2002 , 59, 1205	1
1934	Estimation of surgical costs using a prediction scoring system: estimation of physiologic ability and surgical stress. 2002 , 137, 481-5	21
1933	Antimicrobial therapy for community-acquired pneumonia in adults. 2002 , 6, 82-7	1
1932	Oral fluoroquinolones in the treatment of pneumonia, bronchitis and sinusitis. 2002 , 13, 293-300	7
1931	3: Community-acquired pneumonia. 2002 , 176, 341-7	31
1930	Managing infections in the elderly: The challenge of long-term care facilities. 2002 , 24, 183-186	2
1929	Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. 2002 , 30, 378-86	57
1928	[Bacterial pneumonias]. 2002 , 43, 375-82, 384-95; quiz 396-7	0
1927	Community-acquired pneumonia and do not resuscitate orders. 2002 , 50, 290-9	37
1926	Community-acquired pneumonia in older veterans: does the pneumonia prognosis index help?. 2002 , 50, 434-8	7

1925	Resistant pathogens in respiratory tract infections in older people. 2002 , 50, S236-41	14
1924	Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. 2002 , 8 Suppl 2, 1-11	38
1923	Foot & mouth disease. 2002 , 8, 1-394	3
1922	Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. 2002 , 28, 1030-5	45
1921	Designing a Research Agenda to Improve the Quality of Emergency Care. 2002 , 9, 1124-1130	2
1920	Oral and early-switch therapies can be used safely for community-acquired pneumonia. 2002 , 6, 49-50	
1919	The reliability of vital sign measurements. 2002 , 39, 233-7	111
1918	A Research Agenda for Geriatric Emergency Medicine. 2003 , 10, 251-260	13
1917	Continuity of antibiotic therapy in patients admitted from the emergency department. 2003 , 42, 117-23	11
1916	A predictive model for the management of community-acquired pneumonia. 2003 , 31, 3-8	14
1915	It's Not Just the Hospital Anymore. 2003 , 5, 277-278	
1914	[Community-acquired and nosocomial pneumonia]. 2003 , 44 Suppl 1, S44-58	0
1913	A 7-year study of severe hospital-acquired pneumonia requiring ICU admission. 2003 , 29, 1981-8	58
1912	Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. 2003 , 22, 151-7	112
1911	Aetiology and clinical presentation of mild community-acquired bacterial pneumonia. 2003 , 22, 584-91	29
1910	What's new in âRespiratory disorders. 2003 , 31, 1-4	
1909	Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. 2003 , 23, 1167-74	21
1908	Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of <i>Streptococcus pneumoniae</i> . 2003 , 23, 349-59	15

1907	Pneumonia versus aspiration pneumonitis in nursing home residents: diagnosis and management. 2003 , 51, 17-23	73
1906	Determinants for hospitalization in " low-risk" community acquired pneumonia. 2003 , 3, 11	25
1905	Ertapenem therapy for community-acquired pneumonia in the elderly. 2003 , 51, 1526-32	31
1904	The pathophysiological significance of prognostic factors for fatal outcome in lower respiratory tract infections. 2003 , 8, 53-7	3
1903	Treatment and outcome of 104 hospitalized patients with legionnaires' disease. 2003 , 33, 484-8	18
1902	Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. 2003 , 9, 691-703	37
1901	High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. 2003 , 37, 752-60	251
1900	[Community-acquired pneumonia: repercussions on the clinical management]. 2003 , 121, 117	
1899	Community-acquired pneumonia in elderly patients. 2003 , 19, 101-20	31
1898	[Respiratory infections outside the hospital. DIRA study]. 2003 , 21, 410-6	4
1897	Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management. 2003 , 21, 395-420	16
1896	Neumonía comunitaria por Legionella pneumophila serogrupo 1. Estudio de 97 casos. 2003 , 21, 394-400	
1895	Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting. 2003 , 78, 1113-24	19
1894	[Pneumonia in the patient with chronic obstructive pulmonary disease. Levels of severity and risk classification]. 2003 , 39, 101-5	5
1893	[Clinical management of community-acquired pneumonia]. 2003 , 21, 350-7	1
1892	[Pneumococcal pneumonia in hospitalized patients. Therapeutic implications of resistances to penicillin and erythromycin]. 2003 , 120, 292-4	
1891	Neumonía adquirida en la comunidad en pacientes ingresados: mortalidad, comorbilidad y clases de riesgo. 2003 , 203, 64-67	2
1890	[Community-acquired pneumonia requiring hospitalization in immunocompetent elderly patients: clinical features, prognostic factors and treatment]. 2003 , 39, 333-40	13

1889	[Community-acquired pneumococcal infection: approach to improve the election of antibiotic therapy]. 2003 , 120, 297-302	
1888	[Hospitalization of patients with community-acquired pneumonia]. 2003 , 39, 241	1
1887	Valoraci3n de la gravedad y estimaci3n de los recursos sanitarios en los pacientes ingresados por neumon3a adquirida en la comunidad. 2003 , 18, 27-32	
1886	Community-acquired pneumonia in the elderly. 2003 , 19, 729-48	32
1885	[Respiratory infections in adults hospitalized in internal medicine and pneumology departments. DIRA (Adult Respiratory Infection Day) study]. 2003 , 21, 180-7	5
1884	Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. 2003 , 115, 343-51	77
1883	Effects of previous influenza vaccination on subsequent readmission and mortality in elderly patients hospitalized with pneumonia. 2003 , 115, 454-61	23
1882	A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. 2003 , 185, 369-75	33
1881	[Implication of emergency departments in the regulation of public hospitalizations]. 2003 , 24, 602-12	9
1880	Community-acquired pneumonia. 2003 , 362, 1991-2001	361
1879	Factors associated with hospitalization costs for patients with community-acquired pneumonia. 2003 , 25, 593-610	20
1878	Prescriptions d'antibiotiques dans 34 services d'accueil et de traitement des urgences fran3ais. 2003 , 33, 70-77	6
1877	Delirium in the elderly resulting from azithromycin therapy. 2003 , 59, 509-11	17
1876	Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. 2003 , 97, 625-33	30
1875	Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. 2003 , 97, 1134-42	25
1874	Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). 2003 , 45, 279-85	105
1873	Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. 2003 , 3, 476-88	42
1872	Community-acquired pneumonia in adults. 2003 , 30, 155-71	6

1871	Management of respiratory infections in the elderly. 2003 , 1, 505-16	8
1870	Management of community-acquired pneumonia: a focus on conversion from hospital to the ambulatory setting. 2003 , 2, 385-94	4
1869	Optimizing treatment outcomes in severe community-acquired pneumonia. 2003 , 2, 39-54	13
1868	Validation of the Pneumonia Severity Index Among Patients Treated at Home or in the Hospital. 2003 , 11, 595-601	2
1867	Cost-effectiveness of community-acquired pneumonia therapy. 2003 , 3, 749-56	
1866	Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia. 2003 , 188, 769-76	36
1865	Pneumonia in older persons. 2003 , 37, 1335-9	68
1864	Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to <i>Chlamydia pneumoniae</i> . 2003 , 51, 1025-8	16
1863	Reply. 2003 , 36, 936-937	1
1862	Variations in lung cancer risk among smokers. 2003 , 95, 470-8	443
1861	<i>P. carinii</i> pneumonia in African children and the ineffectiveness of TMP-SMX prophylaxis. 2003 , 36, 937-9; author reply 939-40	1
1860	Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. 2003 , 290, 2581-7	958
1859	Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. 2003 , 36, 328-36	36
1858	Algorithm to determine cost savings of targeting antimicrobial therapy based on results of rapid diagnostic testing. 2003 , 41, 4708-13	18
1857	Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. 2003 , 10, 813-20	88
1856	A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. 2003 , 21, 695-701	53
1855	Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. 2003 , 58, 377-82	1759
1854	Managing skin and soft tissue infections: expert panel recommendations on key decision points. 2003 , 52 Suppl 1, i3-17	205

1853	Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department. 2003 , 20, 521-3	33
1852	Pneumonia: still the old man's friend?. 2003 , 163, 317-23	162
1851	Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?. 2003 , 36, 1239-45	24
1850	Duration of length of stay in pneumonia: influence of clinical factors and hospital type. 2003 , 22, 643-8	43
1849	C-reactive protein levels in community-acquired pneumonia. 2003 , 21, 702-5	82
1848	Risk stratification and bedside prognostication in infective endocarditis. 2003 , 289, 1991-3	8
1847	Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model. 2003 , 51, 1269-82	15
1846	Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. 2003 , 37, 1617-24	130
1845	Community-acquired pneumonia in the elderly: Spanish multicentre study. 2003 , 21, 294-302	86
1844	Mortality during hospitalisation for pneumonia in Alberta, Canada, is associated with physician volume. 2003 , 22, 148-55	34
1843	Evaluation of Non-Resolving and Progressive Pneumonia. 2003 , 175-187	1
1842	Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. 2003 , 21, 135-43	76
1841	Prognostic features of residual pleural thickening in parapneumonic pleural effusions. 2003 , 21, 952-5	29
1840	Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. 2003 , 36, 286-92	219
1839	Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. 2003 , 123, 1503-11	127
1838	. 2003 , 82, 159-169	20
1837	The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. 2003 , 123, 1142-50	160
1836	Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. 2003 , 124, 121-4	77

1835	What is the prognosis for using the pneumonia severity index to make site-of-care decisions in community-acquired pneumonia?. 2003 , 124, 2051-3	11
1834	Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. 2003 , 124, 2148-55	76
1833	Why should the infectious diseases community focus on aging and care of the older adult?. 2003 , 37, 196-200	20
1832	Clinical diagnosis of Legionella pneumonia revisited: evaluation of the Community-Based Pneumonia Incidence Study Group scoring system. 2003 , 37, 483-9	46
1831	[CAPNet--network of competence for community acquired pneumonia: structures and aims]. 2003 , 57, 34-41	3
1830	Shoot, ready, aim: pneumonia care quality and costs in a community hospital. 2003 , 18, 214-9	2
1829	The epidemiology and definition of the acute respiratory distress syndrome. 2003 , 9, 273-82	8
1828	Legionnaires disease and HIV infection. 2003 , 124, 543-7	42
1827	" 'Tis a gift to be simple...". 2003 , 124, 777-8	6
1826	Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. 2003 , 124, 1798-804	74
1825	Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. 2003 , 82, 159-69	132
1824	[Portuguese Respiratory Society guidelines for the management of community-acquired pneumonia in immunocompetent adults]. 2003 , 9, 435-61	1
1823	Community-acquired pneumonia. 2003 , 9, 175-80	30
1822	Severe community-acquired pneumonia: what's in a name?. 2003 , 16, 153-9	24
1821	Variation in management of community-acquired pneumonia requiring admission to Alberta, Canada hospitals. 2003 , 130, 41-51	27
1820	A rapid quantitative D-dimer assay at admission correlates with the severity of community acquired pneumonia. 2003 , 14, 745-8	24
1819	Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. 2003 , 163, 1718-26	22
1818	Early mobilization of patients hospitalized with community-acquired pneumonia. 2003 , 124, 883-9	152

1817	Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule. 2003 , 31, 670-5	416
1816	Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. 2003 , 31, 1367-72	79
1815	Combination antibiotic therapy with macrolides in community-acquired pneumonia: more smoke but is there any fire?. 2003 , 123, 1328-9	11
1814	Testing strategies in the initial management of patients with community-acquired pneumonia. 2003 , 138, 109-18	152
1813	A rapid staging system for predicting mortality from HIV-associated community-acquired pneumonia. 2003 , 123, 1151-60	24
1812	Management of community-acquired pneumonia at a tertiary care medical center in Lebanon. 2003 , 60, 934-8	3
1811	Current and future management of pneumonia. 2003 , 363-402	1
1810	Community-Acquired Pneumonia in Children: A Multidisciplinary Consensus Review. 2003 , 14, 3B-11B	4
1809	Infectious Diseases. 2003 , 801-817	
1808	. 2003 , 10, 162-168	
1807	An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers. 2003 , 7, 62-8	2
1806	Are the Australian guidelines asking too much of the Pneumonia Severity Index (PSI)?. 2004 , 180, 486-487	5
1805	Are the Australian guidelines asking too much of the Pneumonia Severity Index (PSI)?. 2004 , 181, 515-516	1
1804	Impact of an electronic antibiotic advice and approval system on antibiotic prescribing in an Australian teaching hospital. 2004 , 180, 455-8	19
1803	IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics. 2004 , 39, 1069-1075	1
1802	Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia. 2004 , 8, 90-100	6
1801	[Prediction rules in community acquired pneumonia]. 2004 , 132, 1027-30	
1800	Pneumonias adquiridas na comunidade em pacientes idosos: aderência ao Consenso Brasileiro sobre Pneumonias. 2004 , 30, 229-236	1

1799	The use of clinical practice guidelines for community-acquired pneumonia in hospitals in Atlantic Canada. 2004 , 11, 301-3	2
1798	Symptom resolution in patients with <i>Mycoplasma pneumoniae</i> pneumonia. 2004 , 11, 573-7	5
1797	Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic <i>Streptococcus pneumoniae</i> pneumonia in adults. 2004 , 11, 589-93	74
1796	Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals. 2004 , 11, 131-7	12
1795	Utility of follow-up recommendations for patients discharged with community-acquired pneumonia. 2004 , 6, 97-103	
1794	Blood cultures for community-acquired pneumonia: piecing together a mosaic for doing less. 2004 , 169, 327-8	11
1793	Nursing home-acquired pneumonia: an emergency department treatment algorithm. 2004 , 20, 1309-20	29
1792	Predicting bacteremia in patients with community-acquired pneumonia. 2004 , 169, 342-7	160
1791	Medium-term survival after hospitalization with community-acquired pneumonia. 2004 , 169, 910-4	95
1790	Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. 2004 , 20, 739-47	23
1789	Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. 2004 , 164, 1807-11	105
1788	Vascular dysfunction in sleep apnea: a reversible link to cardiovascular disease?. 2004 , 169, 328-9	13
1787	Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. 2004 , 38, 787-98	113
1786	Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. 2004 , 39, 1783-90	106
1785	Patients with community acquired pneumonia discharged from the emergency department according to a clinical practice guideline. 2004 , 21, 667-9	14
1784	Development and validation of a short questionnaire in community acquired pneumonia. 2004 , 59, 591-5	23
1783	Optimizing antibiotic prescribing for acute cough in general practice: a cluster-randomized controlled trial. 2004 , 54, 661-72	71
1782	Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. 2004 , 164, 637-44	532

1781	Sepsis. 2004 ,	1
1780	Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. 2004 , 59, 960-5	175
1779	Cefepime versus ceftazidime for treatment of pneumonia. 2004 , 32, 84-93	7
1778	Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons. 2004 , 189, 450-8	63
1777	Peak expiratory flow (PEF) monitoring. 2004 , 59, 913-4	4
1776	Considerations in clinical trials of combination antifungal therapy. 2004 , 39 Suppl 4, S228-35	13
1775	Enhanced PMN response in chronic bronchitis and community-acquired pneumonia. 2004 , 24, 772-8	11
1774	Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. 2004 , 24, 779-85	114
1773	Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. 2004 , 38, 222-6	149
1772	Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia. 2004 , 42, 3620-5	52
1771	Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. 2004 , 38, 1570-8	81
1770	Clinical stability in human immunodeficiency virus-infected patients with community-acquired pneumonia. 2004 , 38, 271-9	52
1769	Unravelling salt transport in cystic fibrosis. 2004 , 59, 916-7	
1768	Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin. 2004 , 48, 3343-8	31
1767	Validation of predictive rules and indices of severity for community acquired pneumonia. 2004 , 59, 421-7	145
1766	Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. 2004 , 24, 644-8	13
1765	What happens to patients with respiratory disease when they fly?. 2004 , 59, 919-20	5
1764	The BODE index: a new grading system in COPD. 2004 , 59, 427-427	1

1763	Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. 2004 , 164, 502-8	149
1762	Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. 2004 , 38 Suppl 4, S328-40	24
1761	Treating acute infections by telemedicine in the home. 2004 , 39, 1175-81	21
1760	Viral community-acquired pneumonia in nonimmunocompromised adults. 2004 , 125, 1343-51	134
1759	Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. 2004 , 126, 1087-92	119
1758	Appendix B. 2004 , 12, S24	
1757	Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. 2004 , CD004400	10
1756	Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. 2004 , 20, 749-56	12
1755	Antibiotic Use-Changing Paradigms. 2004 , 12, S4-S7	
1754	Appendix A. 2004 , 12, S23	
1753	Identifying failure of empirical treatment for pneumonia: vigilance and common sense. 2004 , 59, 918-9	
1752	Tuberculosis and anti-TNF-alpha treatment. 2004 , 59, 921	14
1751	Difficult bacteria, antibiotic resistance and transmissibility in cystic fibrosis. 2004 , 59, 914-5	13
1750	Prognostic scoring systems for infectious diseases: their applicability to the care of older adults. 2004 , 38, 692-6	22
1749	Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. 2004 , 54, 515-23	80
1748	Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. 2004 , 39, 955-63	103
1747	Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?. 2004 , 54, 481-8	30
1746	Towards an integrated approach to lung health in adolescents in developing countries. 2004 , 24, 117-31	5

1745	Deaths in risk classes I-III: a measure of quality of care in patients hospitalised with CAP?. 2004 , 23, 103-5	11
1744	Community-acquired pneumonia: influence of management practices on length of hospital stay. 2004 , 34, 91-7	11
1743	Improving the implementation of community-acquired pneumonia guidelines. 2004 , 34, 507-9	4
1742	Building in efficacy: developing solutions to combat drug-resistant <i>S. pneumoniae</i> . 2004 , 10 Suppl 2, 18-27	18
1741	Effect of a comprehensive, multidisciplinary, educational program on the use of antibiotics in a geriatric university hospital. 2004 , 52, 112-6	65
1740	Combined use of fasting glucose and hemoglobin a levels in screening for new type 2 diabetes mellitus in elderly men: TCVGHAGE. 2004 , 52, 1777-8	2
1739	Theophylline-improved swallowing reflex in elderly nursing home patients. 2004 , 52, 1787-8	13
1738	Response Letter to Dr. Raschilas et al.. 2004 , 52, 1789-1789	
1737	Type 2 diabetes mellitus as a risk factor for hip fracture. 2004 , 52, 1778-9	13
1736	A case of cutaneous horn in a 99-year-old woman. 2004 , 52, 1779-80	
1735	A clinicopathological study of rest tremors in the elderly. 2004 , 52, 1781-3	4
1734	An 85-year-old Japanese woman with Philadelphia chromosome-positive chronic myelogenous leukemia with del (5q) successfully treated by intermittent imatinib therapy. 2004 , 52, 1783-4	
1733	Buformin-induced lactic acidosis--a symptom of modern healthcare malady. 2004 , 52, 1785	7
1732	Retroperitoneal abscess after sphincterotomy-related perforation. 2004 , 52, 1786	
1731	Gustatory rhinorrhea as a complication of oral surgery. 2004 , 52, 1786-7	4
1730	Outcome predictors of pneumonia in elderly patients: importance of functional assessment. 2004 , 52, 1603-9	155
1729	Indicators of recurrent hospitalization for pneumonia in the elderly. 2004 , 52, 2010-5	34
1728	Management of community-acquired pneumonia in persons with spinal cord injury. 2004 , 42, 450-8	14

1727	Ertapenem therapy for community-acquired pneumonia in the elderly. 2004 , 52, 1788-9; author reply 1789	
1726	Do older people tolerate ambulatory blood pressure monitoring?. 2004 , 52, 1780-1	3
1725	The importance of geriatric-specific instruments and functional status assessment in infectious diseases research: time to start preaching to the congregation instead of the choir. 2004 , 52, 1768-70	20
1724	Estimation of physiologic ability and surgical stress (E-PASS) for a surgical audit in elective digestive surgery. 2004 , 135, 586-94	58
1723	Racial variations in processes of care for patients with community-acquired pneumonia. 2004 , 4, 20	17
1722	Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. 2004 , 23, 82-8	23
1721	Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila. 2004 , 23, 650-2	7
1720	A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology. 2004 , 10, 359-63	94
1719	[Treatment of severe pneumonia--community-acquired and "early onset" nosocomial]. 2004 , 99, 362-71	0
1718	Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. 2004 , 117 Suppl 3A, 39S-50S	41
1717	The emergency department community-acquired pneumonia trial. 2004 , 43, 770-782	42
1716	Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials. 2004 , 20, 969-80	9
1715	Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?. 2004 , 22, 413-20	19
1714	Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines. 2004 , 22, 751-7	36
1713	The threat and prospects for control of an influenza pandemic. 2004 , 3, 35-42	19
1712	A population-based study of the costs of care for community-acquired pneumonia. 2004 , 23, 610-6	56
1711	Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns. 2004 , 24, 531-51	3
1710	Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study. 2004 , 24, 503-30	44

1709 Hospitalizaci3n a domicilio y neumon3a adquirida en la comunidad. R3plica. **2004**, 22, 434-435

1708 [Clinical prediction rules: a readers' guide]. **2004**, 21, S40-6

1707 Brote epid3mico de neumon3a comunitaria por Legionella pneumophila en Barcelona: «el brote de la Barceloneta». Efecto del diagn3stico y tratamiento precoz. **2004**, 204, 70-74

1

1706 Edad, comorbilidad y mortalidad en pacientes hospitalizados por neumon3a adquirida en la comunidad. **2004**, 204, 501

0

1705 [EVAN-65 project: evaluation of the effectiveness of pneumococcus vaccination in the elderly population over 65]. **2004**, 33, 149-53

2

1704 Pneumopathies du sujet 3g3: facteurs pr3disposants, traitement, pr3vention. **2004**, 4, 9-14

1

1703 Tratamiento emp3rico de la neumon3a adquirida en la comunidad. **2004**, 204, 103-105

1

1702 La neumon3a adquirida en la comunidad de los ancianos: diferencias entre los que viven en residencias y en domicilios particulares. **2004**, 40, 547-552

12

1701 Local guidelines for community-acquired pneumonia: development, implementation, and outcome studies. **2004**, 18, 975-91

9

1700 [Usefulness of acute-phase proteins in community-acquired pneumonia]. **2004**, 122, 245-7

2

1699 Community-acquired pneumonia: severity of illness evaluation. **2004**, 18, 791-807; viii

6

1698 [Outpatient care or hospitalization? A crucial decision in the treatment of community-acquired pneumonia]. **2004**, 22, 61-3

3

1697 Edad, comorbilidad y mortalidad en pacientes hospitalizados por neumon3a adquirida en la Comunidad (r3plica). **2004**, 204, 563

1696 [Where should acquired community pneumonia be treated?]. **2004**, 122, 496-8

1

1695 [Scores and clinical evaluation]. **2004**, 21, S37-9

0

1694 Actualizaci3n de las recomendaciones ALAT sobre la neumon3a adquirida en la comunidad. **2004**, 40, 364-374

78

1693 Une insuffisance respiratoire aiguë ^« poumons clairs ». **2004**, 8, 468-471

1692 [Validation of the Pneumonia Severity Index for hospitalizing patients with community-acquired pneumonia]. **2004**, 122, 481-6

3

1691	[Hospital admission, duration of stay and mortality in community-acquired pneumonia in an acute care hospital. Correlation between a pneumonia prognosis index and conventional clinical criteria for assessing severity]. 2004 , 22, 64-9	1
1690	Hospitalizaci3n a domicilio y neumon3a adquirida en la comunidad. R3plica. 2004 , 22, 435-436	
1689	Infections pulmonaires aigu3s chez les patients 3s en institution. 2004 , 21, 99-105	
1688	[Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia]. 2004 , 40, 364-74	4
1687	[Community-acquired pneumonia among the elderly: differences between patients living at home and in nursing homes]. 2004 , 40, 547-52	14
1686	Anti-infective pharmacodynamics 3-maximizing efficacy, minimizing toxicity. 2004 , 1, 505-512	3
1685	Insuffisance respiratoire aigu3. D3marches diagnostique et th3rapeutique. 2004 , 1, 534-546	
1684	Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience. 2004 , 24, 485-90	31
1683	Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). 2004 , 24, 479-84	31
1682	Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. 2004 , 3, 329-36	35
1681	Acute cough in the elderly: aetiology, diagnosis and therapy. 2004 , 21, 243-58	9
1680	Guidelines for community-acquired pneumonia: are they reflected in practice?. 2004 , 3, 67-77	19
1679	Hospital-acquired pneumonia in critically ill patients: mortality risk stratification upon onset. 2004 , 3, 123-31	10
1678	Dysnatremias in the critical care setting. 2004 , 144, 132-57	16
1677	Factors influencing prognosis of pneumonia in elderly patients. 2004 , 16, 467-71	8
1676	Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. 2004 , 20, 555-63	63
1675	Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. 2004 , 20, 1473-81	26
1674	Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. 2004 , 18, 743-59, vii	24

1673	Clinical management of immunocompetent hospitalized patients with community-acquired pneumonia. 2004 , 15, 28-34	14
1672	[The computer-assisted management programs for antibiotic therapies in connection with an application in geriatrics]. 2004 , 52, 589-96	2
1671	Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia. 2004 , 17, 199-203	7
1670	Prospective evaluation of pneumonia severity index in hospitalised patients with community-acquired pneumonia. 2004 , 98, 872-8	25
1669	Short-term outcomes and their predictors for patients hospitalized with community-acquired pneumonia. 2004 , 33, 301-7	46
1668	[Management of communal lower respiratory tract infections in the emergency ward: the role of Ketek (telithromycine)]. 2004 , 34, 51-6	
1667	Predictors of outcome in geriatric patients with urinary tract infections. 2004 , 27, 101-8	28
1666	Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. 2004 , 27, 395-405	32
1665	Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis. 2004 , 116, 385-93	16
1664	Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. 2004 , 117, 305-11	121
1663	Reimbursement denial and reversal by health plans at a university hospital. 2004 , 117, 629-35	6
1662	Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. 2004 , 117, 726-31	145
1661	Lung infections and aging. 2004 , 3, 55-67	69
1660	[Non-justified visits to emergency units. Proposal of differentiated care]. 2004 , 33, 780-3	5
1659	Methodology of observational studies of pneumococcal polysaccharide vaccine. 2004 , 4, 71	2
1658	Pneumonia in the very old. 2004 , 4, 112-24	327
1657	Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumonia. 2004 , 65, 225-38	6
1656	Prediction of outcome of acute GI hemorrhage: a review of risk scores and predictive models. 2004 , 60, 85-93	64

1655	Incremental value of upper endoscopy for triage of patients with acute non-variceal upper-GI hemorrhage. 2004 , 60, 9-14	59
1654	Endoscopic scoring system for Crohn's disease: viva the evolution!. 2004 , 60, 590-1	2
1653	Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. 2004 , 26, 48-62	52
1652	Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia. 2004 , 26, 294-303	15
1651	Limited impact of a multicenter intervention to improve the quality and efficiency of pneumonia care. 2004 , 126, 100-7	37
1650	Can we predict which children with clinically suspected pneumonia will have the presence of focal infiltrates on chest radiographs?. 2004 , 113, e186-9	72
1649	Community-acquired pneumonia-optimizing antibiotic usage. 2004 , 10 Suppl 1, S4-8	1
1648	Identifying strategies to improve outcomes and reduce costs-a role for the hospitalist. 2004 , 10 Suppl 1, S19-22	2
1647	The role of resistance and impact on appropriate antimicrobial use. 2004 , 11 Suppl 1, S1-8	
1646	Overview of national treatment guidelines for common respiratory tract infections. 2004 , 11 Suppl 1, S9-14	
1645	Severe community-acquired pneumonia. 2004 , 10, 369-74	20
1644	Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. 2004 , 32, 2398-402	38
1643	Recommendations for management of community- and hospital-acquired pneumonia-the hospitalist perspective. 2004 , 10 Suppl 1, S23-7	3
1642	Community acquired pneumonia. 2004 , 4, 224-8	1
1641	The Treatment of Community-Acquired Pneumonia. 2004 , 12, S6-S9	
1640	Pneumonia in the Elderly. 2004 , 11, 210-218	7
1639	Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. 2004 , 11, 433-42	23
1638	Infections ^pneumococque. 2004 , 1, 1-13	

1637	Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. 2004 , 32, 625-31	116
1636	Association between surfactant protein B + 1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia. 2004 , 32, 1115-9	116
1635	Community-Acquired Pneumonia. 2004 , 34, 212-217	1
1634	US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era. 2004 , 125, 548-56	8
1633	Plasma d-dimer for outcome assessment in patients with CAP: not a replacement for PSI. 2004 , 126, 1015-6	10
1632	Hospitalist Management of Community-Acquired Pneumonia. 2004 , 12, S17-S22	
1631	Factors influencing length of hospital stay in community-acquired pneumonia: a study in 27 community hospitals. 2004 , 132, 821-9	22
1630	Treating community-acquired pneumonia. 2004 , 29, 11-3	3
1629	Guidelines for community-acquired pneumonia in the ICU. 2004 , 10, 59-64	15
1628	Today's hospital-based case manager: how one hospital integrated/adopted evidenced-based medicine using InterQual criteria. 2004 , 9, 61-71	9
1627	Importance of severity of illness assessment in management of lower respiratory infections. 2004 , 17, 121-5	13
1626	A clinical prediction rule for diagnosing severe acute respiratory syndrome in the emergency department. 2004 , 141, 333-42	33
1625	Treatment costs of community-acquired pneumonia in an employed population. 2004 , 125, 2140-5	99
1624	Which strategies facilitate improvement in quality of care for elderly hospitalized pneumonia patients?. 2004 , 30, 25-35	6
1623	Physician-perceived barriers to adopting a critical pathway for unity-acquired pneumonia. 2004 , 30, 387-95	16
1622	Levofloxacin efficacy in the treatment of community-acquired legionellosis. 2004 , 125, 2135-9	78
1621	Clinical characteristics of pneumonia caused by penicillin resistant and sensitive Streptococcus pneumoniae in Japan. 2004 , 43, 1029-33	9
1620	Community acquired pneumonia in internal medicine: a one-year retrospective study based on pneumonia severity index. 2005 , 18, 575-86	9

1619	The effect of malnutrition on risk and outcome of community-acquired pneumonia. 2005 , 11, 99-108	17
1618	Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. 2005 , 128, 2223-9	145
1617	Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. 2005 , 128, 2230-7	60
1616	Cost analyses of community-acquired pneumonia from the hospital perspective. 2005 , 128, 2238-46	62
1615	Management of community-acquired pneumonia in the emergency room. 2005 , 11, 15-24	16
1614	What have we learned about how to measure quality of care for patients with community-acquired pneumonia?. 2005 , 11, 87-98	4
1613	Commentary: are care guidelines useful in community-acquired pneumonia? Value hinges on improving outcomes. 2005 , 118, 13-4, 17	1
1612	Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. 2005 , 33, 952-61	212
1611	Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. 2005 , 18, 157-63	28
1610	Does Antibiotic Choice Affect Length of Stay for Community-Acquired Pneumonia?. 2005 , 35, 25-27	2
1609	Progressive and nonresolving pneumonia. 2005 , 11, 247-52	5
1608	Administration of first hospital antibiotics for community-acquired pneumonia: does timeliness affect outcomes?. 2005 , 18, 151-6	31
1607	Are Blood Cultures Necessary in Community-Acquired Pneumonia?. 2005 , 12, 146-152	2
1606	Bacteremic pneumococcal pneumonia: a prospective study in Edmonton and neighboring municipalities. 2005 , 84, 147-161	35
1605	Should Do-Not-Resuscitate status be included as a mortality risk adjustor? The impact of DNR variations on performance reporting. 2005 , 43, 658-66	22
1604	Management of community-acquired pneumonia in the home: an American College of Chest Physicians clinical position statement. 2005 , 127, 1752-63	26
1603	Insurance status and access to urgent ambulatory care follow-up appointments. 2005 , 294, 1248-54	181
1602	Administration of first hospital antibiotics for community-acquired pneumonia: does timeliness affect outcomes?. 2005 , 4, 243-248	

1601	Do guidelines guide pneumonia practice? A systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia. 2005 , 11, 1-13	39
1600	Multicenter, multinational observational studies: a new approach to studying community-acquired pneumonia. 2005 , 11, 35-44	4
1599	Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. 2005 , 4, 249-255	
1598	Pneumonies communautaires graves de l'adulte. 2005 , 2, 1-18	
1597	[Effect on duration of antibiotic therapy and drug cost by introducing critical pathway for patients with CAP in Japan]. 2005 , 125, 659-63	
1596	Severe community-acquired pneumonia in an intensive care unit: risk factors for mortality. 2005 , 44, 710-6	42
1595	Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant <i>Streptococcus pneumoniae</i> . 2005 , 51, 201-5	6
1594	The vexatious vital: neither clinical measurements by nurses nor an electronic monitor provides accurate measurements of respiratory rate in triage. 2005 , 45, 68-76	170
1593	Do emergency department blood cultures change practice in patients with pneumonia?. 2005 , 46, 393-400	71
1592	Performance of a population-based cardiac risk stratification tool in Asian patients with chest pain. 2005 , 12, 423-30	14
1591	Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. 2005 , 11, 788-800	51
1590	Serum procalcitonin levels in patients with mild community-acquired pneumonia. 2005 , 11, 1050-1	7
1589	Pneumonia versus aspiration pneumonitis in nursing home residents: prospective application of a clinical algorithm. 2005 , 53, 755-61	38
1588	Community-acquired pneumonia in patients receiving home care. 2005 , 53, 834-9	10
1587	Hospitalization for pneumonia in the Cardiovascular Health Study: incidence, mortality, and influence on longer-term survival. 2005 , 53, 1108-16	50
1586	Usefulness of the Japanese Respiratory Society guidelines for community pneumonia: a retrospective analysis of community-acquired pneumonia between 2000 and 2002 in a general hospital. 2005 , 10, 208-14	8
1585	Severe community-acquired pneumonia: an Australian perspective. 2005 , 35, 699-705	48
1584	Community-acquired pneumonia in older adults. 2005 , 5, 75-81	

1583	B-type natriuretic peptide for risk stratification in community-acquired pneumonia. 2005 , 258, 391-3	44
1582	Predicting dire outcomes of patients with community acquired pneumonia. 2005 , 38, 347-66	38
1581	Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. 2005 , 20, 230-8	32
1580	Cuadro clínico y factores pronósticos de la neumonía adquirida en la comunidad grave en adultos hospitalizados en la unidad de cuidados intensivos. 2005 , 41, 20-26	10
1579	Pacientes ingresados por neumonía adquirida en la comunidad: estudio comparativo en función de la especialidad del servicio médico responsable. 2005 , 41, 300-306	11
1578	Neumonía: predecir la mala evolución. 2005 , 41, 475-477	3
1577	Evaluación pronóstica de las neumonías en pacientes con EPOC. 2005 , 41, 607-611	6
1576	Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials. 2005 , 25, 109S-123S	15
1575	Guías para el manejo de la neumonía comunitaria del adulto que precisa ingreso en el hospital. 2005 , 29, 21-62	5
1574	Community-acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome. 2005 , 51, 69-76	15
1573	Ambulant erworbene Pneumonie. 2005 , 2, 28-33	
1572	Agreement between emergency physician diagnosis and radiologist reports in patients discharged from an emergency department with community-acquired pneumonia. 2005 , 11, 242-6	29
1571	Role of beta-lactam agents in the treatment of community-acquired pneumonia. 2005 , 24, 83-99	23
1570	Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. 2005 , 24, 190-5	98
1569	Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. 2005 , 24, 241-9	119
1568	Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. 2005 , 24, 377-83	41
1567	Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. 2005 , 24, 367-76	37
1566	Sensitivity of urinary antigen test in relation to clinical severity in a large outbreak of Legionella pneumonia in Spain. 2005 , 24, 488-91	39

- 1565 Assessing, treating and preventing community acquired pneumonia in older adults: findings from a community-wide survey of emergency room and family physicians. **2005**, 6, 32 5
- 1564 The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. **2005**, 5, 12 41
- 1563 Pneumonia Guidelines in Practice. **2005**, 37-66
- 1562 Evaluaci3n de la gravedad en la neumon3a del adulto adquirida en la comunidad. **2005**, 22, s39
- 1561 Empiric management of community-acquired pneumonia in Australian emergency departments. **2005**, 183, 520-4 38
- 1560 Telithromycin: the first ketolide for the treatment of respiratory infections. **2005**, 62, 905-16 19
- 1559 Tratamiento de la neumon3a del adulto adquirida en la comunidad. **2005**, 21, 117
- 1558 Etiolog3a de la neumon3a adquirida en la comunidad en adultos hospitalizados en Santiago, Chile: implicancias para las gu3as cl3nicas. **2005**, 21, 23
- 1557 Pneumonien. **2005**, 373-386
- 1556 18.9 Verschattungen im Bereich der Herz-Zwerchfell-Winkel. **2005**,
- 1555 A Case of Rhabdomyolysis with Community Acquired Pneumonia. **2005**, 58, 59 1
- 1554 GP management of community-acquired pneumonia in Italy: the ISOCAP study. **2005**, 63, 23-9 3
- 1553 Neumon3a adquirida en la comunidad en adultos, en el curso de la campaa de invierno 2003 en el Hospital San Juan de D3os. **2005**, 21, 15
- 1552 Evaluaci3n de la gravedad en la neumon3a del adulto adquirida en la comunidad. **2005**, 21, 103
- 1551 Neumon3a grave del adulto adquirida en la comunidad. **2005**, 21, 111
- 1550 BTS Winter Meeting abstracts. **2005**, 60, 173-173 78
- 1549 Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. **2005**, 165, 1992-2000 79
- 1548 Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. **2005**, 294, 2712-9 307

1547	Plasma cell mucositis of the distal airways. 2005 , 60, 173	7
1546	HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. 2005 , 41, 554-6	25
1545	Increased circulating endothelial progenitor cells in patients with bacterial pneumonia: evidence that bone marrow derived cells contribute to lung repair. 2005 , 60, 410-3	110
1544	Management of nonsevere pneumonia in military trainees with the urinary antigen test for <i>Streptococcus pneumoniae</i> : an innovative approach to targeted therapy. 2005 , 40, 1608-16	48
1543	VEGF levels in pulmonary fibrosis. 2005 , 60, 171	5
1542	Host-pathogen relationships among <i>Escherichia coli</i> isolates recovered from men with febrile urinary tract infection. 2005 , 40, 813-22	30
1541	Quality of antibiotic use for lower respiratory tract infections at hospitals: (how) can we measure it?. 2005 , 41, 450-60	48
1540	Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. 2005 , 40, 800-6	108
1539	A prediction rule for clinical diagnosis of severe acute respiratory syndrome. 2005 , 26, 474-9	16
1538	Management of CAP using a validated risk score. 2005 , 60, 172-3	
1537	[S3-guideline on ambulant acquired pneumonia and deep airway infections]. 2005 , 59, 612-64	31
1536	Epidemiology of community- and nursing home-acquired pneumonia in older adults. 2005 , 3, 263-70	12
1535	Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. 2005 , 172, 757-62	128
1534	Costs and Outcomes of Extended-Release vs. Immediate-Release Clarithromycin for Lower Respiratory Tract Infections. 2005 , 2, 217-223	1
1533	Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. 2005 , 41, 1697-705	78
1532	Applicability of prediction rules in patients with community-acquired pneumonia requiring intensive care: a pilot study. 2005 , 20, 226-32	5
1531	Prognostic factors for serious morbidity and mortality from community-acquired lower respiratory tract infections among the elderly in primary care. 2005 , 22, 375-80	41
1530	The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. 2005 , 28, 810-5	325

1529	Quality of medical care during and shortly after acute care restructuring in Newfoundland and Labrador. 2005 , 10 Suppl 2, S2:38-47	6
1528	Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin. 2005 , 51, 186-92	13
1527	Vitamin E supplements in asthma. 2005 , 60, 171-2; author reply 172	3
1526	Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. 2005 , 49, 4035-41	56
1525	Short-Course Antimicrobial Therapy for the Treatment of Pneumonia. 2005 , 18, 18-24	3
1524	Antibiotics for Life-Threatening Illness. 2005 , 18, 336-350	
1523	Severe Acute Respiratory Syndrome (SARS): A Brief Review With Exploration of the Outcomes, Prognostic Factors and Sequelae. 2005 , 1, 85-92	2
1522	Severe Community-Acquired Pneumonia (CAP) due to Atypical Pathogens. 2005 , 1, 265-271	
1521	Total antioxidant status and severity of community-acquired pneumonia: are they correlated?. 2005 , 72, 381-7	13
1520	Factors influencing length of hospital stay in patients with bacterial pleural effusion. 2005 , 72, 587-93	13
1519	Prevalence of TB in healthcare workers in south west London. 2005 , 60, 173-173	78
1518	Accuracy of administrative data for identifying patients with pneumonia. 2005 , 20, 319-28	159
1517	Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. 2005 , 41, 345-51	237
1516	Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. 2005 , 40, 794-9	109
1515	Reply to De Maria et al.. 2005 , 40, 1375-1376	
1514	Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. 2005 , 41, 1438-44	164
1513	Important factors to consider for patients with community-acquired pneumonia. 2005 , 40, 1374-5; author reply 1375-6	1
1512	Asthma deaths and bronchodilator therapy. 2005 , 60, 413-413	78

1511	Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. 2005 , 128, 3854-62	811
1510	Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. 2005 , 17, 636-42	9
1509	Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. 2005 , 128, 3233-9	113
1508	Reappraisal of Clindamycin IV Monotherapy for Treatment of Mild-to-Moderate Aspiration Pneumonia in Elderly Patients. 2005 , 127, 1276-1282	3
1507	Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. 2005 , 127, 1260-70	46
1506	The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. 2005 , 128, 940-6	49
1505	Significance of atypical pathogens among community-acquired pneumonia adult patients admitted to hospital in Kuwait. 2005 , 14, 235-40	12
1504	The spectrum of infection-related morbidity in hospitalized haemodialysis patients. 2005 , 20, 1180-6	48
1503	Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. 2005 , CD004418	14
1502	A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. 2005 , 27, 1251-9	32
1501	The acute chest syndrome. 2005 , 19, 857-79, vi-vii	19
1500	[Appropriate use of antibiotics in hospitals. Investigating clinical practices in management of community-acquired pneumonia]. 2005 , 34, 1687-95	3
1499	Guidelines for the management of adult lower respiratory tract infections. 2005 , 26, 1138-80	501
1498	Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults. 2005 , 37, 791-805	35
1497	Pneumonia in hospitalized children. 2005 , 52, 1059-81, viii	21
1496	Antimicrobial treatment of community-acquired pneumonia. 2005 , 26, 65-73	10
1495	Insuficiencia respiratoria aguda. Diagnóstico y tratamiento. 2005 , 9, 1-8	
1494	Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors. 2005 , 56, 575-82	42

1493	An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care. 2005 , 21, 261-70	
1492	Utility of a pneumonia severity index in the optimization of the diagnostic and therapeutic effort for community-acquired pneumonia. 2005 , 37, 657-63	23
1491	Bench-to-bedside review: outcome predictions for critically ill patients in the emergency department. 2005 , 9, 376-83	42
1490	Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. 2005 , 330, 456	119
1489	Using randomized controlled trial data, the agreement between retrospectively and prospectively collected data comprising the pneumonia severity index was substantial. 2005 , 58, 357-63	10
1488	[Antibiotic in general and current practice in lower respiratory tract infections in adults and children. Arguments]. 2005 , 35, 635-94	5
1487	Pneumonies communautaires graves de l'adulte. 2005 , 2, 141-166	
1486	Etiology of community-acquired pneumonia treated in an ambulatory setting. 2005 , 99, 60-5	52
1485	Management of community-acquired pneumonia and secular trends at different hospitals. 2005 , 99, 268-78	14
1484	Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. 2005 , 99, 1079-86	78
1483	Etiology and outcomes of veterans with spinal cord injury and disorders hospitalized with community-acquired pneumonia. 2005 , 86, 262-7	12
1482	Arterial carbon dioxide tension on admission as a marker of in-hospital mortality in community-acquired pneumonia. 2005 , 118, 145-50	41
1481	Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. 2005 , 118, 384-92	231
1480	Community-acquired pneumonia as the initial manifestation of serious underlying diseases. 2005 , 118, 378-83	17
1479	Low-risk patients admitted with community-acquired pneumonia. 2005 , 118, 1357-63	43
1478	Clinical opinion prevails over the pneumonia severity index. 2005 , 118, 1312-3	9
1477	Cartas al director. 2005 , 124, 277-278	1
1476	[Significance of functional status in mortality of hospitalized elderly people]. 2005 , 124, 278; author reply 278-9	

1475 Cartas al director. **2005**, 124, 278-279

1474 [Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant *Streptococcus pneumoniae* and complicated with empyema]. **2005**, 23, 270-3 7

1473 The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. **2005**, 6, 82 134

1472 Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy. **2005**, 65, 1949-71 6

1471 Efficacy and tolerability of sequential intravenous/oral moxifloxacin therapy in pneumonia: results of the first post-marketing surveillance study with intravenous moxifloxacin in hospital practice. **2005**, 25, 691-700 8

1470 Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). **2005**, 41, 272-289 41

1469 [Patients hospitalized with community-acquired pneumonia: a comparative study of outcomes by medical specialty area]. **2005**, 41, 300-6 1

1468 [Predicting poor outcome of pneumonia]. **2005**, 41, 475-7 1

1467 [Prognosis in patients with pneumonia and chronic obstructive pulmonary disease]. **2005**, 41, 607-11 12

1466 [Clinical picture and prognostic factors for severe community-acquired pneumonia in adults admitted to the intensive care unit]. **2005**, 41, 20-6 5

1465 Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. **2005**, 25, 75-83 37

1464 Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for *Streptococcus pneumoniae*. **2005**, 26, 120-5 19

1463 Community-acquired pneumonia in northern Australia: low mortality in a tropical region using locally-developed treatment guidelines. **2005**, 9, 15-20 27

1462 Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. **2005**, 60, 672-8 107

1461 Should I hospitalize my resident with nursing home-acquired pneumonia?. **2005**, 6, 327-33 40

1460 Short-course antimicrobial therapy for community-acquired pneumonia. **2005**, 4, 231-9 7

1459 Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles. **2005**, 3, 353-60 2

1458 Management of severe bacterial infections. **2005**, 3, 593-600 9

- 1457 Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. **2005**, 142, 165-72 165
- 1456 Nursing home-acquired pneumonia: update on treatment options. **2006**, 23, 377-90 15
- 1455 Neumonías comunitarias graves del adulto. **2006**, 32, 1-20
- 1454 Antibiothérapie aux urgences. **2006**, 15, 514-522 2
- 1453 Adverse outcomes in patients with community acquired pneumonia discharged with clinical instability from Internal Medicine Department. **2006**, 38, 860-6 7
- 1452 Infectious emergencies in the elderly. **2006**, 24, 433-48, viii 16
- 1451 Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. **2006**, 42, 73-81 64
- 1450 Desarrollo y proceso de mejora de la práctica clínica de Neumonía adquirida en la comunidad con ingreso hospitalario en un hospital de ámbito comarcal. **2006**, 21, 299-310 1
- 1449 Neumonía adquirida en la comunidad en el anciano. **2006**, 41, 7-12 0
- 1448 Estrategias diagnósticas en enfermedades infecciosas. **2006**, 9, 3188-3195
- 1447 Protocolo terapéutico de las infecciones de las vías respiratorias bajas en adultos. **2006**, 9, 3297-3301
- 1446 Criterios de ingreso hospitalario desde Urgencias en pacientes con patología respiratoria. **2006**, 9, 4292-4295
- 1445 Empleo de antibióticos empíricos en los síndromes infecciosos en Urgencias. **2006**, 9, 4450-4458
- 1444 Inpatient disposition classification for the creation of hospital surge capacity: a multiphase study. **2006**, 368, 1984-90 89
- 1443 Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. **2006**, 174, 84-93 702
- 1442 [Legionnaire's disease outbreak]. **2006**, 126, 178-82 2
- 1441 Synthèse : score pronostique des pneumonies. **2006**, 23, 31-32 0
- 1440 Should I hospitalize my resident with nursing home-acquired pneumonia?. **2006**, 7, S74-80, 73 18

1439	Indication, intérêts et limites de la déescalade antibiotique en réanimation. 2006 , 15, 159-167	1
1438	Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. 2006 , 81, 1567-74	21
1437	[Evaluation of clinical practice in patients admitted with community-acquired pneumonia over a 4-year period]. 2006 , 42, 283-9	1
1436	Treatment and Course of Community-Acquired Pneumonia Caused by Atypical Pathogens. 2006 , 42, 430-433	
1435	[Lung cancer diagnosis: hospitalization costs]. 2006 , 42, 569-74	8
1434	[Treatment for Legionnaires' disease. Macrolides or quinolones?]. 2006 , 24, 360-4	13
1433	[Prognostic factors of community acquired pneumonia in very old patients]. 2006 , 127, 201-5	8
1432	[Pneumonia in the elderly: old challenge, new perspectives]. 2006 , 127, 214-5	
1431	[EVAN-50 study: Effectiveness of polysaccharide pneumococcus vaccine in preventing pneumococcal infections in the over-50 population]. 2006 , 38, 299-303	
1430	Enhancing the etiologic diagnosis of community-acquired pneumonia in adults using the urinary antigen assay (Binax NOW). 2006 , 10, 124-8	26
1429	The impact of empiric antimicrobial therapy with a ß-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. 2005 , 10, R8	47
1428	Do fluoroquinolones actually increase mortality in community-acquired pneumonia?. 2006 , 10, 403; author reply 403	
1427	Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. 2006 , 10, R97	95
1426	Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. 2006 , 10, R96	162
1425	Managing acute lower respiratory tract infections in an era of antibacterial resistance. 2006 , 24, 329-42	14
1424	In-hospital observation after antibiotic switch in pneumonia: a national evaluation. 2006 , 119, 512.e1-7	22
1423	Current concepts in validity and reliability for psychometric instruments: theory and application. 2006 , 119, 166.e7-16	762
1422	Pneumonia during pregnancy. 2006 , 119, 872-6	23

1421	Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. 2006 , 119, 865-71	106
1420	Antibiotic therapy and 48-hour mortality for patients with pneumonia. 2006 , 119, 859-64	45
1419	Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals. 2006 , 54, 267-75	7
1418	Biochemical and immunologic features of an outbreak of Legionnaires disease: comparative study between community-acquired pneumonias. 2006 , 56, 7-11	6
1417	Whatever happened to the doctor's bag?. 2006 , 17, 1-2	
1416	[Acute community-acquired pneumonia. A review of clinical trials]. 2006 , 36, 650-66	1
1415	[Antibiotherapy for acute CAP in adults]. 2006 , 36, 718-33	1
1414	[Assessment, triage, and follow-up of a patient with: acute CAP COPD]. 2006 , 36, 734-83	
1413	[Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features]. 2006 , 36, 784-802	3
1412	Prise en charge des infections des voies respiratoires basses de l'adulte immunocompetent. Texte long. 2006 , 36, S231-S261	1
1411	[Follow-up criteria for community acquired pneumonias and acute exacerbations of chronic obstructive pulmonary disease]. 2006 , 36, 636-49	1
1410	Predictors of mortality for lower respiratory infections in nursing home residents with dementia were validated transnationally. 2006 , 59, 970-9	47
1409	Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones. 2006 , 30, 377-87	9
1408	Mycoplasma pneumoniae: usual suspect and unsecured diagnosis in the acute setting. 2006 , 30, 371-5	8
1407	Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia. 2006 , 100, 577-85	13
1406	Prior outpatient antibacterial therapy as prognostic factor for mortality in hospitalized pneumonia patients. 2006 , 100, 1342-8	8
1405	Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. 2006 , 100, 2129-36	38
1404	Clinical prognostic rules for severe acute respiratory syndrome in low- and high-resource settings. 2006 , 166, 1505-11	11

1403	Rodent-associated Bartonella febrile illness, Southwestern United States. 2006 , 12, 1081-6	29
1402	[Ambulatory management of community acquired pneumonia in the elderly]. 2006 , 134, 1568-75	1
1401	Risk Factors for Mortality in Community-Acquired Pneumonia Patients Admitted to a Referral Hospital. 2006 , 61, 347	1
1400	A survey on hospitalised community-acquired pneumonia in Italy. 2006 , 65, 82-8	5
1399	[Etiology and prognostics factors of community-acquired pneumonia among adults patients admitted to a regional hospital in Chile]. 2006 , 134, 597-605	4
1398	Discharge Delay in Patients with Community-acquired Pneumonia Managed on a Critical Pathway. 2006 , 17, 109-13	6
1397	Factors associated with length of stay in hospital for suspected community-acquired pneumonia. 2006 , 13, 317-24	17
1396	Pneumonia severity index in the immunocompromised. 2006 , 13, 89-93	25
1395	Conundrums in community-acquired pneumonia. 2006 , 185, 131-2	4
1394	Enfermedades infecciosas de los pulmones. 2006 , 222-336	1
1393	The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. 2006 , 45, 419-28	178
1392	Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. 2006 , 45, 995-9	15
1391	Antimicrobial treatment of community-acquired pneumonia in the elderly. 2006 , 2, 999-1011	3
1390	CAP Management Guidelines. 2006 , 31, 43-53	2
1389	Community-Acquired Pneumonia. 2006 ,	
1388	Volume, quality of care, and outcome in pneumonia. 2006 , 144, 262-9	50
1387	Antibiotics and pneumonia: is timing everything or just a cause of more problems?. 2006 , 130, 1-3	22
1386	Pulse oximetry revisited: "but his O(2) sat was normal!". 2006 , 20, 268-72	9

1385 Insuffisance respiratoire aiguë. Démarches diagnostique et thérapeutique. **2006**, 1, 1-8

1384 Outcomes of outpatient visits for acute respiratory illness in veterans with spinal cord injuries and disorders. **2006**, 85, 718-26

20

1383 Physical Medicine and Rehabilitation Board Review. **2006**, 85, 726

1382 Lower respiratory infections and potential complications in athletes. **2006**, 5, 80-6

11

1381 Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?. **2006**, 129, 968-78

126

1380 CAP Management Guidelines. **2006**, 31, 43-53

4

1379 Impact of Antibiotic Guideline Compliance on Duration of Mechanical Ventilation in Critically Ill Patients With Community-Acquired Pneumonia. **2006**, 130, 93-100

75

1378 Eighteenth Annual Legislative Update. **2006**, 31, 12-38

1377 Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by *Streptococcus pneumoniae*. **2006**, 130, 807-14

27

1376 Snapshots for November 2006. **2006**, 14, 341-344

1375 Round Pneumonia in Adults, an Unusual Presentation of Lung Parenchymal Infection. **2006**, 13, 229-231

5

1374 Moxifloxacin in the treatment of elderly patients with community-acquired pneumonia. **2006**, 2, 383-393

1373 The role of new therapies for severe community-acquired pneumonia. **2006**, 19, 557-64

6

1372 Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. **2006**, 34, 2588-95

223

1371 Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. **2006**, 130, 1165-72

59

1370 Guidelines for the management of adults with health care-associated pneumonia: implications for nursing facility residents. **2006**, 21, 719-25

5

1369 Did you know?. **2006**, 48, 592

1368 Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. **2006**, 6, 12

47

1367	Development and validation of a clinical prediction rule to distinguish bacterial from viral pneumonia in children. 2006 , 41, 331-7	40
1366	Impact of antibiotic restrictions: the physician's perspective. 2006 , 12 Suppl 5, 3-9	7
1365	Impact of antibiotic restrictions: the ethical perspective. 2006 , 12 Suppl 5, 16-24	22
1364	Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. 2006 , 12, 1097-104	27
1363	Markers of acute inflammation in assessing and managing lower respiratory tract infections: focus on procalcitonin. 2006 , 12, 8-16	14
1362	Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. 2006 , 21, 745-52	29
1361	Occurrence and treatment of suspected pneumonia in long-term care residents dying with advanced dementia. 2006 , 54, 290-5	66
1360	Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. 2006 , 54, 296-302	80
1359	Studies of respiratory tract infection in nursing home residents: what are we learning?. 2006 , 54, 362-4	1
1358	Assessment of pneumonia in older adults: effect of functional status. 2006 , 54, 1062-7	55
1357	A validation and potential modification of the pneumonia severity index in elderly patients with community-acquired pneumonia. 2006 , 54, 1212-9	31
1356	Survival to discharge among patients treated with continuous renal replacement therapy. 2006 , 10, 82-7	30
1355	Mannose-binding lectin does not act as an acute-phase reactant in adults with community-acquired pneumococcal pneumonia. 2006 , 145, 228-34	38
1354	CRB-65 predicts death from community-acquired pneumonia. 2006 , 260, 93-101	193
1353	Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. 2006 , 260, 568-76	51
1352	Prospective validation of the San Francisco Syncope Rule: will it change practice?. 2006 , 47, 455-6	5
1351	Dear SIRS: it's time to return to sepsis as we have known it. 2006 , 48, 591-2	11
1350	The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. 2006 , 53, 166-74	143

1349	Treatment of pneumonia in elderly patients. 2006 , 7, 499-507	14
1348	Profiles in patient safety: Antibiotic timing in pneumonia and pay-for-performance. 2006 , 13, 787-90	30
1347	Systematic delays in antibiotic administration in the emergency department for adult patients admitted with pneumonia. 2006 , 13, 939-45	23
1346	Improving ambulatory prescribing safety with a handheld decision support system: a randomized controlled trial. 2006 , 13, 171-9	52
1345	Use of a personal digital assistant for managing antibiotic prescribing for outpatient respiratory tract infections in rural communities. 2006 , 13, 627-34	35
1344	Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. 2006 , 118, 170-4	26
1343	Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. 2006 , 25, 159-66	34
1342	Clinical outcomes of bacteremic pneumococcal infections in an area with high resistance. 2006 , 25, 323-7	20
1341	Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. 2006 , 25, 457-62	51
1340	Optimal therapy for severe pneumococcal community-acquired pneumonia. 2006 , 32, 971-80	24
1339	[Pneumonia - pathogen-based or constellation-based therapy?]. 2006 , 47 Suppl 1, S14-9	
1338	Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. 2006 , 52, 169-77	52
1337	Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment. 2006 , 34, 190-5	8
1336	Comparison of surgical outcome using the prediction scoring system of E-PASS for thoracic surgery. 2006 , 54, 391-5	7
1335	[Community acquired pneumonia CAP]. 2006 , 118, 153-75	1
1334	Coste hospitalario del diagnóstico del cáncer de pulmón. 2006 , 42, 569-574	11
1333	Socioeconomic status and hospital utilization among younger adult pneumonia admissions at a Canadian hospital. 2006 , 6, 152	17
1332	Evaluación de la práctica clínica en los pacientes ingresados por neumonía adquirida en la comunidad durante un período de 4 años. 2006 , 42, 283-289	10

1331	Neumonía adquirida en la comunidad por gérmenes atípicos: tratamiento y evolución. 2006 , 42, 430-433	5
1330	Community-acquired pneumonia: defining quality care. 2006 , 1, 344-53	12
1329	"Above or below?". 2006 , 1, 36-41	1
1328	Effectiveness of ceftriaxone plus doxycycline in the treatment of patients hospitalized with community-acquired pneumonia. 2006 , 1, 7-12	11
1327	Community-acquired pneumonia: a practical approach to management for the hospitalist. 2006 , 1, 177-90	4
1326	Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. 2006 , 129, 1219-25	118
1325	Fulminant community-acquired <i>Acinetobacter baumannii</i> pneumonia as a distinct clinical syndrome. 2006 , 129, 102-9	122
1324	Short- and Long-term Functional Outcome of Hospitalized Older Adults With Community-acquired Pneumonia. 2006 , 14, 365-368	1
1323	Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. 2006 , 130, 11-5	112
1322	Adverse Events in Patients With Community-Acquired Pneumonia at an Academic Tertiary Emergency Department. 2006 , 14, 350-359	1
1321	Pneumonia: update on diagnosis and management. 2006 , 332, 1077-9	64
1320	Statins and outcomes in patients with pneumonia: not only healthy user bias. 2006 , 333, 1123-4	4
1319	Validation of a model to predict adverse outcomes in patients with pulmonary embolism. 2006 , 27, 476-81	201
1318	Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. 2006 , 333, 999	188
1317	Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. 2006 , 333, 1193	113
1316	Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. 2006 , 332, 1355	190
1315	Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations. 2006 , 3, 252-6	18
1314	Decision rules and pneumonia: What are we "predicting," and for whom?. 2006 , 174, 1169-70	4

1313	Pneumonia in the Elderly. 2006 , 2, 75-87	1
1312	A prediction rule to identify low-risk patients with pulmonary embolism. 2006 , 166, 169-75	110
1311	Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. 2006 , 27, 9-11	49
1310	PNEUMONIA Community Acquired Pneumonia, Bacterial and Other Common Pathogens. 2006 , 417-431	
1309	Information technology for optimizing the management of infectious diseases. 2006 , 63, 957-65	12
1308	Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. 2006 , 28, 695-702	58
1307	Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations. 2006 , 42, 1345-7; author reply 1347-8	2
1306	Can we rely on blood urea nitrogen as a biomarker to determine when to initiate dialysis?. 2006 , 1, 903-4	34
1305	Validation of a predictive rule for the management of community-acquired pneumonia. 2006 , 27, 151-7	247
1304	Mortality in COPD patients with community-acquired pneumonia: who is the third partner?. 2006 , 28, 262-3	21
1303	Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. 2006 , 27, 1010-9	66
1302	Still awaiting a useful tool for predicting severe CAP. 2006 , 61, 1098; author reply 1098-9	
1301	Mixed community-acquired pneumonia in hospitalised patients. 2006 , 27, 795-800	71
1300	Assessment of pneumonia severity: a European perspective. 2006 , 27, 6-8	46
1299	Queen of Punt. 2006 , 42, 1344-5	3
1298	Bacterial co-infection and interpretation of immunological data from BAL fluid specimens in severe RSV bronchiolitis. 2006 , 61, 1098	1
1297	Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. 2006 , 50, 1164-9	10
1296	Sporadic and epidemic community legionellosis: two faces of the same illness. 2007 , 29, 138-42	24

1295	Reply to Bodi et al. 2006 , 42, 1345	3
1294	Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. 2006 , 42, 1093-101	125
1293	Infection Management for Geriatrics in Long-Term Care Facilities. 2006 ,	1
1292	Obesity and Diabetes. 2006 ,	4
1291	Disorders of the Respiratory Tract. 2006 ,	1
1290	COPD is associated with increased mortality in patients with community-acquired pneumonia. 2006 , 28, 346-51	191
1289	Wide geographic variation between Pennsylvania counties in the population rates of hospital admissions for pneumonia among children with and without comorbid chronic conditions. 2006 , 117, 176-80	17
1288	Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant <i>Streptococcus pneumoniae</i> . 2006 , 57, 536-45	16
1287	A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. 2006 , 61, 419-24	123
1286	Development and validation of a clinical prediction rule for severe community-acquired pneumonia. 2006 , 174, 1249-56	229
1285	Severity assessment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients. Should SOAR (systolic blood pressure, oxygenation, age and respiratory rate) criteria be used in older people? A compilation study of two prospective cohorts. 2006 , 35, 286-91	95
1284	Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. 2006 , 27, 1210-6	132
1283	Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. 2007 , 30, 517-24	39
1282	Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. 2007 , 45, 983-91	47
1281	Hospital-acquired hyponatremia--why are hypotonic parenteral fluids still being used?. 2007 , 3, 374-82	99
1280	Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. 2007 , 53, 2193-201	43
1279	Pneumonia. 2007 , 351-357	
1278	Unplayed Melodies: Javanese Gamelan and the Genesis of Music Theory:Unplayed Melodies: Javanese Gamelan and the Genesis of Music Theory. 2007 , 29, 247-253	

1277	A worldwide perspective of atypical pathogens in community-acquired pneumonia. 2007 , 175, 1086-93	171
1276	Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. 2007 , 167, 1655-63	527
1275	Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. 2007 , 176, 913-20	606
1274	Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. 2007 , 131, 466-73	132
1273	Treatment failure in community-acquired pneumonia. 2007 , 132, 1348-55	56
1272	Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. 2007 , 131, 1865-9	167
1271	Pneumonia severity related to detection of pneumococcal polysaccharides in urine and serum. 2007 , 39, 645-8	1
1270	Clinical characteristics of pneumonia caused by beta-lactamase negative ampicillin resistant Haemophilus influenzae (BLNAR). 2007 , 39, 521-4	4
1269	One More Prediction Rule: Has Anything New Been Added?. 2007 , 175, 743-743	1
1268	Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. 2007 , 56, 1625-1629	76
1267	The Pneumonia Severity Index score: time to move to a prospective study of patients with community-acquired pneumonia who are discharged from emergency departments to be managed on an ambulatory basis. 2007 , 44, 50-2	41
1266	Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. 2007 , 44, 41-9	83
1265	Severe community-acquired pneumonia: approach to therapy. 2007 , 8, 593-606	5
1264	Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. 2007 , 62, 348-53	116
1263	Effects of systemic steroids in patients with severe community-acquired pneumonia. 2007 , 30, 951-6	1144
1262	Severity assessment in community-acquired pneumonia: moving on. 2007 , 62, 287-8	2
1261	Pulmonary exacerbations in cystic fibrosis and bronchiectasis. 2007 , 62, 288-90	17
1260	A prediction rule for elderly primary-care patients with lower respiratory tract infections. 2007 , 29, 969-75	37

1259	Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia. 2007 , 60, 1131-6	10
1258	Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. 2007 , 167, 1393-9	223
1257	Is co-morbidity taken into account in the antibiotic management of elderly patients with acute bronchitis and COPD exacerbations?. 2007 , 24, 317-22	11
1256	The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. 2007 , 62, 253-9	90
1255	Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. 2007 , 60, 112-20	56
1254	Evaluating the use of a Streptococcus pneumoniae urinary antigen detection kit for the management of community-acquired pneumonia in Japan. 2007 , 74, 387-93	27
1253	Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia. 2007 , 45, 1326-31	7
1252	Optimal Treatment of Severe Community-Acquired Pneumonia. 2007 , 3, 233-239	
1251	Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. 2007 , 59, 977-89	20
1250	Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia. 2007 , 29, 751-6	24
1249	Ethical triage and scarce resource allocation during public health emergencies: tenets and procedures. 2007 , 85, 16-25	25
1248	The association between pneumococcal pneumonia and acute cardiac events. 2007 , 45, 158-65	226
1247	Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. 2007 , CD004400	21
1246	The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. 2007 , 167, 1664-9	29
1245	Management and prevention strategies for community-acquired pneumonia in the Gulf Corporation Council. 2007 , 19 Suppl 1, 33-46	12
1244	[Purpura fulminans due to pneumococcal pneumonia in a healthy adult: a case report]. 2007 , 81, 194-9	
1243	Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. 2007 , 132, 515-22	85
1242	Risk indexes for exacerbations and hospitalizations due to COPD. 2007 , 131, 20-8	154

1241	Contribution of a pleural antigen assay (Binax NOW) to the diagnosis of pneumococcal pneumonia. 2007 , 131, 1442-7	47
1240	Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. 2007 , 26, 868-78	58
1239	Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. 2007 , 35, 2509-14	85
1238	Predicting outcomes of primary care patients with major depression: development of a depression prognosis index. 2007 , 58, 1049-56	35
1237	Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in community-acquired pneumonia. 2007 , 35, 990-1	34
1236	Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. 2007 , 13, 578-85	85
1235	Prognostic scoring systems: which one is best?. 2007 , 20, 165-9	8
1234	Necrotizing Pneumonia and Pulmonary Gangrene. 2007 , 14, 166-170	1
1233	Using automated clinical data for risk adjustment: development and validation of six disease-specific mortality predictive models for pay-for-performance. 2007 , 45, 789-805	90
1232	One more prediction rule: has anything new been added?. 2007 , 175, 743; author reply 743-4	
1231	Imagerie des infections pulmonaires bactériennes chez le patient immunocompétent. 2007 , 2, 1-20	1
1230	Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: A propensity-adjusted analysis. 2007 , 131, 480-8	47
1229	Etiology of community-acquired pneumonia in hospitalized patients in chile: the increasing prevalence of respiratory viruses among classic pathogens. 2007 , 131, 779-787	78
1228	Community-acquired pneumonia: what is relevant and what is not?. 2007 , 13, 177-85	10
1227	New guidelines for the management of adult community-acquired pneumonia. 2007 , 20, 170-6	15
1226	Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. 2007 , 35, 1061-7	187
1225	Timing of antibiotics in CAP. 2007 , 20, 341-345	
1224	Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. 2007 , 167, 53-9	43

1223	Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. 2007 , 167, 1938-43	88
1222	A case series of macrolide treatment failures in community acquired pneumonia. 2007 , 19, 536-45	23
1221	Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. 2007 , 86, 103-111	80
1220	An exploratory spatial analysis of pneumonia and influenza hospitalizations in Ontario by age and gender. 2007 , 135, 253-61	50
1219	[Pronostic value of C-reactive protein measure in elderly patient with acquired pneumonia: correlation with Fine's score]. 2007 , 28, 213-7	1
1218	100 years of respiratory medicine: pneumonia. 2007 , 101, 875-81	10
1217	Managing community-acquired pneumonia: a European perspective. 2007 , 101, 1864-73	40
1216	Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. 2007 , 101, 1909-15	23
1215	Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study. 2007 , 101, 2168-75	22
1214	Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. 2007 , 101, 2139-44	57
1213	Vital-sign abnormalities as predictors of pneumonia in adults with acute cough illness. 2007 , 25, 631-6	22
1212	Using the pneumonia severity index to guide hospitalization decisions. 2007 , 120, e21	1
1211	Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. 2007 , 120, 783-90	125
1210	[Initial management of severe sepsis in adults and children]. 2007 , 26, 53-73	14
1209	Characteristics of low-risk patients hospitalized with community-acquired pneumonia. 2007 , 18, 209-14	10
1208	Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. 2007 , 38, 117-23	79
1207	Macro and microvascular complications are determinants of increased infection-related mortality in Brazilian type 2 diabetes mellitus patients. 2007 , 75, 51-8	18
1206	Managing postacute hospital care: a case for biopsychosocial needs. 2007 , 62, 513-9	8

1205	Selective use of blood cultures in emergency department pneumonia patients. 2007 , 33, 1-8	40
1204	Respiratory rate at rest was not associated with long-term mortality in healthy males. 2007 , 60, 742-5	1
1203	International classification of diseases codes showed modest sensitivity for detecting community-acquired pneumonia. 2007 , 60, 834-8	78
1202	Infecciones respiratorias. 2007 , 42, 51-59	1
1201	Neumonía en Urgencias. 2007 , 9, 5787-5792	
1200	Avances en la antibioterapia empírica. Aplicaciones prácticas al tratamiento de las neumonías, de las infecciones urinarias, abdominales, de partes blandas y de sepsis de origen desconocido. 2007 , 9, 5959-5966	
1199	Diagnostic and Prognostic Value of Hormokines as Biomarkers in Severe Infections. 2007 , 22-31	
1198	Obtaining Positive Outcomes with Insulin Therapy in Hospitalized Patients. 2007 , 2, S47-S56	2
1197	Predictive value of serial measurements of sTREM-1 in the treatment response of patients with community-acquired pneumonia. 2007 , 106, 187-95	10
1196	Hyponatremia in community-acquired pneumonia. 2007 , 27, 184-90	101
1195	[Evaluating care in community acquired pneumonia]. 2007 , 24, 183-96	0
1194	A Bayesian Adjustment for Covariate Misclassification with Correlated Binary Outcome Data. 2007 , 34, 1019-1034	7
1193	Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US. 2007 , 25, 677-83	7
1192	Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. 2007 , 51, 3977-82	76
1191	Cost effectiveness of oseltamivir for the treatment of influenza in adults, adolescents and children in Finland. 2007 , 10, 199-214	1
1190	Type 2 diabetes and pneumonia outcomes: a population-based cohort study. 2007 , 30, 2251-7	161
1189	Diagnosis and treatment of severe sepsis. 2007 , 11 Suppl 5, S2	28
1188	Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. 2007 , 30, 556-73	200

1187	Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. 2007 , 28, 1290-8	116
1186	Endocrine aspects of critical illness. 2007 , 68, 290-8	11
1185	Diagnosis and treatment of acute otitis media: evaluating the evidence. 2007 , 21, 409-26, vi	11
1184	Prise en charge initiale des états septiques graves de l'adulte et de l'enfant. 2007 , 16, S1-S21	18
1183	Infections respiratoires des sujets âgés : intérêt d'une structure spécialisée. 2007 , 9, 233-236	0
1182	Bacterial community-acquired pneumonia in older patients. 2007 , 23, 515-34, vi	35
1181	Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. 2007 , 44 Suppl 2, S27-72	4193
1180	Infections in the elderly. 2007 , 23, 441-56, viii	66
1179	Fallacious reasoning and complexity as root causes of clinical inertia. 2007 , 8, 349-54	18
1178	Pneumonies infectieuses du sujet âgé : particularités étiologiques et approche thérapeutique. 2007 , 7, 39-44	
1177	Acute respiratory infections in persons with spinal cord injury. 2007 , 18, 203-16, v-vi	26
1176	[Community-acquired respiratory infections in non-immunocompromised adults]. 2007 , 24, 381-6	1
1175	[Pneumonia in the elderly population over 70 years with limited functional condition: case-control study of institutionalized patients]. 2007 , 207, 548-54	0
1174	[Importance of advanced age in infections: myth and reality]. 2007 , 25, 609-11	3
1173	Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. 2007 , 67, 773-92	18
1172	What drives our choices? Evidence, guidelines or habit?. 2007 , 29 Suppl 1, S17-22	4
1171	Drug Development. 2007 , 173-202	1
1170	Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. 2007 , 14, 212-6	19

1169	Health care-associated <i>Staphylococcus aureus</i> pneumonia. 2007 , 18, 181-8	11
1168	Community-Acquired Pneumonia. 2007 , 260-277	
1167	Use of elastin fibres detected in non-directed low volume bronchial lavage in ventilated ICU patients. 2007 , 35, 189-93	
1166	Generation of knowledge for clinical decision support. 2007 , 227-248	4
1165	Conundrums in community-acquired pneumonia. 2007 , 186, 102; author reply 103	0
1164	Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. 2007 , 56, 2679-86	38
1163	Which observations from the complete blood cell count predict mortality for hospitalized patients?. 2007 , 2, 5-12	20
1162	Using discordance to improve classification in narrative clinical databases: an application to community-acquired pneumonia. 2007 , 37, 296-304	19
1161	Knowledge translation: closing the evidence-to-practice gap. 2007 , 49, 355-63	194
1160	Unanticipated death after discharge home from the emergency department. 2007 , 49, 735-45	69
1159	Comparison of four clinical prediction rules for estimating risk in heart failure. 2007 , 50, 127-35, 135.e1-2	38
1158	The impact of emergency department crowding measures on time to antibiotics for patients with community-acquired pneumonia. 2007 , 50, 510-6	220
1157	Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. 2007 , 7, 10	254
1156	Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. 2007 , 12, 111-6	33
1155	Community-acquired pneumonia: an Asia Pacific perspective. 2007 , 12, 162-4	7
1154	A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia. 2007 , 12, 754-8	44
1153	The United States guidelines for the management of community-acquired pneumonia and their relevance to Australasia. 2007 , 37, 789-91	3
1152	Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. 2007 , 261, 597-604	115

1151	Low mannose-binding lectin complement activation function is associated with predisposition to Legionnaires' disease. 2007 , 149, 97-102	17
1150	Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. 2007 , 37, 145-52	146
1149	Community-acquired legionella pneumonia in elderly patients: characteristics and outcome. 2007 , 55, 114-9	19
1148	Pneumonia and lower respiratory infections in nursing home residents: predictors of hospitalization and mortality. 2007 , 55, 414-9	34
1147	Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. 2007 , 13, 153-161	24
1146	Investigation of the ability of the Pneumonia Severity Index to accurately predict clinically relevant outcomes: a European study. 2007 , 13, 923-31	18
1145	Community-acquired Pneumonia in North American Emergency Departments: Drug Resistance and Treatment Success with Clarithromycin. 2007 , 14, 607-615	5
1144	Identifying severe community-acquired pneumonia in the emergency department: a simple clinical prediction tool. 2007 , 19, 418-26	49
1143	Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. 2007 , 7, 102	91
1142	Physiological-social score (PMEWS) vs. CURB-65 to triage pandemic influenza: a comparative validation study using community-acquired pneumonia as a proxy. 2007 , 7, 33	37
1141	A spatial analysis of the determinants of pneumonia and influenza hospitalizations in Ontario (1992-2001). 2007 , 64, 1636-50	43
1140	Imaging of bacterial pulmonary infection in the immunocompetent patient. 2007 , 42, 122-45	21
1139	Tratamiento empírico de las infecciones en el adulto. 2007 , 14, 7-58	1
1138	Entropy is more resistant to artifacts than bispectral index in brain-dead organ donors. 2007 , 33, 133-6	24
1137	Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. 2007 , 33, 2069-78	66
1136	Severity of illness assessment for managing community-acquired pneumonia. 2007 , 33, 2043-4	10
1135	[Diagnostic procedures for patients with community acquired pneumonia]. 2007 , 48, 468, 470-2, 474-5	0
1134	The risk factors for mortality of community-acquired pneumonia in Japan. 2007 , 13, 157-65	15

1133	Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. 2007 , 185, 249-255	106
1132	Monotherapy versus combination antibiotic therapy for patients with bacteremic <i>Streptococcus pneumoniae</i> community-acquired pneumonia. 2007 , 26, 447-51	27
1131	Procalcitonin and pneumonia: is it a useful marker?. 2007 , 9, 233-40	17
1130	Lack of discriminating signs and symptoms in clinical diagnosis of influenza of patients admitted to the hospital. 2007 , 35, 65-8	25
1129	Antibiotic treatment of community acquired pneumonia varies widely across Germany. 2007 , 54, 446-53	9
1128	Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. 2007 , 55, 400-7	34
1127	Assessing the sensibility of two clinical decision support systems. 2008 , 32, 361-8	16
1126	Prior outpatient antibiotic use as predictor for microbial aetiology of community-acquired pneumonia: hospital-based study. 2008 , 64, 405-10	16
1125	The value of prognostic indices for pneumonia. 2008 , 10, 215-22	9
1124	Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli. 2008 , 27, 657-61	38
1123	Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. 2008 , 8, 22	36
1122	Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. 2008 , 8, 16	67
1121	Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department. 2008 , 51, 45-57	75
1120	Validation of the Acute Heart Failure Index. 2008 , 51, 37-44	57
1119	Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia. 2008 , 51, 651-62, 662.e1-2	58
1118	Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. 2008 , 52, 48-58.e2	160
1117	Evidence-based perspectives on pay for performance and quality of patient care and outcomes in emergency medicine. 2008 , 51, 622-31	31
1116	Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy. 2008 , 52, 274-85	14

1115	Risk stratification of community-acquired pneumonia: what does all of this mean?. 2008 , 52, 61-2	
1114	Clinical prediction rules for hospitalists. 2008 , 75, 472-7	0
1113	Outcome assessment in emergency medicine--a beginning: results of the Council of Emergency Medicine Residency Directors (CORD) emergency medicine consensus workgroup on outcome assessment. 2008 , 15, 267-77	27
1112	Community-acquired pneumonia: the evolving challenge. 2008 , 7, 30-38	
1111	Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome. 2008 , 9, 609-15	34
1110	Pleural fluid interleukin-8 and C-reactive protein for discriminating complicated non-purulent from uncomplicated parapneumonic effusions. 2008 , 13, 58-62	27
1109	Antimicrobial susceptibilities of <i>Streptococcus pneumoniae</i> isolated from adult patients with community-acquired pneumonia in Japan. 2008 , 13, 240-6	13
1108	Procalcitonin is a valuable prognostic marker in ARDS caused by community-acquired pneumonia. 2008 , 13, 505-9	32
1107	Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. 2008 , 13, 731-5	98
1106	Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society guidelines. 2008 , 13, 880-5	36
1105	Limited role for outpatient parenteral antibiotic therapy for community-acquired pneumonia. 2008 , 13, 893-6	9
1104	Empiric antibiotic prescribing for patients with community-acquired pneumonia: where can we improve?. 2008 , 38, 174-7	8
1103	Predictors of length of stay between the young and aged in hospitalized community-acquired pneumonia patients. 2008 , 8, 227-33	18
1102	Improving inpatient management of community-acquired pneumonia in remote northern Australia. 2008 , 16, 383-4	1
1101	Alveolar-arterial oxygen gradient, pneumonia severity index and outcomes in patients hospitalized with community acquired pneumonia. 2008 , 35, 1032-7	13
1100	'A local habitation and a name': how narrative evidence-based medicine transforms the translational research paradigm. 2008 , 14, 732-41	23
1099	Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. 2008 , 264, 166-76	70
1098	The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study. 2008 , 8, 222	66

1097	Improving antibiotic prescribing for adults with community acquired pneumonia: Does a computerised decision support system achieve more than academic detailing alone?--A time series analysis. 2008 , 8, 35	44
1096	Impact of prior outpatient antibiotic use on mortality for community acquired pneumonia: a retrospective cohort study. 2008 , 1, 120	5
1095	Bacterial pneumonia. 2008 , 36, 285-290	3
1094	A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. 2008 , 24, 1279-84	8
1093	Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. 2008 , 62, 381-4	17
1092	Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis. 2008 , 68, 1841-54	94
1091	Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. 2008 , 68, 2469-81	55
1090	[Antibiotic treatment onset delay and clinical evolution in admitted patients with community-acquired pneumonia]. 2008 , 130, 366-70	2
1089	Functional status as a risk factor for mortality in very elderly patients with pneumonia. 2008 , 131, 167-70	28
1088	[Hospital admission in community-acquired pneumonia]. 2008 , 131, 216-7	1
1087	Simple criteria to assess mortality in patients with community-acquired pneumonia. 2008 , 131, 201-4	3
1086	Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. 2008 , 31, 107-14	123
1085	Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. 2008 , 122, 368-74, 374.e1-2	93
1084	Pneumonia. 2008 , 133-144	
1083	A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. 2008 , 24, 737-51	10
1082	Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. 2008 , 40, 293-300	44
1081	Evaluation and management of geriatric infections in the emergency department. 2008 , 26, 319-43, viii	28
1080	Improving outcomes of elderly patients with community-acquired pneumonia. 2008 , 25, 585-610	21

1079	Clinical judgment versus the Pneumonia Severity Index in making the admission decision. 2008 , 34, 261-8	17
1078	Health care-associated pneumonia: identification and initial management in the ED. 2008 , 26, 1-11	95
1077	SHEA/APIC Guideline: Infection prevention and control in the long-term care facility. 2008 , 36, 504-35	145
1076	C-reactive protein is an independent predictor of severity in community-acquired pneumonia. 2008 , 121, 219-25	242
1075	Declining length of hospital stay for pneumonia and postdischarge outcomes. 2008 , 121, 845-52	34
1074	Prior statin use is associated with improved outcomes in community-acquired pneumonia. 2008 , 121, 1002-1007.e1	131
1073	Community-acquired pneumonia: treatment at home or in the hospital?. 2008 , 121, 1038-40	1
1072	A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. 2008 , 102, 1287-95	54
1071	Efficacy of clinical guideline implementation to improve the appropriateness of chest physiotherapy prescription among inpatients with community-acquired pneumonia. 2008 , 102, 1257-63	13
1070	Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. 2008 , 26, 1955-62	30
1069	Prognostication--the lost skill of medicine. 2008 , 19, 155-64	29
1068	Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. 2008 , 392, 41-5	45
1067	Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. 2008 , 30, 358-71	27
1066	[Community-acquired pneumonia in the fragile elderly]. 2008 , 43, 388-9	0
1065	Fe de errores. 2008 , 43, 389	
1064	Community-acquired pneumonia. 2008 , 371, 455-8	28
1063	Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. 2008 , 372, 398-405	137
1062	<i>Streptococcus pneumoniae</i> -caused CAP in hospitalised patients: mortality predictors. 2008 , 14, 601-615	

1061	Severe sepsis and septic shock in the emergency department. 2008 , 22, 1-31, v	21
1060	The importance of case-mix adjustment for infection rates and the need for more research. 2008 , 29, 693-4	15
1059	SHEA/APIC guideline: infection prevention and control in the long-term care facility, July 2008. 2008 , 29, 785-814	171
1058	[Factors predicting mortality during an outbreak of Legionnaire's disease in the north of France]. 2008 , 25, 285-94	1
1057	Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. 2008 , 179, 1269-77	56
1056	Pneumonia in the emergency department. 2008 , 26, 389-411, ix	8
1055	Diagnosis and management of pneumonia in the emergency department. 2008 , 22, 53-72, vi	8
1054	Aetiological diagnosis of community acquired pneumonia: utility of rapid microbiological methods with respect to disease severity. 2008 , 40, 131-8	24
1053	Escherichia coli: an unknown and infrequent cause of community acquired pneumonia. 2008 , 40, 424-7	7
1052	Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. 2008 , 46, 1142-51	134
1051	The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. 2008 , 46, 1513-21	162
1050	The role of corticosteroids in severe community-acquired pneumonia: a systematic review. 2008 , 12, R76	54
1049	Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. 2008 , 12 Suppl 6, S2	37
1048	Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. 2008 , 46, 550-6	113
1047	Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. 2008 , 32, 726-32	78
1046	Position Paper: Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Community-Acquired Pneumonia. 2008 , 47, S249-S265	43
1045	Procalcitonin: Importance for the diagnosis of bacterial infections1. 2008 , 32, -	
1044	CRB-65 for the assessment of pneumonia severity: who could ask for more?. 2008 , 63, 665-6	22

1043	Primary early thoracoscopy and reduction in length of hospital stay and additional procedures among children with complicated pneumonia: results of a multicenter retrospective cohort study. 2008 , 162, 675-81	49
1042	Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. 2008 , 47, 1571-4	55
1041	Procalcitonin und seine Bedeutung für die Diagnose bakterieller Infektionen / Procalcitonin: Importance for the diagnosis of bacterial infections. 2008 , 32, 425-433	1
1040	Antibiotic Policies: Fighting Resistance. 2008 ,	3
1039	The early prediction of mortality in acute pancreatitis: a large population-based study. 2008 , 57, 1698-703	393
1038	Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. 2008 , 31, 349-55	789
1037	Determinants of hospital costs in community-acquired pneumonia. 2008 , 31, 1061-7	27
1036	Can CAP guideline adherence improve patient outcome in internal medicine departments?. 2008 , 32, 902-10	45
1035	Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. 2008 , 46, 1499-509	62
1034	Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value. 2008 , 47 Suppl 3, S145-9	7
1033	Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. 2008 , 87, 329-334	107
1032	Performance-based functional assessment in older hospitalized patients: feasibility and clinical correlates. 2008 , 63, 1393-8	97
1031	The place of varenicline in smoking cessation treatment. 2008 , 63, 666-8	8
1030	Risk Factors for Multidrug-Resistant Pneumococcal Pneumonia. 2008 , 16, 368-375	
1029	Predicting need for ICU in community-acquired pneumonia. 2008 , 133, 587; author reply 588	6
1028	Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. 2008 , 134, 955-962	85
1027	Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. 2008 , 134, 947-954	50
1026	Nonventilatory Treatments for ARDS?. 2008 , 133, 587	1

1025	A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programme. 2008 , 94, 1032-7	10
1024	Markers of treatment failure in hospitalised community acquired pneumonia. 2008 , 63, 447-52	110
1023	Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. 2008 , 32, 139-46	131
1022	Severity scores for community-acquired pneumonia. 2008 , 2, 261-71	
1021	Biomarkers in the management of pneumonia. 2008 , 2, 565-72	12
1020	SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. 2008 , 47, 375-84	351
1019	Human metapneumovirus pneumonia in adults: results of a prospective study. 2008 , 46, 571-4	53
1018	Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. 2008 , 31, 611-7	110
1017	Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes--proceedings of the HCAP Summit. 2008 , 46 Suppl 4, S296-334; quiz 335-8	85
1016	Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues. 2008 , 47 Suppl 3, S121-2	1
1015	The pneumonia severity index: a decade after the initial derivation and validation. 2008 , 47 Suppl 3, S133-9	72
1014	What can we learn from the time course of untreated and partially treated community-onset <i>Streptococcus pneumoniae</i> pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia. 2008 , 47 Suppl 3, S157-65	7
1013	Can a change in policy reduce emergency hospital admissions? Effect of admission avoidance team, guideline implementation and maximising the observation unit. 2008 , 25, 575-8	11
1012	Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. 2008 , 47 Suppl 3, S193-201	32
1011	Issues in noninferiority trials: the evidence in community-acquired pneumonia. 2008 , 47 Suppl 3, S108-20	43
1010	Detection of <i>Mycoplasma pneumoniae</i> in adult community-acquired pneumonia by PCR and serology. 2008 , 57, 1491-1495	42
1009	An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia. 2008 , 20, 225-32	2
1008	Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. 2008 , 32, 892-901	57

1007	Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. 2008 , 20, 77-86	14
1006	Adrenal function in patients with community-acquired pneumonia. 2008 , 31, 1268-73	33
1005	Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. 2008 , 52, 2395-402	32
1004	Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. 2008 , 31, 1068-76	23
1003	Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumonia. 2008 , 25, 144-8	19
1002	Recent changes in the management of community acquired pneumonia in adults. 2008 , 336, 1429-33	19
1001	Mechanisms of Resistance by Gram-Positive Bacteria (Streptococci and Enterococci). 2008 , 1-46	
1000	Reassessing the design, conduct, and analysis of clinical trials of therapy for community-acquired pneumonia. 2008 , 46, 1152-6	6
999	Clinical end points of therapy for patients with mild community-acquired pneumonia. 2008 , 47 Suppl 3, S140-4	9
998	Epidemiology of Community-Acquired Pneumonia Outside Hospital. 1-4	
997	Overview of recent studies of community-acquired pneumonia. 2008 , 47 Suppl 3, S150-6	11
996	Treatment of community-acquired pneumonia Down Under versus the United States: is it really that different?. 2008 , 46, 1522-4	4
995	Novel targets in the management of pneumonia. 2008 , 2, 387-400	6
994	Early mortality in patients with community-acquired pneumonia: causes and risk factors. 2008 , 32, 733-9	83
993	Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. 2008 , 63, 698-702	59
992	Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. 2008 , 130, 578-84	43
991	Incidence and characteristics of viral community-acquired pneumonia in adults. 2008 , 63, 42-8	273
990	Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective. 2008 , 47 Suppl 3, S166-75	24

989	[Infection diagnostics in pneumology. Part 1. Survey and methods]. 2008 , 62, 730-43	3
988	[Antibiotic therapy in elderly patients]. 2008 , 133, 350-3	1
987	Evaluation of PCR as rapid microbiological method in diagnosis of pneumococcal pneumonia. 2008 , 40, 843-5	3
986	Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. 2008 , 177, 1242-7	293
985	[Clinical features and diagnosis of bronchopulmonary infections in the elderly]. 2008 , 62, 297-304	0
984	Spectrum of microbial etiology of community-acquired pneumonia in hospitalized patients: implications for selection of the population for enrollment in clinical trials. 2008 , 47 Suppl 3, S189-92	6
983	Pharmacotherapy of pneumonia occurring in older patients. 2008 , 9, 2867-79	
982	Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. 2008 , 47, 510-6	259
981	Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. 2008 , 136, 1628-37	54
980	Nonventilatory treatments for ARDS?: future directions. 2008 , 133, 586-7; author reply 587	1
979	Diagnosing and treating CAP in immunocompetent adults. 2008 , 21, 26-30	2
978	A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. 2008 , 133, 610-7	157
977	Choc septique. 2008 , 5, 1-16	
976	Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia. 2008 , 133, 220-5	17
975	Emerging Treatments for Resistant Bacterial Infections and Pathogen-Focused Therapy. 2008 , 16, S1-S20	
974	The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. 2008 , 133, 618-24	70
973	Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. 2008 , CD004418	15
972	Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. 2008 , 134, 1141-1148	227

- 971 Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections. **2008**, 15
- 970 [Prevention of in-hospital infection by drug-resistant organisms]. **2008**, 97, 2642-7
- 969 The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant *Staphylococcus aureus* pneumonia. **2008**, 133, 363-9 35
- 968 Evaluation of ICU admission criteria and diagnostic methods for patients with severe community-acquired pneumonia: current practice survey. **2008**, 133, 828-9 6
- 967 Pneumonia: criteria for patient instability on hospital discharge. **2008**, 134, 595-600 21
- 966 Internamento devido a PAC por *Streptococcus pneumoniae* – Avaliação de factores de mortalidade. **2008**, 14, 601-615 2
- 965 Non-Responding Pneumonia. 213-227
- 964 Association of hydrophilic versus lipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality. **2008**, 336, 462-6 11
- 963 Guidelines for the approach to nursing home-acquired pneumonia. **2008**, 4, 561-566 1
- 962 Treatment and outcomes for patients with bacteremic pneumococcal pneumonia. **2008**, 87, 160-166 30
- 961 Role of Fluoroquinolones in the Treatment of Community-Acquired Pneumonia. 193-212
- 960 [Procalcitonin - importance for the diagnosis of bacterial infections]. **2008**, 65, 559-68 5
- 959 . **2008**,
- 958 Respiratory rate: the neglected vital sign. **2008**, 189, 531 9
- 957 Epidemiology of Adult Hospitalized Community-Acquired Pneumonia. 5-19
- 956 Neumonía adquirida en la comunidad en el anciano hospitalizado: Aspectos clínicos y nutricionales. **2008**, 136, 5
- 955 Pneumonia. **2008**, 635-644
- 954 Pneumonia in the elderly: a review of severity assessment, prognosis, mortality, prevention, and treatment. **2008**, 101, 1134-40; quiz 1132, 1179 15

953	Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. 2008 , 19, 173-84	245
952	Sputum examination in the clinical management of community-acquired pneumonia. 2008 , 34, 152-8	7
951	Community-Acquired Pneumonia. 221-228	
950	Pneumonia: Considerations for the Critically Ill Patient. 2008 , 867-883	
949	Comorbidades e sinais de alerta da pneumonia adquirida na comunidade: análise de pacientes com mais de 50 anos. 2008 , 33,	
948	Principle of Primacy of Patient Welfare. 115-153	
947	Cough, fever and shortness of breath in a 62-year-old male. 117-120	
946	. 2009 ,	3
945	Factores pronósticos, evolución y mortalidad en el adulto inmunocompetente hospitalizado por neumonía neumocócica adquirida en la comunidad. 2009 , 137,	2
944	Evaluación y manejo del adulto inmunocompetente hospitalizado por neumonía adquirida en la comunidad, en un hospital de baja complejidad, basado en la Guía Clínica Chilena. 2009 , 137,	
943	Brazilian guidelines for community-acquired pneumonia in immunocompetent adults - 2009. 2009 , 35, 574-601	37
942	Serum and pleural fluid procalcitonin in predicting bacterial infection in patients with parapneumonic effusion. 2009 , 24, 398-402	12
941	Quality and Affecting Factor of Care for Patients Hospitalized with Pneumonia. 2009 , 66, 300	2
940	Usefulness of Procalcitonin in the Assessing the Severity of Community-Acquired Pneumonia Patient. 2009 , 67, 430	2
939	Prognosis of primary care patients aged 80 years and older with lower respiratory tract infection. 2009 , 59, e110-5	9
938	Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. 2009 , 15, 438-45	92
937	Tigecycline in the Treatment of Community-Acquired Pneumonia. 2009 , 1, CMT.S2351	
936	The science of selecting antimicrobials for community-acquired pneumonia (CAP). 2009 , 15, S5-11	25

935	Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. 2009 , 25, 2151-7	41
934	<i>Streptococcus pneumoniae</i> DNA load in blood as a marker of infection in patients with community-acquired pneumonia. 2009 , 47, 3308-12	63
933	Community-acquired pneumonia in elderly patients. 2009 , 5, 763-774	78
932	Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. 2009 , 32, 594-6	104
931	Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. 2009 , 25, 859-68	12
930	New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. 2009 , 64, 1062-9	228
929	Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. 2009 , 63, 1025-33	62
928	Pitfalls in the diagnosis and therapy of infections in elderly patients--a mini-review. 2009 , 55, 241-9	30
927	The Fcgamma receptor IIA-R/R131 genotype is associated with severe sepsis in community-acquired pneumonia. 2009 , 16, 1087-90	38
926	The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. 2009 , 23, 2403-11	80
925	Diagnosis of community-acquired pneumonia in adults. 2009 , 3, 153-64	3
924	Measurement of serum procalcitonin: a step closer to tailored care for respiratory infections?. 2009 , 302, 1115-6	9
923	Severe community-acquired pneumonia (CAP) and the Infectious Diseases Society of America/American Thoracic Society CAP guidelines prediction rule: validated or not. 2009 , 48, 386-8	15
922	Does early review by a respiratory physician lead to a shorter length of stay for patients with non-severe community-acquired pneumonia?. 2009 , 64, 709-12	10
921	Hyponatremia in preterm neonates: not a benign condition. 2009 , 124, e1014-6	21
920	Procalcitonin as a biomarker of acute lower respiratory tract infections. 2009 , 3, 67-79	3
919	Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. 2009 , 19, 64-68	41
918	Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. 2009 , 136, 205-211	42

917	Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. 2009 , 135, 1572-1579	85
916	Is COPD really a cardiovascular disease?. 2009 , 136, 329-330	13
915	Severity assessment in community-acquired pneumonia: a review. 2009 , 102, 379-88	61
914	[Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany]. 2009 , 63, e1-68	89
913	Healthcare-associated pneumonia in the emergency department. 2009 , 30, 46-51	7
912	The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. 2009 , 30, 3-9	48
911	Prolonged Physiologic Doses of Corticosteroids for the Treatment of Severe Community Acquired Pneumonia. 2009 , 5, 90-95	1
910	Nursing home-acquired pneumonia. 2009 , 30, 16-25	12
909	Admission hypoglycaemia is associated with adverse outcome in community-acquired pneumonia. 2009 , 34, 932-9	20
908	PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. 2009 , 37, 456-62	165
907	Community-acquired pneumonia: the U.S. perspective. 2009 , 30, 179-88	37
906	Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. 2009 , 33, 153-9	139
905	The European vision of community-acquired pneumonia. 2009 , 30, 136-45	11
904	Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. 2009 , 169, 1525-31	138
903	Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. 2009 , 34, 1148-58	64
902	Severe community-acquired pneumonia. 2009 , 9, 87-91	
901	The multidimensional prognostic index predicts short- and long-term mortality in hospitalized geriatric patients with pneumonia. 2009 , 64, 880-7	63
900	Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. 2009 , 64, 592-7	110

899	Stability in community-acquired pneumonia: one step forward with markers?. 2009 , 64, 987-92	47
898	Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk score. 2009 , 169, 1595-602	60
897	Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. 2009 , 169, 1515-24	78
896	Development of a prognostic index for 90-day mortality in patients discharged after admission to hospital for community-acquired pneumonia. 2009 , 64, 496-501	15
895	A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. 2009 , 49, 409-16	70
894	Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. 2009 , 150, 19-26	227
893	Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. 2009 , 64, 598-603	71
892	Reasons why emergency department providers do not rely on the pneumonia severity index to determine the initial site of treatment for patients with pneumonia. 2009 , 49, e100-8	48
891	Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. 2009 , 48, 377-85	116
890	Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. 2009 , 48, 149-71	188
889	Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. 2009 , 64, 1070-6	57
888	Establishment of new severity ratings based on analysis of hospital-acquired pneumonia. 2009 , 14 Suppl 2, S4-9	6
887	[From safety to prevention: A(H1N1) influenza, a new challenge for intensivists]. 2009 , 33, 265-6	4
886	[A year's experience in an intermediate respiratory care unit]. 2009 , 45, 533-9	6
885	CKD and risk of hospitalization and death with pneumonia. 2009 , 54, 24-32	119
884	[Infectious comorbidity in COPD]. 2009 , 45 Suppl 4, 59-64	
883	Usefulness of initial blood cultures in patients admitted with pneumonia from an emergency department in Japan. 2009 , 15, 180-6	20
882	Prognostic value of procalcitonin in Legionella pneumonia. 2009 , 28, 55-60	50

881	Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia. 2009 , 28, 913-9	29
880	Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected. 2009 , 28, 971-6	10
879	Antibiotica bij acute bronchitis en COPD-exacerbaties met comorbiditeit. 2009 , 52, 130-134	1
878	De prognose van lageluchtweginfecties bij patiënten van 80 jaar en ouder. 2009 , 52, 639-643	
877	Severe community-acquired pneumonia and PIRO: a new paradigm of management. 2009 , 11, 343-8	31
876	[Community-acquired pneumonia]. 2009 , 50, 331-9; quiz 340	4
875	Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study. 2009 , 9, 157	17
874	Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia. 2009 , 9, 36	13
873	The Queensland experience of participation in a national drug use evaluation project, Community-Acquired Pneumonia Towards Improving Outcomes Nationally (CAPTION). 2009 , 9, 38	3
872	Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency department. 2009 , 9, 4	62
871	Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. 2009 , 9, 44	42
870	Acute-phase responsiveness of mannose-binding lectin in community-acquired pneumonia is highly dependent upon MBL2 genotypes. 2009 , 156, 488-94	35
869	Off-service resident education in the emergency department: outline of a national standardized curriculum. 2009 , 16, 1325-1330	9
868	Community-acquired pneumonia in older patients: does age influence systemic cytokine levels in community-acquired pneumonia?. 2009 , 14, 210-6	25
867	Road ahead to respiratory health: experts chart future research directions. 2009 , 14, 625-36	8
866	Making sense of scoring systems in community acquired pneumonia. 2009 , 14, 327-35	41
865	Serum hydrogen sulfide as a novel marker predicting bacterial involvement in patients with community-acquired lower respiratory tract infections. 2009 , 14, 746-52	31
864	Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia. 2009 , 14, 1098-105	46

863	Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. 2009 , 57, 375-94	76
862	Effect of antibiotic guidelines on outcomes of hospitalized patients with nursing home-acquired pneumonia. 2009 , 57, 1030-5	49
861	Risk factors for death in elderly emergency department patients with suspected infection. 2009 , 57, 1184-90	22
860	Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China. 2009 , 12, 40-6	15
859	Procalcitonin kinetics in Legionella pneumophila pneumonia. 2009 , 15, 1020-5	13
858	Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. 2009 , 15, 1046-50	5
857	Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. 2009 , 15, 1026-32	40
856	Severity of illness scoring systems in patients with bacteraemic pneumococcal pneumonia: implications for the intensive care unit care. 2009 , 15, 850-7	48
855	Evaluation of the performance of CURB-65 with increasing age. 2009 , 15, 858-64	24
854	High prevalence of multidrug-resistant Pneumococcal molecular epidemiology network clones among Streptococcus pneumoniae isolates from adult patients with community-acquired pneumonia in Japan. 2009 , 15, 1039-45	21
853	Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. 2009 , 58, 417-24	84
852	Prognostic factors for fatal adult influenza pneumonia. 2009 , 58, 439-45	38
851	Admission D-dimer can identify low-risk patients with community-acquired pneumonia. 2009 , 53, 633-8	44
850	Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. 2009 , 54, 704-31	33
849	Een prognostische score voor patiënten met pneumonie en dementie. 2009 , 34, 70-73	1
848	Neuropsychologische diagnostiek, de klinische praktijk. 2009 , 34, 73-73	1
847	BTS guidelines for the management of community acquired pneumonia in adults: update 2009. 2009 , 64 Suppl 3, iii1-55	735
846	Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. 2009 , 13, R54	54

845	ICU admission and severity assessment in community-acquired pneumonia. 2009 , 13, 156	26
844	Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. 2009 , 13, R122	41
843	Candidemia on presentation to the hospital: development and validation of a risk score. 2009 , 13, R156	33
842	Le polmoniti nei pazienti provenienti da residenze sanitarie assistenziali: l'è necessaria una strategia terapeutica dedicata?. 2009 , 3, 212-219	2
841	[Factors associated with prolonged hospital stay in community-acquired pneumonia]. 2009 , 27, 160-4	7
840	Hospital medicine (Part 2): what would improve acute hospital care?. 2009 , 20, 465-9	8
839	Ability of physiological parameters versus clinical categories to predict mortality on admission to an internal medicine ward. 2009 , 20, 636-9	3
838	[Oropharyngeal dysphagia and aspiration]. 2009 , 44 Suppl 2, 22-8	5
837	Epidemiology of community-acquired pneumonia in older adults: a population-based study. 2009 , 103, 309-16	136
836	Is it possible to predict which patients with mild pneumonias will develop hypoxemia?. 2009 , 103, 1871-7	12
835	[Clinical management of community-acquired pneumonia in adults]. 2009 , 133, 63-73	11
834	Evaluation of lung ultrasound for the diagnosis of pneumonia in the ED. 2009 , 27, 379-84	139
833	Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by <i>Streptococcus pneumoniae</i> . 2009 , 27, 968-74	29
832	The Reply. 2009 , 122, e13	
831	Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. 2009 , 302, 1059-66	653
830	[Time to first antibiotic dose in community-acquired pneumonia diagnosed in an emergency department]. 2009 , 209, 409-14	3
829	[Parapneumonic pleural effusions and empyema in adults:current practice]. 2009 , 209, 485-94	12
828	Should patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases?. 2009 , 3, 585-96	7

827	A Year's Experience in an Intermediate Respiratory Care Unit. 2009 , 45, 533-539	
826	Early antibiotic treatment failure. 2009 , 34 Suppl 3, S14-9	30
825	Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. 2009 , 10, 65	82
824	Treatment strategies for Legionella infection. 2009 , 10, 1109-21	44
823	Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy. 2009 , 7, 69-81	1
822	The Respiratory Tract in Pediatric Critical Illness and Injury. 2009 ,	1
821	Management of Sepsis: The PIRO Approach. 2009 ,	1
820	Pulmonary Problems in Pregnancy. 2009 ,	
819	Indici di gravit�e applicazioni in rianimazione. 2009 , 14, 1-10	
818	Acute heart failure risk stratification: can we define low risk?. 2009 , 5, 75-83, vii	27
817	Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. 2009 , 64, 587-91	146
816	C-reactive protein, severity of pneumonia and mortality in elderly, hospitalised patients with community-acquired pneumonia. 2009 , 38, 693-7	42
815	Mycoplasma pneumoniae bronchiolitis in adults: clinoradiologic features and clinical course. 2009 , 41, 515-9	9
814	Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization. 2009 , 7, 913-23	9
813	Clinical review: primary influenza viral pneumonia. 2009 , 13, 235	69
812	Infectious diseases and the use of antibiotics in outpatients at the emergency department of the University Hospital of Le�, Nicaragua. 2009 , 13, 349-54	7
811	�ndices de gravedad y aplicaciones en reanimaci�. 2009 , 35, 1-11	
810	Shock s�ptico. 2009 , 35, 1-18	

809	Repeated pneumonia severity index measurement after admission increases its predictive value for mortality in severe community-acquired pneumonia. 2009 , 108, 219-23	6
808	Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. 2009 , 374, 712-9	155
807	Indices de gravité et applications en réanimation. 2009 , 13, 6-18	2
806	Severe community-acquired pneumonia. 2009 , 23, 503-20	55
805	Early hemoconcentration predicts increased mortality only among transferred patients with acute pancreatitis. 2009 , 9, 639-43	20
804	Shock settico. 2009 , 14, 1-16	
803	Infections respiratoires et mucoviscidose. 2009 , 1, S80-S91	
802	Réanimation. 2009 , 1, S175-S188	
801	Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. 2009 , 37, 2867-74	109
800	ICU Rounds. 2009 , 16, 284	
799	Early Ceftriaxone Combined With Azithromycin. 2009 , 17, 90-94	
798	Using electronic health records to measure physician performance for acute conditions in primary care: empirical evaluation of the community-acquired pneumonia clinical quality measure set. 2009 , 47, 208-16	40
797	Can we improve the clinical utility of respiratory rate as a monitored vital sign?. 2009 , 31, 574-80	19
796	Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. 2009 , 37, 2519-26; quiz 2535	47
795	Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. 2009 , 37, 3010-6	91
794	Further Exploring the Link Between Sleep Apnea and Hypertension. 2009 , 16, 285-286	
793	Triaging severe pneumonia: what is the "score" on prediction rules?. 2009 , 37, 3166-8	6
792	Racial and ethnic disparities in pneumonia treatment and mortality. 2009 , 47, 1009-17	35

791	Pneumococcal pneumonia: clinical features, diagnosis and management in HIV-infected and HIV noninfected patients. 2009 , 15, 236-42	7
790	Differences in immune response may explain lower survival among older men with pneumonia. 2009 , 37, 1655-62	59
789	Taking a Longer View of CAP. 2009 , 16, 285	
788	Acute lung injury outside of the ICU: incidence in respiratory isolation on a general ward. 2009 , 135, 261-268	27
787	Pneumonia in the Elderly. 199-209	
786	Effectiveness of meropenem for the treatment of aspiration pneumonia in elderly patients. 2009 , 48, 129-35	37
785	Influence of human T lymphotropic virus type I infection on the etiology of community-acquired pneumonia. 2009 , 48, 959-65	8
784	Indices de gravité et applications en réanimation. 2009 , 6, 1-10	
783	SMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia. 2009 , 2009, 114-115	
782	Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. 2009 , 136, 823-831	107
781	Creation of surge capacity by early discharge of hospitalized patients at low risk for untoward events. 2009 , 3, S10-6	44
780	Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. 2009 , 135, 165-172	32
779	Severity of pneumococcal pneumonia associated with genomic bacterial load. 2009 , 136, 832-840	163
778	Multiple tests and multivariable decision rules. 156-185	
777	Admission chest radiograph lacks sensitivity in the diagnosis of community-acquired pneumonia. 2009 , 337, 236-40	67
776	Unmet Needs for the Treatment of Moderate-to-Severe or Hospitalized Community-Acquired Pneumonia. 2009 , 16, 243-251	1
775	Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. 2009 , 136, 1079-1085	66
774	Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. 2009 , 10, 13-21	39

773	Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. 2010 , 29, 607-12	81
772	Common medications that increase the risk for developing community-acquired pneumonia. 2010 , 23, 145-51	7
771	Admission hypoglycaemia is associated with adverse outcome in community-acquired pneumonia. 2010 , 2010, 210-211	
770	Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia. 2010 , 138, 1371-6	26
769	Presentations to EDs in Alberta, Canada, for pneumonia: a large population-based study. 2010 , 138, 1363-70	1
768	Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study. 2010 , 2010, 148-150	
767	Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. 2010 , 138, 121-9	207
766	Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. 2020 , 56,	56
765	Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study. 2020 , 56,	12
764	Of coccus, Rocco and scores: pneumococcal disease, Rocky Graziano and pneumonia severity scoring systems. 2020 , 52, 612-615	
763	Immunoglobulins concentration and B cell counts as severity markers in adult community-acquired pneumonia: Cross sectional study. 2020 , 99, e22390	1
762	Neutrophil-to-Lymphocyte Ratio Predicts Mortality in Adult Renal Transplant Recipients with Severe Community-Acquired Pneumonia. 2020 , 9,	2
761	Development and Internal Validation of a Prediction Model to Risk Stratify Children With Suspected Community-Acquired Pneumonia. 2021 , 73, e2713-e2721	6
760	The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome. 2020 , 18, 457	35
759	Admission C-Reactive Protein-to-Albumin Ratio Predicts the 180-Day Mortality of AIDS-Related Pneumocystis Pneumonia. 2020 , 36, 753-761	1
758	Troponin Elevation in Older Patients with Acute Pneumonia: Frequency and Prognostic Value. 2020 , 9,	4
757	Risk stratification scores for patients with acute heart failure in the Emergency Department: A systematic review. 2020 , 9, 375-398	11
756	Usual and Advanced Monitoring in Patients Receiving Oxygen Therapy. 2020 , 65, 1591-1600	3

755	Early and late cardiovascular events in patients hospitalized for community-acquired pneumonia. 2020 , 56, 551-558	1
754	Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials. 2020 , 7, ofaa209	0
753	Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. 2020 ,	10
752	Cold-inducible RNA-binding protein might determine the severity and the presences of major/minor criteria for severe community-acquired pneumonia and best predicted mortality. 2020 , 21, 192	5
751	Do-not-resuscitate orders in patients with community-acquired pneumonia: a retrospective study. 2020 , 20, 201	3
750	Deep-learning artificial intelligence analysis of clinical variables predicts mortality in COVID-19 patients. 2020 , 1, 1364	39
749	Infectious Diseases in the Intensive Care Unit. 2020 ,	
748	Serum suPAR associated with disease severity and mortality in elderly patients with community-acquired pneumonia. 2020 , 80, 515-522	1
747	Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease. 2020 , 41, 817-829	3
746	Oral meal intake as a prognostic predictor of community-acquired pneumonia: A retrospective cohort study. 2020 , 26, 1186-1191	
745	[Variables associated with mortality in a selected sample of patients older than 80 years and with some degree of functional dependence hospitalized for COVID-19 in a Geriatrics Service]. 2020 , 55, 317-325	8
744	Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. 2020 , 56, 1-10	11
743	Comparison of clinical, laboratory, and radiological characteristics between SARS-CoV-2 infection and community-acquired pneumonia caused by influenza virus: A cross-sectional retrospective study. 2020 , 99, e23064	6
742	Serum cholesterol as a predictor of mortality among the elderly patients with pneumonia in the emergency department. 2021 , 45, 404-409	0
741	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. 2020 , 324, 1298-1306	229
740	Outpatient management or hospitalization of patients with proven or suspected SARS-CoV-2 infection: the HOME-CoV rule. 2020 , 15, 1525-1531	4
739	Declined Functional Status Prolonged Hospital Stay for Community-Acquired Pneumonia in Seniors. 2020 , 15, 1513-1519	4
738	Risk prediction of in-hospital mortality among patients with type 2 diabetes mellitus and concomitant community-acquired pneumonia. 2020 , 9, 3313-3325	6

737	Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. 2020 , 17,	2
736	Predicting outcome of patients with severe urinary tract infections admitted via the emergency department. 2020 , 1, 502-511	0
735	Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease. 2020 , 9,	2
734	Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients. 2020 , 20, 668	4
733	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. 2020 , 370, m3339	378
732	Can lactate dehydrogenase (LDH) be used as a marker of severity of pneumonia in patients with renal transplant?. 2020 , 8, 911	1
731	Hospital Admission Patterns in Adult Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and a Macrolide by Disease Severity across United States Hospitals. 2020 , 9,	4
730	[Guidelines for the Management of Community Acquired Pneumonia in Children and Adolescents (Pediatric Community Acquired Pneumonia, pCAP) - Issued under the Responsibility of the German Society for Pediatric Infectious Diseases (DGPI) and the German Society for Pediatric Pulmonology (GPP)]. 2020 , 74, 515-544	4
729	Predicting severe COVID-19 in the Emergency Department. 2020 , 4, 100042	8
728	Assessing the need for transfer to the intensive care unit for Coronavirus-19 disease: Epidemiology and risk factors. 2020 , 174, 106203	5
727	Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation. 2020 , 56,	8
726	Age, Pulse, Urea and Albumin (APUA) Model: A Tool for Predicting in-Hospital Mortality of Community-Acquired Pneumonia Adapted for Patients with Type 2 Diabetes. 2020 , 13, 3617-3626	1
725	Dynamics of cytokines, immune cell counts and disease severity in patients with community-acquired pneumonia - Unravelling potential causal relationships. 2020 , 136, 155263	2
724	Splenic volume in pneumococcal pneumonia patients is associated with disease severity and mortality. 2020 , 26, 977-985	1
723	Multiple Tests and Multivariable Risk Models. 2020 , 175-204	
722	Suspected cases of COVID-19: study protocol for reporting characteristics and the outcomes. 2020 , 8,	3
721	D-dimer as A Biomarker of Severity and Adverse Outcomes in Patients with Community Acquired Pneumonia. 2020 , 51, 429-435	2
720	FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients. 2020 , 21, 109	2

719	Cloud-Based Smart Dog Music Therapy and Pneumonia Detection System for Reducing the Difficulty of Caring for Patients With Dementia. 2020 , 8, 20977-20990	5
718	How biomarkers can improve pneumonia diagnosis and prognosis: procalcitonin and mid-regional-pro-adrenomedullin. 2020 , 14, 549-562	5
717	Clostridioides difficile infection after pneumonia in older patients: Which antibiotic is at lower risk?. 2020 ,	3
716	The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. 2020 , 158, 1008-1016	8
715	Clinical and Chest Radiography Features Determine Patient Outcomes in Young and Middle-aged Adults with COVID-19. 2020 , 297, E197-E206	167
714	Community-acquired pneumonia in critically ill very old patients: a growing problem. 2020 , 29,	21
713	Comparison of Clinical Outcomes among Intensive Care Unit Patients Receiving One or Two Grams of Ceftriaxone Daily. 2020 , 64,	3
712	Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials. 2020 , 7, ofaa145	5
711	Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial. 2020 , 20, 160	3
710	Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia. 2020 , 11, 796	4
709	Case Report: Clinical Treatment of the First Critical Patient With Coronavirus Disease (COVID-19) in Liaocheng, Shandong Province. 2020 , 7, 249	5
708	Non-bacteremic pneumococcal pneumonia: general characteristics and early predictive factors for poor outcome. 2020 , 52, 603-611	0
707	Multicenter Emergency Department Validation of the Canadian Syncope Risk Score. 2020 , 180, 737-744	19
706	Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. 2020 , 180, 934-943	4532
705	Impact of Hyponatremia on COPD Exacerbation Prognosis. 2020 , 9,	7
704	Prognosis in patients with cancer-associated venous thromboembolism: Comparison of the RIETE-VTE and modified Ottawa score. 2020 , 18, 1154-1161	3
703	Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study. 2020 , 56,	100
702	Risk Factors of In-Hospital Mortality in Patients Treated for Pneumonia at a Tertiary Care Centre in Switzerland. 2020 , 99, 637-645	1

701	Concordance of Early and Late End Points for Community-acquired Bacterial Pneumonia Trials. 2021 , 73, e2607-e2612	3
700	Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea. 2020 , 9,	26
699	Valoraci3n cl3nica de una neumon3: Criterios de sospecha de neumon3 at3pica, grave o tuberculosis. 2020 , 27, 263-270	
698	Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. 2020 , 80, 388-393	580
697	Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. 2020 , 180, 552-560	22
696	Prognostic factors in nursing and healthcare-associated pneumonia. 2020 , 26, 563-569	5
695	Markov State Modelling of Disease Courses and Mortality Risks of Patients with Community-Acquired Pneumonia. 2020 , 9,	2
694	Treatment update: Outpatient management of community-acquired pneumonia. 2020 , 45, 16-25	
693	The impact of cytomegalovirus infection on clinical severity and outcomes in kidney transplant recipients with Pneumocystis jirovecii pneumonia. 2020 , 64, 356-365	8
692	Mild to moderate hyponatremia at discharge is associated with increased risk of recurrence in patients with community-acquired pneumonia. 2020 , 75, 44-49	9
691	The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study. 2020 , 92, 228-233	6
690	Efficacy of the quick sequential organ failure assessment for predicting clinical outcomes among community-acquired pneumonia patients presenting in the emergency department. 2020 , 20, 316	4
689	Polmonite acuta comunitaria dell'adulto al Pronto Soccorso. 2020 , 24, 1-15	
688	Pulmonary Infections in Pregnancy. 2020 , 57-66	
687	The relationship between neutrophil-to-lymphocyte ratio and the first occurrence of pneumonia in peritoneal dialysis patients. 2020 , 24, 770-778	0
686	Is antipseudomonal antibiotic treatment needed for all nursing and healthcare-associated pneumonia patients at risk for antimicrobial resistance?. 2020 , 22, 441-447	0
685	Viral respiratory infections: a cause of community-acquired pneumonia or a predisposing factor?. 2020 , 26, 208-214	8
684	Using a machine learning approach to predict mortality in critically ill influenza patients: a cross-sectional retrospective multicentre study in Taiwan. 2020 , 10, e033898	34

683	Prognostic Prediction Value of qSOFA, SOFA, and Admission Lactate in Septic Patients with Community-Acquired Pneumonia in Emergency Department. 2020 , 2020, 7979353	8
682	Neutrophil Gelatinase-Associated Lipocalin for Predicting Intensive Care Unit Admission and Mortality in Patients with Pneumonia. 2020 , 250, 243-251	0
681	Prognostic value of albumin-red cell distribution width score in patients with severe community-acquired pneumonia. 2020 , 9, 759-765	8
680	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. 2020 , 17, 879-891	128
679	Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis. 2021 , 72, 1979-1989	6
678	Impact of changing the admission process of patients with pneumonia on the length of stay in the emergency department. 2021 , 41, 170-173	0
677	miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. 2021 , 106, 1636-1646	15
676	Utility of the blood urea nitrogen to serum albumin ratio as a prognostic factor of mortality in aspiration pneumonia patients. 2021 , 43, 175-179	21
675	Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study. 2021 , 40, 871-877	
674	Influenza. 2021 ,	
673	Controlling Nutritional Status score: A novel prognostic marker for patients with community-acquired pneumonia. 2021 , 28, 227-232	0
672	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. 2021 , 74, 567-577	151
671	A quick prediction tool for unfavourable outcome in COVID-19 inpatients: Development and internal validation. 2021 , 82, e11-e15	9
670	[Lung Ultrasound to Predict Unfavorable Progress in Patients Hospitalized for COVID-19]. 2021 , 57, 47-54	4
669	Gender differences in incidence and in-hospital outcomes of community-acquired, ventilator-associated and nonventilator hospital-acquired pneumonia in Spain. 2021 , 75, e13762	2
668	Role of the inflammatory response in community-acquired pneumonia: clinical implications. 2021 , 1-14	
667	New-onset atrial fibrillation in patients with pneumococcal pneumonia. Impact of timing and duration on short- and medium-term mortality. 2021 , 82, 67-75	0
666	Abnormal lung quantification in chest CT images of COVID-19 patients with deep learning and its application to severity prediction. 2021 , 48, 1633-1645	62

665	Specific pathogens as predictors of poor long-term prognosis after hospital discharge for community-acquired pneumonia. 2021 , 176, 106279	0
664	Associations between hematological parameters and disease severity in patients with SARS-CoV-2 infection. 2021 , 35, e23604	14
663	Performance of the quick COVID-19 severity index and the Brescia-COVID respiratory severity scale in hospitalized patients with COVID-19 in a community hospital setting. 2021 , 102, 571-576	20
662	Development of a novel risk score for the prediction of critical illness amongst COVID-19 patients. 2021 , 75, e13915	1
661	Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Community-Acquired Pneumonia. 2021 , 77, e1-e57	1
660	Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire [®] Pneumonia FilmArray [®] Panel. 2021 , 99, 115246	9
659	Evaluation of a novel urinary antigen test kit for diagnosing Legionella pneumonia. 2021 , 103, 42-47	9
658	Sodium: sign, signifier, or signified, of sepsis?. 2021 , 83, 10-11	
657	Association of SARS-CoV-2 Genomic Load with Outcomes in Patients with COVID-19. 2021 , 18, 900-903	26
656	Kidney disease and mortality in patients with respiratory tract infections: a systematic review and meta-analysis. 2021 , 14, 602-611	4
655	Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. 2021 , 82, 76-83	2
654	Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. 2021 , 18, 257-265	4
653	The Impact of the Duration of Antibiotic Therapy in Patients With Community-Onset Pneumonia on Readmission Rates: A Retrospective Cohort Study. 2021 , 34, 523-528	
652	Predictive and prognostic roles of electrical cardiometry in noninvasive assessments of community-acquired pneumonia patients with dyspnoea. 2021 , 28, 205-214	0
651	The role of qSOFA score and biomarkers in assessing severity of community-acquired pneumonia in adults. 2021 , 29, 65-75	
650	Noninvasive ventilation in critically ill very old patients with pneumonia: A multicenter retrospective cohort study. 2021 , 16, e0246072	3
649	Effects of Diabetes and Blood Glucose on COVID-19 Mortality: A Retrospective Observational Study.	
648	Pulmonary Infection (Pneumonia). 2021 , 119-141	0

647	Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline. 2021 , 27, 61-66	81
646	Validation of PSI/PORT, CURB-65 and SCAP scoring system in COVID-19 pneumonia for prediction of disease severity and 14-day mortality. 2021 , 15, 467-471	8
645	Protein-Energy Malnutrition Increases Mortality in Patients Hospitalized With Bacterial Pneumonia: A Retrospective Nationwide Database Analysis. 2021 , 13, e12645	2
644	Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. 2020 , 7, 613928	27
643	Predictive and Prognostic Utility of the Serum Level of Resistin-Like Molecule Beta for Risk Stratification in Patients with Community-Acquired Pneumonia. 2021 , 10,	0
642	Comment on: Predicting In-Hospital Mortality in COVID-19 Older Patients with Specifically Developed Scores. 2021 , 69, 884-886	1
641	Charlson Comorbidity Index and other predictors of in-hospital mortality among adults with community-acquired pneumonia. 2021 , 47, e20200257	5
640	RDW-based clinical score to predict long-term survival in community-acquired pneumonia: a European derivation and validation study. 2021 , 16, 1547-1557	0
639	Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. 2021 , 100, 116-126	44
638	Home quarantine in COVID-19: A study on 50 consecutive patients in Austria. 2021 , 21, e9-e13	4
637	Comparison of CURB-65, PSI, and qSOFA for predicting pneumonia mortality in patients with idiopathic pulmonary fibrosis. 2021 , 11, 3880	0
636	The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults. 2021 , 10,	2
635	Preventing cardiovascular events after pneumonia with aspirin: one step forward, but still many to go. 2021 , 57,	0
634	Predictive Value of the Pneumonia Severity Score on Mortality due to Aspiration Pneumonia. 2021 , 19, 47-53	0
633	A safe protocol to identify low-risk patients with COVID-19 pneumonia for outpatient management. 2021 , 16, 1663-1671	2
632	Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature. 2021 , 37, 152-160	
631	Prediction of an increase in oxygen requirement of SARS-CoV-2 pneumonia using three different scoring systems. 2021 , 27, 336-341	6
630	Community-acquired versus nosocomial Legionella pneumonia: factors associated with Legionella-related mortality. 2021 , 40, 1419-1426	2

629	ABC2-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores.	2
628	Pneumococcal pneumonia in adult hospitalised solid organ transplant recipients: Nationwide, population-based surveillance. 2021 , 75, e14126	0
627	Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. 2021 , 104, 501-509	1
626	Clinical and Radiological Presentations of Various Pulmonary Infections in Hospitalized Diabetes Mellitus Patients: A Prospective, Hospital-Based, Comparative, Case Series Study. 2021 , 2021, 8878746	0
625	Developing the Pneumonia-Optimized Ratio for Community-acquired pneumonia: An easy, inexpensive and accurate prognostic biomarker. 2021 , 16, e0248897	0
624	The Performance of CURB-65 and PSI for Predicting In-Hospital Mortality of Community-Acquired Pneumonia in Patients with Type 2 Diabetes Compared with the Non-Diabetic Population. 2021 , 14, 1359-1366 ³	
623	Significance of the physician's and the patient's sex in hospitalized patients with community-acquired pneumonia. 2021 , 53, 538-545	0
622	[Pneumonia in old age]. 2021 , 18, 1-6	
621	COVID-19 and liver disease: mechanistic and clinical perspectives. 2021 , 18, 348-364	90
620	The prognostic value of serum albumin levels and respiratory rate for community-acquired pneumonia: A prospective, multi-center study. 2021 , 16, e0248002	1
619	Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction score. 2021 , 76, 696-703	8
618	Association of early antibiotic therapy and in-hospital mortality in adult mild-to-moderate acute aspiration pneumonitis: a cohort study. 2021 , 16, 1841-1848	1
617	Prevalence and impact on outcome of sodium and potassium disorders in patients with community-acquired pneumonia: A retrospective analysis. 2021 , 85, 63-67	8
616	Utility of a Clinical Scoring System for Point of Care Triaging in COVID-19 Pneumonia.	
615	Undetected Causes of Death in Hospitalized Elderly with COVID-19: Lessons from Autopsy. 2021 , 10,	1
614	Combining Initial Radiographs and Clinical Variables Improves Deep Learning Prognostication in Patients with COVID-19 from the Emergency Department. 2021 , 3, e200098	21
613	Discontinuing β -lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. 2021 , 397, 1195-1203	19
612	Evaluation of a Multiplex PCR Panel for the Microbiological Diagnosis of Pneumonia in Hospitalized Patients: Experience from an Academic Medical Center. 2021 , 104, 354-360	3

611	An Early Screening Tool for Discharge Planning Shortened Length of Hospital Stay for Elderly Patients with Community-Acquired Pneumonia. 2021 , 16, 443-450	3
610	Derivation of a Contextually-Appropriate COVID-19 Mortality Scale for Low-Resource Settings. 2021 , 87, 31	1
609	Klebsiella pneumoniae pneumonia in patients with rheumatic autoimmune diseases: clinical characteristics, antimicrobial resistance and factors associated with extended-spectrum β -lactamase production. 2021 , 21, 366	0
608	Renal Replacement Therapy in Patients with Influenza Pneumonia Related Acute Respiratory Distress Syndrome. 2021 , 10,	1
607	Clinical scores to predict prognosis in COVID-19 critically ill patients. 2021 , 10,	0
606	Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation with Vitamin K Antagonists for Venous Thromboembolism. 2021 , 121, 1512-1522	1
605	COLI-NET: Fully Automated COVID-19 Lung and Infection Pneumonia Lesion Detection and Segmentation from Chest CT Images.	3
604	Prognostic value of serial neutrophil-to-lymphocyte ratio measurements in hospitalized community-acquired pneumonia. 2021 , 16, e0250067	3
603	Does seafarers' limited access to health care increase risk for community-acquired pneumonia requiring hospital care? A longitudinal register-based analysis. 2021 , 64, 639-645	0
602	A COMPARATIVE STUDY OF CLINICAL AND BIOCHEMICAL PROFILE AMONG SURVIVORS AND NON SURVIVORS OF PATIENTS WITH COVID-19 INFECTION - A RETROSPECTIVE STUDY.. 2021 , 4-6	
601	Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis. 2021 , 8, ofab169	2
600	Clinical relevance of emphysema in patients hospitalized with community-acquired pneumonia: Clinical features and prognosis. 2021 , 15, 826-834	1
599	The association between L1 skeletal muscle index derived from routine CT and in-hospital mortality in CAP patients in the ED. 2021 , 42, 49-54	3
598	[Prognostic Scales of COVID-19 Morbidity and Mortality: Necessary but also Reliable]. 2021 , 57, 62-63	1
597	Clinical and radiological imaging as prognostic predictors in COVID-19 patients. 2021 , 52,	0
596	The effectiveness of continuous respiratory rate monitoring in predicting hypoxic and pyrexia events: a retrospective cohort study. 2021 , 42,	1
595	Outpatient Management of Patients With COVID-19: Multicenter Prospective Validation of the Hospitalization or Outpatient Management of Patients With SARS-CoV-2 Infection Rule to Discharge Patients Safely. 2021 , 160, 1222-1231	3
594	Blood urea nitrogen-to-serum albumin ratio and A-DROP are useful in assessing the severity of Pneumocystis pneumonia in patients without human immunodeficiency virus infection. 2021 , 27, 707-714	4

593	Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: How many admissions are potentially avoidable?. 2021 , 49, 1528-1534	3
592	In which cases of pneumonia should we consider treatments for <i>Stenotrophomonas maltophilia</i> ?. 2021 , 111, 169-175	0
591	A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic. 2021 , 11, 9784	6
590	Infections in Older Adults. 2021 , 39, 379-394	4
589	Cost Effectiveness of Different Initial Antimicrobial Regimens for Elderly Community-Acquired Pneumonia Patients in General Ward. 2021 , 14, 1845-1853	1
588	Clinical diagnosis of severe COVID-19: A derivation and validation of a prediction rule. 2021 , 9, 2994-3007	2
587	Pneumonia severity indices predict prognosis in coronavirus disease-2019. 2021 , 79, 100826	4
586	Cardiopulmonary Emergencies in Older Adults. 2021 , 39, 323-338	0
585	Impact of acute kidney injury on in-hospital outcomes in Chinese patients with community acquired pneumonia. 2021 , 21, 143	2
584	Prognostic Value of Blood Urea Nitrogen/Creatinine Ratio for Septic Shock: An Analysis of the MIMIC-III Clinical Database. 2021 , 2021, 5595042	2
583	Associations of Toll-like Receptor Gene Polymorphisms with NETosis Activity as Prognostic Criteria for the Severity of Pneumonia. 2021 , 13, 47-53	2
582	Efficacy of clarithromycin on COVID-19 pneumonia without oxygen administration; protocol for multicenter, open-label, randomized-controlled, 3-armed parallel group comparison, exploratory trial (CAME COVID study).	1
581	Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study. 2021 , 8, ofab135	1
580	Etiology, Clinical Course, and Outcomes of Pneumonia in the Elderly: A Retrospective and Prospective Cohort Study in Thailand. 2021 ,	3
579	Cyclovirus detection in Chilean adults with and without community-acquired pneumonia. 2021 , 93, 4786-4793	0
578	Clinically Significant Monocyte Biomarker for Differential Diagnosis of COVID-19 Pneumonia in the Emergency Department. 2021 , 40, 26-31	
577	Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial. 2021 , 60, 781-792	1
576	Bacterial and viral respiratory tract microbiota and host characteristics in adults with lower respiratory tract infections: a case-control study. 2021 ,	1

575 Les facteurs pronostiques dans la Covid-19. **2021**, 21, 304-304

574 Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired Pneumonia. **2021**, 65, e0041721

0

573 Improvement of pneumococcal pneumonia diagnosis using quantitative real-time PCR targeting lytA in adult patients: a prospective cohort study. **2021**,

572 Evaluation of severity scoring systems in patients with severe community acquired pneumonia. **2021**, 59, 394-402

571 A prospective observational study of community acquired pneumonia in Kenya: the role of viral pathogens. **2021**, 21, 703

1

570 An Original Risk Score to Predict Early Major Bleeding in Acute Pulmonary Embolism: The Syncope, Anemia, Renal Dysfunction (PE-SARD) Bleeding Score. **2021**, 160, 1832-1843

4

569 Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study. **2021**, 27, 1037.e1-1037.e8

11

568 Influence of Prednisone on Inflammatory Biomarkers in Community-Acquired Pneumonia: Secondary Analysis of a Randomized Trial. **2021**, 61, 1406-1414

2

567 Association between NT-proBNP Level and the Severity of COVID-19 Pneumonia. **2021**, 2021, 5537275

2

566 Chest CT severity score and radiological patterns as predictors of disease severity, ICU admission, and viral positivity in COVID-19 patients. **2021**, 59, 436-445

2

565 Fibrosis-4 Predicts the Need for Mechanical Ventilation in a National Multiethnic Cohort of Corona Virus Disease 2019. **2021**, 5, 1605-1615

1

564 Seasonal burden of severe influenza virus infection in the critically ill patients, using the Assistance Publique-Hôpitaux de Paris clinical data warehouse: a pilot study. **2021**, 11, 117

1

563 Clinical characteristics and outcomes of community-acquired pneumonia in western Saudi Arabia: A four-year retrospective analysis of medical records. **2021**, 14, 960-966

1

562 [Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIM), the German Virological Society (DGV), the Competence Network

7

561 Computerized Mortality Prediction for Community-acquired Pneumonia at 117 Veterans Affairs Medical Centers. **2021**, 18, 1175-1184 (DGG), the German. **2021**, 75, 665-729

1

560 Association between Early Antibiotic Therapy and In-Hospital Mortality among Older Patients with SARS-CoV-2 Pneumonia. **2021**,

2

559 Real-time interactive artificial intelligence of things-based prediction for adverse outcomes in adult patients with pneumonia in the emergency department. **2021**, 28, 1277-1285

1

558 Application of BAP-65 Score for Risk Stratification of Acute Exacerbation of Chronic Obstructive Pulmonary Disease - A Prospective Observational Study in a Tertiary Care Institute in Telangana. **2021**, 8, 2667-2673

557	Influenza and pneumococcal vaccination coverage in Latin American patients with systemic lupus erythematosus: a cross-sectional and comparative study. 2021 , 61, 46	1
556	Diagnostic yield of bacteriological tests and predictors of severe outcome in adult patients with COVID-19 presenting to the emergency department. 2021 , 38, 685-691	4
555	Persistent Lung Inflammation After Clinical Resolution of Community-Acquired Pneumonia as Measured by FDG-PET/CT Imaging. 2021 , 160, 446-453	1
554	Molecular characterization of isolates derived from severe pneumonia: a retrospective monocentre study. 2021 , 53, 811-819	1
553	The Risk Factor and Outcome of Metachronous Periprosthetic Joint Infections: A Retrospective Analysis With a Minimum Ten-Year Follow-Up. 2021 , 36, 3734-3740	3
552	Remdesivir and Mortality in Patients with COVID-19. 2021 ,	5
551	An epigenetic and transcriptomic signature of immune tolerance in human monocytes through multi-omics integration. 2021 , 13, 131	1
550	Peripheral oxygen saturation to inspiratory oxygen fraction ratio-based identification of critically ill coronavirus disease patients for early therapeutic interventions. 2021 , 35, 827-836	
549	[Application of validated severity scores for pneumonia caused by SARS-CoV-2]. 2021 , 157, 99-105	2
548	Application of validated severity scores for pneumonia caused by SARS-CoV-2. 2021 , 157, 99-105	2
547	Time Trend of the Sensitivity of the Pneumococcal Urinary Antigen Test for Diagnosing Pneumococcal Community-Acquired Pneumonia: An Analysis of 15-Year, Prospective Cohort Data. 2021 , 10, 2309-2322	1
546	DEVELOPMENT AND VALIDATION OF A MODEL FOR THE PREDICTION OF MORTALITY IN CHILDREN UNDER FIVE YEARS WITH CLINICAL PNEUMONIA IN RURAL GAMBIA.	
545	Clinical Outcomes of Immunocompromised Adults Hospitalized with Pneumococcal Pneumonia: A Case-Control Study. 2021 , 9,	
544	Sarcopenia measured with paraspinous muscle using computed tomography for predicting prognosis in elderly pneumonia patients. 102490792110418	
543	Specific Features of the Coagulopathy Signature in Severe COVID-19 Pneumonia. 2021 , 8, 675191	3
542	Prognostic Value of Immune-Inflammatory Index in PSI IV-V Patients with COVID-19. 2021 , 2021, 9987931	
541	Prediction accuracy of commonly used pneumonia severity scores in Aboriginal patients with severe community-acquired pneumonia - a retrospective study. 2021 ,	
540	Rectal bacteriome and virome signatures and clinical outcomes in community-acquired pneumonia: An exploratory study. 2021 , 39, 101074	0

539	The COVID-19 Assessment for Survival at Admission (CASA) Index: A 12 Months Observational Study. 2021 , 8, 719976	2
538	ABC-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores. 2021 , 110, 281-308	5
537	Sodium alterations impair the prognosis of hospitalized patients with COVID-19 pneumonia. 2021 , 10, 1344-1351	2
536	Study of factors related to recurrence within 30 days after pneumonia treatment for community-onset pneumonia. 2021 , 27, 1683-1688	0
535	CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia.. 2021 , 29, 408-415	1
534	Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study). 2021 , 11, e053325	0
533	Clinical and epidemiological characteristics of patients hospitalized for SARS-CoV-2 infection in two hospitals in Córdoba. 2021 , 78, 303-312	0
532	Predictors and usefulness of targeted therapy for pneumococcal community-acquired pneumonia diagnosed by the urinary antigen test: a prospective, observational cohort study. 2021 , 101, 115457	
531	Validity of Pneumonia Severity Assessment Scores in Africa and South Asia: A Systematic Review and Meta-Analysis. 2021 , 9,	2
530	Risk factors, predictions, and progression of acute kidney injury in hospitalized COVID-19 patients: An observational retrospective cohort study. 2021 , 16, e0257253	5
529	Community-acquired pneumonia. 2021 , 398, 906-919	7
528	Inpatient versus outpatient intravenous diuresis for the acute exacerbation of chronic heart failure. 2021 , 36, 100860	0
527	External Validation and Recalibration of the CURB-65 and PSI for Predicting 30-Day Mortality and Critical Care Intervention in Multiethnic Patients with COVID-19. 2021 , 111, 108-116	3
526	A Scoring System for Predicting the Prognosis of Late-Onset Severe Pneumonia after Allogeneic Hematopoietic Stem Cell Transplantation. 2021 , 27, 870.e1-870.e7	
525	Refinement of microbiota analysis of specimens from patients with respiratory infections using next-generation sequencing. 2021 , 11, 19534	1
524	Evaluation and management of pleural sepsis. 2021 , 187, 106553	0
523	Increased risk of Legionella pneumonia as community-acquired pneumonia after heavy rainfall in 2018 in west Japan. 2021 , 27, 1429-1435	1
522	Usefulness of ßactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study. 2021 , 27, 1447-1453	0

521 Community-Acquired Pneumonia. **2022**, 198-205

520 Simulated Adoption of 2019 Community-Acquired Pneumonia Guidelines Across 114 Veterans Affairs Medical Centers: Estimated Impact on Culturing and Antibiotic Selection in Hospitalized Patients. **2021**, 72, S59-S67 0

519 Incidence, characteristics and clinical relevance of acute stroke in old patients hospitalized with COVID-19. **2021**, 21, 52 7

518 Development of a Predictive Model for Mortality in Hospitalized Patients With COVID-19. **2021**, 1-9 2

517 Respiratory Tract Infections: Bacteria. **2021**,

516 Quantifying causality in data science with quasi-experiments. **2021**, 1, 24-32 6

515 Performance of CURB-65, PSI, and APACHE-II for predicting COVID-19 pneumonia severity and mortality. **2021**, 19, 205873922110270 2

514 Reply to: Comment on Predicting In-Hospital Mortality in COVID-19 Older Patients with Specifically Developed Scores. **2021**, 69, 886-887

513 Infectious Disease Concerns in Football. **2021**, 369-383

512 New guidelines for severe community-acquired pneumonia. **2021**, 27, 210-215 1

511 Effects of age and comorbidities on serum levels of inflammatory markers in community-acquired pneumonia. **2021**, 51, e13480 1

510 Age is not the only risk factor in COVID-19: the role of comorbidities and of long staying in residential care homes. **2021**, 21, 63 25

509 The development of clinical prediction rules. 139-147 1

508 Clinical Prediction Rules. **2012**, 317-336 2

507 Bronchitis and Pneumonia. **2001**, 53-65 0

506 Lung Infections and Aging. **2009**, 95-112 1

505 Pneumonia in the Pregnant Patient. **2009**, 177-196 7

504 Differential Diagnosis of Types of Pneumonia in the Elderly. **2020**, 35-66 2

503	Triage of Older ED Patients. 2018 , 17-22	1
502	Acute Exacerbations of Chronic Bronchitis: In Search of a Definition. 2000 , 24-35	1
501	Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. 2009 , 19, 64-8	22
500	Costs associated with community acquired pneumonia in France. 2018 , 19, 533-544	8
499	Prognostic value of blood pressure drops during the first 24'h after hospital admission for risk stratification of community-acquired pneumonia: a retrospective cohort study. 2020 , 48, 267-274	5
498	Quinolones. 2010 , 487-510	6
497	Acute Pneumonia. 2010 , 891-916	5
496	Streptococcus pneumoniae. 2010 , 2623-2642	15
495	Pneumococcal polysaccharide vaccines. 2008 , 569-604	9
494	Care at the End of Life for Patients with Respiratory Failure. 2010 , 2160-2179	1
493	Prognostic Value of Hyponatremia During Acute Painful Episodes in Sickle Cell Disease. 2020 , 133, e465-e482	0
492	Neutrophil Count Percentage and Neutrophil-Lymphocyte Ratio as Prognostic Markers in Patients Hospitalized for Community-Acquired Pneumonia. 2019 , 55, 472-477	14
491	Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia. 2020 , 56, 551-558	5
490	Predictors of In-Hospital Mortality in Older Patients With COVID-19: The COVIDAge Study. 2020 , 21, 1546-1554.e3	60
489	Outcome prediction using the Mortality in Emergency Department Sepsis score combined with procalcitonin for influenza patients. 2019 , 153, 411-417	4
488	CURB-65 may serve as a useful prognostic marker in COVID-19 patients within Wuhan, China: a retrospective cohort study. 2020 , 148, e241	19
487	Use of indicators to evaluate the quality of community-acquired pneumonia management. 2002 , 34, 318-23	21
486	Management decisions regarding community-acquired pneumonia. 1999 , 12, 133-6	4

485	Relationship of provider characteristics to outcomes, process, and costs of care for community-acquired pneumonia. 1998 , 36, 977-87	66
484	The relationship of gender and in-hospital death: increased risk of death in men. 1999 , 37, 318-24	23
483	Evaluation of Antibiotic Usage With a Local Community-Acquired Pneumonia Guideline. 2005 , 13, 60-64	2
482	Performance and comparison of assessment models to predict 30-day mortality in patients with hospital-acquired pneumonia. 2020 , 133, 2947-2952	4
481	Variability in processes of care and outcomes among children hospitalized with community-acquired pneumonia. 2012 , 31, 1036-41	74
480	A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19.	13
479	Review and methodological analysis of trials currently testing treatment and prevention options for COVID-19 globally.	1
478	Association of SARS-CoV-2 Genomic Load with COVID-19 Patient Outcomes.	3
477	Profiles in Patient Safety: Antibiotic Timing in Pneumonia and Pay-for-performance. 2006 , 13, 787-790	3
476	Incidence rate of community-acquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America. 2018 , 8, e019439	8
475	Solutions for difficult diagnostic cases of community-acquired pneumonia. 2001 , 47 Suppl 4, 3-10; discussion 26-7	2
474	SARS-CoV-2 Infection in a Spanish Cohort of CKD-5D Patients: Prevalence, Clinical Presentation, Outcomes, and De-Isolation Results. 2021 , 50, 531-538	9
473	SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. 2020 , 130, 6477-6489	110
472	Severity assessment tools in CAP. 2014 , 88-104	1
471	The Role of Macrolides in the Treatment of Community-Acquired Pneumonia. 2003 , 59-74	1
470	Predicting 30-Day Pneumonia Readmissions Using Electronic Health Record Data. 2017 , 12, 209-216	18
469	Evaluation of pneumonia severity and acute physiology scores to predict ICU admission and mortality in patients hospitalized for influenza. 2010 , 5, e9563	33
468	Using the electronic medical record to identify community-acquired pneumonia: toward a replicable automated strategy. 2013 , 8, e70944	26

467	Severity assessment of lower respiratory tract infection in Malawi: derivation of a novel index (SWAT-Bp) which outperforms CRB-65. 2013 , 8, e82178	8
466	Iterative thoracentesis as first-line treatment of complicated parapneumonic effusion. 2014 , 9, e84788	14
465	Using highly detailed administrative data to predict pneumonia mortality. 2014 , 9, e87382	34
464	Using data-driven rules to predict mortality in severe community acquired pneumonia. 2014 , 9, e89053	11
463	Characteristics of hospitalized acute Q fever patients during a large epidemic, The Netherlands. 2014 , 9, e91764	21
462	Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. 2014 , 9, e105854	33
461	Undertriage in older emergency department patients--tilting against windmills?. 2014 , 9, e106203	29
460	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. 2015 , 10, e0122520	52
459	Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia. 2015 , 10, e0125212	19
458	A Clinical Predictor Score for 30-Day Mortality among HIV-Infected Adults Hospitalized with Pneumonia in Uganda. 2015 , 10, e0126591	22
457	The Pneumonia Severity Index as a Predictor of In-Hospital Mortality in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. 2015 , 10, e0133160	14
456	Clinical and Microbiological Factors Associated with High Nasopharyngeal Pneumococcal Density in Patients with Pneumococcal Pneumonia. 2015 , 10, e0140112	14
455	Risk Factors for Long-Term Mortality after Hospitalization for Community-Acquired Pneumonia: A 5-Year Prospective Follow-Up Study. 2016 , 11, e0148741	32
454	Streptococcus pyogenes Pneumonia in Adults: Clinical Presentation and Molecular Characterization of Isolates 2006-2015. 2016 , 11, e0152640	14
453	Association between Obstructive Sleep Apnea and Community-Acquired Pneumonia. 2016 , 11, e0152749	24
452	Predictors and Implications of Early Clinical Stability in Patients Hospitalized for Moderately Severe Community-Acquired Pneumonia. 2016 , 11, e0157350	11
451	Efficacy and Safety of Adjunctive Corticosteroids Therapy for Severe Community-Acquired Pneumonia in Adults: An Updated Systematic Review and Meta-Analysis. 2016 , 11, e0165942	32
450	The TRIAGE-ProADM Score for an Early Risk Stratification of Medical Patients in the Emergency Department - Development Based on a Multi-National, Prospective, Observational Study. 2016 , 11, e0168076	15

449	Clinical Features and Courses of Adenovirus Pneumonia in Healthy Young Adults during an Outbreak among Korean Military Personnel. 2017 , 12, e0170592	20
448	Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial. 2017 , 12, e0175634	7
447	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. 2017 , 12, e0178022	9
446	Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia. 2017 , 12, e0182436	15
445	Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. 2018 , 13, e0191721	41
444	Usefulness of circulating microRNAs miR-146a and miR-16-5p as prognostic biomarkers in community-acquired pneumonia. 2020 , 15, e0240926	5
443	Factors Influencing In-hospital Mortality in Community-Acquired Pneumonia*. 2005 , 127, 1260	147
442	Efficacy of quick Sequential Organ Failure Assessment with lactate concentration for predicting mortality in patients with community-acquired pneumonia in the emergency department. 2019 , 6, 1-8	13
441	Clinical, epidemiological, and etiological profile of inpatients with community-acquired pneumonia at a general hospital in the Sumar'microregion of Brazil. 2011 , 37, 200-8	13
440	Lactate dehydrogenase as a prognostic marker of renal transplant recipients with severe community-acquired pneumonia: a 10-year retrospective study. 2019 , 7, 660	6
439	Use of intravenous antibiotics for the treatment of community-acquired pneumonia in the emergency department. 2005 , 1, 49-54	1
438	Validation of a prediction rule for prognosis of severe community-acquired pneumonia. 2008 , 2, 67-71	3
437	Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: an analysis of risk factors. 2013 , 7, 13-20	4
436	Impact of blood cultures on the changes of treatment in hospitalized patients with community-acquired pneumonia. 2013 , 7, 60-6	2
435	COVID-19 Outcome Prediction and Monitoring Solution for Military Hospitals in South Korea: Development and Evaluation of an Application. 2020 , 22, e22131	10
434	An Easy-to-Use Machine Learning Model to Predict the Prognosis of Patients With COVID-19: Retrospective Cohort Study. 2020 , 22, e24225	16
433	Putting Meaning into Meaningful Use: A Roadmap to Successful Integration of Evidence at the Point of Care. 2016 , 4, e16	21
432	[Treatment of community-acquired pneumonia using the modern therapeutical guides]. 2006 , 63, 967-70	1

431	Gender differences in community-acquired pneumonia. 2020 , 111, 153-165	10
430	[Severity classification and prognosis in hospitalized elderly patients with community-acquired pneumonia]. 2007 , 44, 483-9	5
429	[Pearls and pitfalls on diagnosing infections in the elderly]. 2011 , 48, 447-50	2
428	Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu, Korea. 2020 , 35, e209	40
427	D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients. 2020 , 10,	13
426	Tendencias de morbilidad y mortalidad por neumonía en adultos mexicanos (1984-2010). 2015 , 74, 4-12	2
425	Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. 2009 , 24, 337-42	38
424	Outcome of pandemic H1N1 pneumonia: clinical and radiological findings for severity assessment. 2011 , 26, 160-7	23
423	Clinical manifestations of pneumonia according to the causative organism in patients in the intensive care unit. 2015 , 30, 829-36	4
422	Incidence and Clinical Characteristics of Severe Community-Acquired Pneumococcal Pneumonia: Comparisons with Non-Pneumococcal Pathogens. 2012 , 82, 52	2
421	Pneumonia in the long-term care setting: etiology, management, and prevention. 2004 , 30, 14-23; quiz 54-5	6
420	Analysis of the severity and prognosis assessment of aged patients with community-acquired pneumonia: a retrospective study. 2013 , 5, 626-33	7
419	Reasons and Risk Factors for Readmission Following Hospitalization for Community-acquired Pneumonia in South Korea. 2020 , 83, 147-156	3
418	Pneumonia Observed in a Geriatric Hospital. 2015 , 19, 80-88	3
417	Hospital Treatment Costs and Factors Affecting These Costs in Community-Acquired Pneumonia. 2015 , 16, 107-113	5
416	Factors Affecting Cost of Patients with Severe Community-Acquired Pneumonia in Intensive Care Unit. 2019 , 20, 216-223	4
415	B-type natriuretic peptide in predicting the severity of community-acquired pneumonia. 2015 , 6, 131-6	5
414	Management of severe community-acquired pneumonia in Brazil: a secondary analysis of an international survey. 2015 , 27, 57-63	3

413	Prognostic value of procalcitonin in hospitalized patients with lower respiratory tract infections. 2016 , 28, 179-89	5
412	Pneumonia in the elderly hospitalized in the Department of Veteran Affairs Health Care System. 2011 , 176, 214-7	2
411	Early prediction of level-of-care requirements in patients with COVID-19. 2020 , 9,	22
410	Predicting COVID-19 Using Retrospective Data: Impact of Obesity on Outcomes of Adult Patients With Viral Pneumonia. 2020 , 12, e10291	4
409	Value of Blood Cultures in the Management of Children Hospitalized with Community-Acquired Pneumonia. 2020 , 12, e8222	0
408	Significance of Acute Phase Reactants as Prognostic Biomarkers for Pneumonia in Children. 2021 , 14, 1309-1321	0
407	Effectiveness of expiratory technique and induced sputum in obtaining good quality sputum from patients acutely hospitalized with suspected lower respiratory tract infection: a statistical analysis plan for a randomized controlled trial. 2021 , 22, 675	2
406	Utility of conventional clinical risk scores in a low-risk COVID-19 cohort. 2021 , 21, 1094	1
405	Application of self-assessment triage tool in COVID-19 pandemic (Preprint).	
404	Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. 2021 , 4, e2129566	3
403	Stratifying risk outcomes among adult COVID-19 inpatients with high flow oxygen: The R4 score. 2021 ,	0
402	Prognostic factors in patients hospitalized with community-acquired aspiration pneumonia. 2022 , 28, 47-53	
401	Burden of primary influenza and respiratory syncytial virus pneumonia in hospitalized adults: insights from a two-year multi-centre cohort study (2017-2018). 2021 ,	
400	Community and Hospital Acquired Pneumonia.. 2022 , 57, 3-17	
399	Urea-to-Albumin Ratio and In-Hospital Mortality in Severe Pneumonia Patients. 2021 , 2021, 5105870	
398	Removable Denture Wearing as a Risk Predictor for Pneumonia Incidence and Time to Event in Older Adults. 2021 , 23800844211049406	1
397	Comparison of prone positioning and extracorporeal membrane oxygenation in acute respiratory distress syndrome: A multicenter cohort study and propensity-matched analysis. 2021 ,	0
396	Differentiating severe and non-severe lower respiratory tract illness in patients hospitalized with influenza: Development of the Influenza Disease Evaluation and Assessment of Severity (IDEAS) scale. 2021 , 16, e0258482	0

- 395 Comparison of Frailty Index to Pneumonia Severity Measures in Older Patients With Pneumonia. **2021**, 1
- 394 Serology-based therapeutic strategy in SARS-CoV-2-infected patients. **2021**, 101, 108214 1
- 393 Clinical Needs in the Millennium â€Community Acquired Pneumonia. **2000**, 147-153
- 392 Atemwegserkrankungen. **2000**, 85-111
- 391 Diagnosis and Management of Pneumonia. **2001**, 143-156
- 390 Hemochromatosis as a Risk Factor for Fulminant Staphylococcus aureus Pneumonia*. **2001**, 10, 44-49
- 389 Pulmonary Disease. **2001**, 329-354
- 388 Pneumonie und Abszess. **2002**, 325-363
- 387 Current Dilemmas in the Management of Adults with Severe Community-Acquired Pneumonia. **2003**, 162-174 1
- 386 Pulmonary Infections. **2003**, 719-729
- 385 Pneumonien. **2003**, 354-367
- 384 Pre-ICU Factors. **2003**, 119-126
- 383 Estimated frequency of nursing facility-acquired pneumonia?. **2003**, 167, 1287-8; author reply 1288 2
- 382 Treatment of Hospitalized Patients with Community-Acquired Pneumonia. **2003**, 279-306
- 381 Cost Considerations in the Use of Antibiotics for the Treatment of Community-Acquired Respiratory Tract Infections. **2003**, 43-58
- 380 Treatment of Pneumonia in Nonhospitalized Patients. **2003**, 255-278
- 379 Infektionen der unteren Atemwege. **2004**, 243-300
- 378 Community-Acquired Pneumonia (International Vision). **2004**, 22-40

377 Severe Community-Acquired Pneumonia. **2004**, 41-52

376 Altersspezifische Veränderungen des Immunsystems und deren assoziierte Krankheitsbilder. **2004**, 429-464 1

375 Respiratory Disease in the Elderly. **2005**, 48, 113

374 Hoofdstuk 3 Afwijkingen van het respiratoire systeem. **2005**, 72-99

373 Severe Pneumonia. **2005**, 1-24

372 Why Do Some Patients Get Severe Pneumonia?. **2005**, 25-38

371 Critical Care of the Cancer Patient with Pulmonary Infiltrates. **2005**, 579-668

370 Pulmonary Disease. **2006**, 249-274

369 Polmoniti. **2006**, 467-493

368 Community-Acquired Pneumonia. **2006**, 569-579

367 Pneumonia and Bronchitis. **2006**, 215-232

366 Patient Stratification and Decision to Hospitalize Patients with Community-Acquired Pneumonia. **2007**, 50, 868 2

365 Severe Community-Acquired Pneumonia. **2007**, 394-403

364 Current Concepts of Severe Pneumococcal Community-acquired Pneumonia. **2007**, 133-144

363 Chronic Obstructive Pulmonary Disease and Lower Respiratory Infections. **2007**, 546-559

362 Community-Acquired Respiratory Complications in the Intensive Care Unit: Pneumonia and Acute Exacerbations of COPD. **2007**, 435-448

361 Current Concepts of Severe Pneumococcal Community-acquired Pneumonia. **2007**, 33, 133-144 7

360 Efficacy of short course asythromycin in non-severe community-acquired pneumonia. **2007**, 93-98

359 Within the inflamed lung. Signs, symptoms & treatment of pneumonia in adults & children. **2007**, 32, 64-75; quiz 76

358 [Economic aspects of hospitaly treated pneumococcal pneumonia and the results of Pneumo 23 vaccine use in Serbia]. **2008**, 136, 625-8

357 Factors Associated with the Hospitalization of Low-risk Patients with Community-acquired Pneumonia in a Cluster-Randomized Trial. **2008**, 2008, 229-230

356 Bacterial Pneumonia. **2008**, 290-321

o

355 Pneumonie. **2008**, 215-226

354 Unterer Respirationstrakt. **2008**, 313-358

353 Type 2 Diabetes and Concomitant Illness. **2008**, 203-233

352 Management of Infectious Diseases. 63-71

351 Optimal Antibiotic Use in Severe Community-Acquired Pneumonia. **2008**, 85-95

350 When a Patient's Health Care Agent Does Not Fulfill Her Obligations. **2008**, 31-37

349 Community-Acquired PneumoniaâBack to Basics. **2008**, 175-191

348 Infectious Diseases. **2008**, 469-499

347 Evaluation of therapeutic similarity of generic levofloxacin in lower respiratory tract infections. **2008**, 93-100

346 Pneumonia and Empyema. **2009**, 1-10

345 Etiology of fatal community-acquired pneumonia in adults. **2008**, 53-58

344 An Overwhelming Postsplenectomy Infection Syndrome Associated with Diabetes Mellitus. **2009**, 59, 275-280

1

343 Multiple Organ Failure Followed by Intrauterine Klebsiella Pneumoniae Infection Associated with Diabetes Mellitus. **2009**, 59, 151-155

o

342 Ventilator-Associated Pneumonia PIRO Score. **2009**, 39-49

341 A PIRO-Based Approach for Severity Assessment in Community-Acquired Pneumonia. **2009**, 51-63

340 Severe Health-care Associated Pneumonia among the Solid Cancer Patients on Chemotherapy. **2009**, 24, 140

339 Literatur. **2009**, 133-143

338 NHG-Standaard Influenzapandemie. **2009**, 1333-1352

337 Community-Acquired Pneumonia. **2009**, 101-109

336 [Severe form of Legionnaires' disease in an immunocompetent patient]. **2009**, 66, 1010-4

1

335 Case Studies: Infectious Diseases. **2009**, cs16-cs19

334  **2009**, 33-41

333 Pneumonia. **2010**, 169-182

332 Pleural Disease. **2010**, 939-946

1

331 Infectious Lung Diseases. **2010**, 173-193

0

330 Outpatient Parenteral Antimicrobial Therapy. **2010**, 699-703

329 Community Acquired Pneumonia. **2010**, 31, 503

2

328 Use of antibiotics in common respiratory infections. **2010**, 344-346

327 Community-acquired pneumonia. **2010**, 284-293

326 Nonobstructive Lung Disease and Thoracic Tumors. **2010**, 376-384

325 Community-Acquired Pneumonia. **2010**, 689-697.e1

324 Pneumonia. **2010**, 927-938

- 323 16 Longziekten. **2010**, 529-621 1
- 322 Usefulness of Serum Cortisol in Assessment for the Severity of Community-Acquired Pneumonia. **2010**, 69, 450
- 321 Bacterial Infections of the Lower Respiratory Tract.
- 320 Diagnóstico y terapia inicial de la neumonía adquirida en la comunidad (NAC). **2010**, 10,
- 319 Completing an ironman triathlon with pneumonia: a case report. **2010**, 1, 223-7 1
- 318 Community-Acquired Pneumonia. **2011**, 450-463
- 317 Pneumonien. **2011**, 233-248
- 316 Pneumonie. **2011**, 275-288
- 315 Antibiotics: The Miracle Menaced. **2011**, 271-282
- 314 Healthcare-Associated Pneumonia. **2011**, 70, 105 1
- 313 Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures?. **2011**, 2, 272-8 3
- 312 A Study on analysis of severity-adjustment length of stay in hospital for community-acquired pneumonia. **2011**, 12, 1234-1243 3
- 311 Lung Disease in Older Patients with HIV. **2012**, 227-252
- 310 Chest Pain. 1-17
- 309 The Respiratory System. **2012**, 321-394
- 308 Validation of a Novel Risk Score for Severity of Illness in Acute Exacerbations of COPD. **2012**, 2012, 256-258
- 307 Systemic Corticosteroid Treatment in Severe Community-Acquired Pneumonia Requiring Mechanical Ventilation: Impact on Outcomes and Complications. **2012**, 72, 149
- 306 Observation Unit Admission Inclusion and Exclusion Criteria. **2012**, 165-171

- 305 Emergency Department Pneumonia Patients Who do not Meet the Six-Hour Criteria for Antibiotic Administration: Do They Have a Different Clinical Presentation?. **2012**, 4, 338-45 2
- 304 Community-Acquired Pneumonia, Bacterial. **2012**, 127-136
- 303 La pneumonie du patient âgé. **2012**, 17, 34-37
- 302 High-Dose Levofloxacin in Community-Acquired Pneumonia. **2012**, 32, 569-576
- 301 Pneumonia. 248-254
- 300 Validation of a Risk-Based Biomarker-Enhanced Scoring System for Lower Respiratory Tract Infections (OPTIMA I Basel)âAn Observational Survey. **2013**, 04, 69-77
- 299 CHANGING BACTERIAL ORGANISMS AND ANTIMICROBIAL RESISTANCE PATTERN AMONG HOSPITALIZED COMMUNITY ACQUIRED PNEUMONIA PATIENTS IN A TERTIARY CARE CENTER. **2013**, 2, 2123-2130
- 298 RAPID DIAGNOSIS OF PNEUMOCOCCAL MENINGITIS AND PNEUMONIA WITH SYNPNEMONIC EFFUSION USING A NOVEL STREPTOCOCCUS PNEUMONIAE IMMUNOCHROMATOGRAPHIC ASSAY. **2013**, 2, 3011-3017
- 297 Regressing in Rehab. 231-238
- 296 Pneumonie. **2014**, 277-292
- 295 Calidad de la atención médica en neumonía bacteriana adquirida en la comunidad. **2014**, 73, 106-113
- 294 Corticosteroids as Adjunctive Treatment in Community-Acquired Pneumonia. **2014**, 53-63
- 293 CAP phenotypes. **2014**, 105-116
- 292 Early recognition and treatment of severe sepsis and septic shock in CAP. **2014**, 184-204 0
- 291 Severe Pneumonia in the Elderly. **1999**, 141-151
- 290 Polymerase Chain Reaction in the Diagnosis of Respiratory Tract Infections. **1999**, 163-180
- 289 Pneumococcal Pneumonia in Adults: Epidemiology, Clinical Features, Diagnosis, and Therapy. 117-138 1
- 288 TREATMENT OUTCOME PROFILE OF NON RESOLVING PNEUMONIA AMONG HOSPITALIZED COMMUNITY ACQUIRED PNEUMONIA PATIENTS IN TERTIARY CARE CENTRE: AN OBSERVATIONAL STUDY. **2014**, 3, 8608-8613

- 287 CHANGES IN EPIDEMIOLOGY, CLINICAL FEATURES AND SEVERITY OF INFLUENZA A (H1N1) 2009 PNEUMONIA IN THE POST - PANDEMIC INFLUENZA SEASON (JAN 2011 TO JAN 2014). **2014**, 1, 1106-1114
- 286 Role of serum proadrenomedullin in assessment of the severity and outcome of hospitalized healthcare-associated pneumonia patients. **2014**, 8, 108-114
- 285 Afwijkingen van het respiratoire systeem. **2015**, 105-152
- 284 Introduction to pneumonia. **2015**, 1-5
- 283 Management of pneumonia. **2015**, 75-98
- 282 Role of Semi-quantitative Serum Procalcitonin in Assessing Prognosis of Community Acquired Bacterial Pneumonia Compared to PORT PSI, CURB-65 and CRB-65. **2015**, 9, OC01-4 4
- 281 Diagnosis and classification of Pneumonia. **2015**, 39-56
- 280 Afwijkingen van het respiratoire systeem. **2015**, 55-75
- 279 Afwijkingen van het respiratoire systeem. **2015**, 67-103
- 278 Unique Antibacterial Agents. **2015**, 440-446.e2 1
- 277 VALIDIFICATION OF SMART - COP IN PREDICTING THE NEED FOR IRVS IN COMMUNITY ACQUIRED PNEUMONIA (CAP) PATIENTS. **2015**, 4, 16602-16604
- 276 The Use of Guidelines for Lower Respiratory Tract Infections in Tanzania: A Lesson from Kilimanjaro Clinicians. **2016**, 6, 100-8
- 275 [Pneumonia at a multidisciplinary hospital]. **2016**, 88, 13-17
- 274 [Prognostic value of acute kidney injury in patients with community-acquired pneumonia]. **2016**, 88, 9-13
- 273 COMMUNITY ACQUIRED PNEUMONIA IN TYPE 2 DIABETES MELLITUS: A STUDY OF CLINICAL AND BACTERIOLOGICAL PROFILE. **2016**, 3, 656-661
- 272 Fatty acid binding proteins as biomarkers of disease severity and response to treatment in severe pneumonia required admission to intensive care unit. **2016**, 4, 415
- 271 SEVERITY ASSESSMENT OF COMMUNITY9ACQUIRED PNEUMONIA IN REAL CLINICAL PRACTICE IN A MULTI9PROFILE HOSPITAL IN RUSSIA. **2016**, 26, 521-528 3
- 270 Dyspnea. **2017**, 133-144

- 269 Longziekten. **2017**, 551-628 0
- 268 Pneumonia in Geriatric Patients. **2017**, 1-11
- 267 Certification Review for the Ortho PA. **2017**, 5, e13
- 266 Pneumonia in GP practice and treatment. **2017**, 14, 123-126
- 265 Evaluation of PSI and CURB-65 scoring systems which patients were diagnosed as community-acquired pneumonia in emergency department. **2017**, 39, 586-596
- 264 Anhang. **2018**, 161-168
- 263 Information significance of the qSOFA scale for current clinical medicine. Literature review. **2018**, 30-37 1
- 262 Diez respuestas puntuales sobre neumonía adquirida en la comunidad en adultos. **2018**, 23, 62-82
- 261 Clinical decision rules in emergency care. **2018**, 59, 169
- 260 Characteristics and Clinical outcomes of Elders with Aspiration Pneumonia. **2018**, 20, 45-55 1
- 259 Integrating Host Response and Unbiased Microbe Detection for Lower Respiratory Tract Infection Diagnosis in Critically Ill Adults.
- 258 Encyclopedia of Gerontology and Population Aging. **2019**, 1-7
- 257 The impact of adjuvant atorvastatin therapy on community-acquired pneumonia outcome: a prospective study of clinical and inflammatory responses in relation to mortality reduction. **2019**, 13, 249-257
- 256 Model for end-stage liver disease and pneumonia: An improved scoring model for critically ill cirrhotic patients with pneumonia. **2019**, 30, 532-540 1
- 255 Management of Community acquired pneumonia in the Emergency Room. **2019**, 1, 3-15 1
- 254 Diagnostic et Prise en Charge de l'Acidose Métabolique Recommandations formalisées d'experts communes Société de réanimation de langue française (SRLF) à la Société française de médecine d'urgence (SFMU). **2019**, 9, 387-408 1
- 253 [Low-risk community-acquired pneumonia: implications of its outcome due to the determining factors for admission not contemplated by the scores]. **2019**, 45, 516-522 0
- 252 Analysis of Risk Factors for Mortality of Parapneumonic Pleural Effusion in Intensive Care Unit. **2020**, 10, 953-961 1

- 251 [Bilateral bronchopneumonia simulating cardiac decompensation easily detected with multi-window ultrasound]. **2020**, 55, 183-185 1
- 250 Is the neutrophil/lymphocyte rate as effective as CURB-65 in the patient management of the community-acquired pneumonia patients admitted to the Emergency Medicine?.
- 249 Derivation and Validation of Clinical Prediction Rule for COVID-19 Mortality in Ontario, Canada. 1
- 248 Healthcare-associated pneumonia: a prospective study in Spain. **2020**, 33, 358-368 0
- 247 Decision models to improve healthcare-associated C. difficile PCR test use in patients with community-acquired pneumonia.
- 246 Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.
- 245 Comparison of Different Scoring Systems for Prediction of Mortality and ICU Admission in Elderly CAP Population. **2021**, 16, 1917-1929 1
- 244 COLI-Net: Deep learning-assisted fully automated COVID-19 lung and infection pneumonia lesion detection and segmentation from chest computed tomography images.. **2021**, 1
- 243 [Community-acquired pneumonia: selection of empirical treatment and sequential therapy. SARS-CoV-2 implications]. **2021**, 34, 599-609 2
- 242 Predictors of in-hospital outcomes in patients with Cirrhosis and Coronavirus disease-2019. **2021**, 0
- 241 Impact of Protein Energy Malnutrition on Outcomes of Adults With Viral Pneumonia: A Nationwide Retrospective Analysis. **2020**, 12, e12274 1
- 240 Racial Disparities in Outcomes of Adults Hospitalized for Viral Pneumonia. **2020**, 12, e11909
- 239 Short-term exposure to fine particulate matter and pneumonia-related hospitalizations: a systematic review and meta-analysis. **2020**, 15, 123012 1
- 238 Cascaded deep transfer learning on thoracic CT in COVID-19 patients treated with steroids. **2021**, 8, 014501 1
- 237 Diagnóstico y tratamiento temprano de neumonía ante la pandemia por COVID-19 en San Luis Potosí ¿Es posible implementar una estrategia para lograrlo?. **2020**, 79, 214-220
- 236 Outcome prediction value of National Early Warning Score in septic patients with community-acquired pneumonia in emergency department: A single-center retrospective cohort study. **2020**, 11, 206-215 2
- 235 Comparison of pneumonia severity scores for patients diagnosed with pneumonia in emergency department. **2020**, 152, 368-377 1
- 234 Severe Community-Acquired Pneumonia. **2020**, 59-86 1

- 233 Mortality Risk Score for Critically Ill Patients with Viral or Unspecified Pneumonia: Assisting Clinicians with COVID-19 ECMO Planning. **2020**, 336-347 o
- 232 Issues in Community-Acquired Pneumonia. **2020**, 59-79 o
- 231 Pneumologische Notfälle. **2020**, 235-252
- 230 Predicting outcomes in patients with community-acquired pneumonia using weighted track & trigger early warning systems: Lessons learnt & insights for future use. **2020**, 152, 332-334
- 229 Impact of Urinary Antigen Testing in Patients With Community-Acquired Pneumonia Admitted Within a Large Academic Health System.. **2022**, 9, ofab522 o
- 228 Correlation Between Serum Levels of 25-Hydroxyvitamin D and Severity of Community-Acquired Pneumonia in Hospitalized Patients Assessed by Pneumonia Severity Index: An Observational Descriptive Study. **2020**, 12, e8947 1
- 227 Diagnosis and treatment of community acquired pneumonia - the German perspective. **2007**, 1-14 1
- 226 Pneumonie. **2006**, 217-226
- 225 Ambulant erworbene Pneumonie: Diagnostik und Therapie. **2005**, 140-144
- 224 Diagnostic and Prognostic Value of Hormokines as Biomarkers in Severe Infections. **2007**, 22-31
- 223 Severe community-acquired pneumonia. 101-116
- 222 Defining severe bronchiectasis. 62-81
- 221 COPD: treatment and prevention of pulmonary exacerbations. 147-166
- 220 Infections in Diabetes Mellitus. **2006**, 377-401
- 219 Pneumonia. **2006**, 235-247
- 218 Schwere ambulant erworbene Pneumonie. 203-210
- 217 Clinical Profile of Community Acquired Pneumonia (CAP) in Patients with Type 2 Diabetes Mellitus â A Hospital Based Study. **2020**, 9, 3181-3185
- 216 An Easy-to-Use Machine Learning Model to Predict the Prognosis of Patients With COVID-19: Retrospective Cohort Study (Preprint).

215	Classification of Pneumonia Complicated with Influenza Viral Infection: What Are the Patterns of Pneumonia?. 2021 , 107-114	
214	The impact of vital signs on the death of patients with new coronavirus pneumonia: A systematic review and meta-analysis.	1
213	The microbes strike back. 1997 , 157, 1703-4	2
212	Treatment and outcomes of community-acquired pneumonia at Canadian hospitals. 2000 , 162, 1415-20	16
211	Antibiotic prescribing and admissions with major suppurative complications of respiratory tract infections: a data linkage study. 2002 , 52, 187-90, 193	48
210	BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. 2001 , 56 Suppl 4, IV1-64	136
209	Antibiotic prescribing for acute cough: the effect of perceived patient demand. 2006 , 56, 183-90	105
208	Just the berries. Management of community-acquired pneumonia. Evidence-based update. 2002 , 48, 1773-5	
207	Diagnosing community-acquired pneumonia with a Bayesian network. 1998 , 632-6	20
206	The impact of modeling the dependencies among patient findings on classification accuracy and calibration. 1998 , 592-6	1
205	An integrated decision support system for diagnosing and managing patients with community-acquired pneumonia. 1999 , 197-201	10
204	Automating a severity score guideline for community-acquired pneumonia employing medical language processing of discharge summaries. 1999 , 256-60	26
203	Combining decision support methodologies to diagnose pneumonia. 2001 , 12-6	16
202	Automatic identification of patients eligible for a pneumonia guideline. 2000 , 12-6	6
201	Using medical language processing to support real-time evaluation of pneumonia guidelines. 2000 , 235-9	11
200	Email recruitment to use web decision support tools for pneumonia. 2002 , 255-9	2
199	Can we predict which patients with community-acquired pneumonia we can keep out of hospital?. 1997 , 43, 1230-2	
198	Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin. 2007 , 3, 441-8	3

- 197 It's time to step up the management of community-acquired pneumonia. **2002**, 94, 178-81
- 196 Evidence-based anomaly detection in clinical domains. **2007**, 319-23 17
- 195 How usability of a web-based clinical decision support system has the potential to contribute to adverse medical events. **2008**, 257-61 13
- 194 Clinical applications of azithromycin microspheres in respiratory tract infections. **2007**, 2, 551-9 13
- 193 A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP). **2007**, 2, 179-87 9
- 192 Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. **2008**, 47 Suppl 3, S249-65 18
- 191 Distance Metric Learning for Conditional Anomaly Detection. **2008**, 21, 684-689 3
- 190 Community-acquired pneumonia. **2008**, 2008, 1
- 189 Community-acquired pneumonia. **2010**, 2010, 4
- 188 Overview of lower respiratory tract infections: diagnosis and treatment. **2002**, 4, 227-33 1
- 187 Full blood count pattern of pre-chemotherapy breast cancer patients in Lagos, Nigeria. **2013**, 4, 574-9 7
- 186 Conditional anomaly detection methods for patient-management alert systems. **2008**, 2008, 6
- 185 Can Procalcitonin Add to the Prognostic Power of the Severity Scoring System in Adults with Pneumonia?. **2015**, 14, 95-106 2
- 184 Community-acquired pneumonia: pneumococcal vaccine. **2015**, 2015, 1
- 183 Learning a Severity Score for Sepsis: A Novel Approach based on Clinical Comparisons. **2015**, 2015, 1890-8
- 182 [Recommendations for the care of patients with community-acquired pneumonia in the Emergency Department]. **2018**, 31, 186-202 3
- 181 Rebounds after discharge from the emergency department for community-acquired pneumonia: focus on the usefulness of severity scoring systems. **2018**, 88, 519-528 1
- 180 Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models. **2019**, 12, 168-176 2

179	PIRO, SOFA and MEDS Scores in Predicting One-Month Mortality of Sepsis Patients; a Diagnostic Accuracy Study. 2019 , 7, e59	3
178	Challenges in the virtual assessment of COVID-19 infections in the community. 2021 , 67, e6-e8	3
177	Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units. 2021 , 11, e048187	0
176	Lactate dehydrogenase to albumin ratio as a prognostic factor in lower respiratory tract infection patients. 2021 , 52, 54-58	1
175	Important scoring systems for assessing the severity of COVID-19 based on COVID-19-related deaths in Wuhan, China. 2021 , 1, 29-36	
174	A literature review of severity scores for adults with influenza or community-acquired pneumonia - implications for influenza vaccines and therapeutics. 2021 , 1-15	1
173	Role of Chest Computed Tomography in Patients Hospitalized with Community-Acquired Complicated Parapneumonic Effusion or Empyema: Role of CT in Parapneumonic Effusion. 2021 ,	0
172	How Do Geriatric Scores Predict 1-Year Mortality in Elderly Patients with Suspected Pneumonia?. 2021 , 6,	
171	Neutrophil count, lymphocyte count and neutrophil-to-lymphocyte ratio in relation to response to adjunctive dexamethasone treatment in community-acquired pneumonia. 2021 ,	1
170	Intensive care unit staff preparedness as an independent factor for death of patients during COVID-19 pandemic: An observational cohort study. 2021 , 25, 101653	0
169	Prognostic utility of CURB-65 and E-CURB-65 scoring systems in healthcare associated pneumonia patients: Short- and long-term mortality. 2021 , 24, 1706-1711	
168	Mitoquinol mesylate ameliorates hematological aberration in cirrhotic-hepatocellular carcinogenic rats. 2021 , 9, 144	
167	Cost impact analysis of novel host-response diagnostic for patients with community-acquired pneumonia in the emergency department.. 2022 , 1-46	1
166	Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia.. 2021 , 191, 106714	1
165	Pneumonia. 2021 , 3840-3846	
164	Factors associated with survival in patients with COVID -19 admitted to a community hospital in New York City. 2021 , 8, 27-33	
163	High Fibrinogen to Albumin Ratio: A Novel Marker for Risk of Stroke-Associated Pneumonia?. 2021 , 12, 747118	1
162	Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study.. 2022 , 17, e0262342	2

161	A prediction rule for severe adverse events in all inpatients with community-acquired pneumonia: a multicenter observational study.. 2022 , 22, 34	0
160	Hepcidin predicts 5-year mortality after community-acquired pneumonia.. 2022 , 1-7	1
159	Influence of overweight and obesity on the mortality of hospitalized patients with community-acquired pneumonia.. 2022 , 10, 104-116	0
158	Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia.. 2022 , 1	0
157	Development and Validation of Nomogram for Hospital Mortality in Immunocompromised Patients with Severe Pneumonia in Intensive Care Units: A Single-Center, Retrospective Cohort Study.. 2022 , 15, 451-463	0
156	Association of hyperferritinemia with distinct host response aberrations in patients with community-acquired pneumonia.. 2022 ,	0
155	Elevated BMI and NT-proBNP: a potential safety predictor for community acquired pneumonia discharge from the emergency department.. 2022 ,	
154	The Impact of Principal Diagnosis on Readmission Risk among Patients Hospitalized for Community-Acquired Pneumonia.. 2022 ,	
153	Prevalence, Characteristics, and Outcomes of Emergency Department Discharge Among Patients With Sepsis.. 2022 , 5, e2147882	3
152	Inflammatory biomarkers are not useful for predicting prognosis in nursing and healthcare-associated pneumonia: A prospective, cohort study.. 2022 ,	
151	Prognosis of COVID-19 pneumonia can be early predicted combining Age-adjusted Charlson Comorbidity Index, CRB score and baseline oxygen saturation.. 2022 , 12, 2367	1
150	The Japanese Respiratory Society guidelines may reduce unnecessary chest computed tomography in patients with pneumonia requiring hospitalization: A retrospective study.. 2021 , 60, 264-264	
149	Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia and type 2 diabetes mellitus. 2021 , 25, 419	3
148	Severe community-acquired pneumonia in adults. Clinical recommendations from Russian Federation of Anaesthesiologists and Reanimatologists. 2022 , 6	0
147	Contribution of clinical severity and geriatric risk factors in predicting short-term mortality of older hospitalized pneumonia patients: the Pneumonia in Italian Acute Care for Elderly units (PIACE) study.. 2022 , 1	0
146	The Expansion of Myeloid-Derived Suppressor Cells Correlates With the Severity of Pneumonia in Kidney Transplant Patients.. 2022 , 9, 795392	
145	Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial.. 2022 , 15, 605-617	
144	Infecciones por neumococo. 2022 , 13, 2919-2926	

- 143 The Association of Anemia with the Clinical Outcomes of Community-Acquired Pneumonia in Children.. **2022**,
- 142 Trends in Illness Severity, Hospitalization, and Mortality for Community-Onset Pneumonia at 118 US Veterans Affairs Medical Centers.. **2022**, 1
- 141 New-Onset Dementia Among Survivors of Pneumonia Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.. **2022**, 9, ofac115 1
- 140 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type .. **2022**, 10, 1
- 139 Diagnostic index for acute eosinophilic pneumonia without bronchoscopy in military smokers.. **2021**,
- 138 Sphingosine-1-phosphate and CRP as potential combination biomarkers in discrimination of COPD with community-acquired pneumonia and acute exacerbation of COPD.. **2022**, 23, 63 1
- 137 Title: Effects of Antibiotics on Respiratory Symptoms in Terminally Ill Cancer Patients With Pneumonia: A Multicenter Cohort Study.. **2022**, 10499091211058156 0
- 136 Circulating Thrombomodulin (TM): Release Mechanisms, Measurements and Levels in Diseases and Medical Procedures. 1
- 135 Obesity Impacts Hospitalizations for Bacterial Pneumonia. **2022**, 30, 1-5 0
- 134 Sex-Dependent Performance of the Neutrophil-to-Lymphocyte, Monocyte-to-Lymphocyte, Platelet-to-Lymphocyte and Mean Platelet Volume-to-Platelet Ratios in Discriminating COVID-19 Severity.. **2022**, 9, 822556 0
- 133 Application of self-assessment triage tool in COVID-19 pandemic: descriptive study.. **2022**,
- 132 Development and Validation of a Two-Step Predictive Risk Stratification Model for Coronavirus Disease 2019 In-hospital Mortality: A Multicenter Retrospective Cohort Study.. **2022**, 9, 827261 0
- 131 WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales.. **2022**, 1 1
- 130 Presepsin as a Novel Biomarker in predicting Inhospital Mortality in COVID-19 Pneumonia Patients.. **2022**, 2
- 129 Prognosis of patients hospitalized with a diagnosis of COVID-19 pneumonia in a tertiary hospital in Turkey. **2021**, 41, 327-335 0
- 128 How Would You Treat This Patient Hospitalized With Community-Acquired Pneumonia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.. **2021**, 174, 1719-1726
- 127 The pneumonia severity index: assessment and comparison to popular machine learning classifiers.
- 126 Association between neutrophil to lymphocyte ratio and mortality among community acquired pneumonia patients: a meta-analysis.. **2021**, 0

125	Significance of the Modified NUTRIC Score for Predicting Clinical Outcomes in Patients with Severe Community-Acquired Pneumonia.. 2021 , 14,	3
124	Clinical features of patients with Legionnaires disease showing initial clinical improvement but radiological deterioration: A retrospective single-center analysis.. 2021 , 100, e28402	
123	Role of Clinical Characteristics and Biomarkers at Admission to Predict One-Year Mortality in Elderly Patients with Pneumonia.. 2021 , 11,	0
122	Guà de pràctica clínic para el manejo de la neumonà adquirida en la comunidad. 2021 , 70, e93814	
121	Predicting acute respiratory distress syndrome in influenza pneumonia patients using delta mean platelet volume. 2021 , 21, 405	0
120	Development and validation of a new scoring system for prognostic prediction of community-acquired pneumonia in older adults.. 2021 , 11, 23878	0
119	Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study.. 2021 , 25, 432	0
118	A safe protocol to identify low risk patients with COVID-19 pneumonia for outpatient management.	1
117	Age- and sex-related differences in community-acquired pneumonia at presentation to the emergency department: a retrospective cohort study. 8 , Publish Ahead of Print,	
116	Characteristics and Economic Burden of Hospitalized Elderly Patients (> 65 Years) Due to Community-Acquired Pneumonia.	
115	Comparison between the Severity Scoring Systems A-DROP and CURB-65 for Predicting Safe Discharge from the Emergency Department in Patients with Community-Acquired Pneumonia.. 2022 , 2022, 6391141	
114	Data_Sheet_1.docx. 2018 ,	
113	Image_1.TIF. 2018 ,	
112	Data_Sheet_1.docx. 2020 ,	
111	Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units. 2021 , 11, e048187	2
110	Challenges in the virtual assessment of COVID-19 infections in the community. 2021 , 67, e6-e8	3
109	Nutritional and Functional Impact of Acute SARS-CoV-2 Infection in Hospitalized Patients.. 2022 , 11,	1
108	The pneumonia severity index: Assessment and comparison to popular machine learning classifiers.. 2022 , 163, 104778	0

107	Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia.	0
106	Comparison of Pneumonia Severity Indices, qCSI, 4C-Mortality Score and qSOFA in Predicting Mortality in Hospitalized Patients with COVID-19 Pneumonia. 2022 , 12, 801	1
105	Desempeño de PSI/PORT y SOFA para predicción de ventilación mecánica invasiva en neumonía por SARS-CoV-2. 2022 , 36, 155-160	
104	Mallampati Score Is an Independent Predictor of Active Oxygen Therapy in Patients with COVID-19. 2022 , 11, 2958	
103	Lung Ultrasound Improves Outcome Prediction over Clinical Judgment in COVID-19 Patients Evaluated in the Emergency Department. 2022 , 11, 3032	0
102	The mortality risk factor of severe community-acquired pneumonia (SCAP) patients with Sepsis: a retrospective study.	
101	Remote investigation and assessment of vital signs (RIA-VS) – proof of concept for contactless estimation of blood pressure, pulse, respiratory rate, and oxygen saturation in patients with suspicion of COVID-19. 1-10	
100	Age, Pulse, Urea, and Albumin Score: A Tool for Predicting the Short-Term and Long-Term Outcomes of Community-Acquired Pneumonia Patients With Diabetes. 2022 , 13,	
99	Validity of Pneumonia Severity Index and CURB-65 Severity Scoring Systems in Community Acquired Pneumonia in an Indian Setting. 2022 , 52, 9-17	23
98	Comparison of the prognostic performance of the CURB-65 and a modified version of the pneumonia severity index designed to identify high-risk patients using the International Community-Acquired Pneumonia Collaboration Cohort. 2022 , 106884	
97	Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 – April 2019.	0
96	Effect of diagnosis level of certainty on adherence to antibiotics guidelines in ED patients with pneumonia: a post-hoc analysis of an interventional trial. Publish Ahead of Print,	
95	Federal guidelines on diagnosis and treatment of community-acquired pneumonia. 2022 , 32, 295-355	1
94	New Cardiovascular Events in the Convalescent Period Among Survivors of SARS-CoV-2 Infection. 174749302211145	
93	Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Compliant). 2022 , 11, 4140	0
92	The severity of nutrition and pneumonia predicts survival in patients with aspiration pneumonia: A retrospective observational study.	1
91	Machine-Learning Model for Mortality Prediction in Patients with Community-acquired Pneumonia: Development and validation study. 2022 ,	0
90	Sex and 'gender' differences in community-acquired pneumonia.	0

89 Pulmonary Issues. **2022**, 270-285

88 Rectal microbiota are coupled with altered cytokine production capacity following community-acquired pneumonia hospitalization. **2022**, 104740

o

87 Report on the Thirteenth Aberdeen Spring Symposium on Respiratory Medicine: Where are we now and Where Will we be in Ten YearsâTime?. **2000**, 30, 1-15

86 The Use of the SMART-COP Score in Predicting Severity Outcomes Among Patients With Community-Acquired Pneumonia: A Meta-Analysis. **2022**,

85 Methicillin resistant Staphylococcus aureus necrotizing pneumonia and ceftaroline fosamil: An alternative regimen. **2017**, 6, 1-6

84 IL-7/IL7R axis dysfunction in adults with severe community-acquired pneumonia (CAP): a cross-sectional study. **2022**, 12,

83 Decreased Levels of SARS-CoV-2 Fusion-Inhibitory Antibodies in the Serum of Aged COVID-19 Patients. **2022**, 12, 1813

82 Decreased plasma fetuin-A level as a novel bioindicator of poor prognosis in community-acquired pneumonia: A multi-center cohort study. 9,

81 Comparison of 6 Mortality Risk Scores for Prediction of 1-Year Mortality Risk in Older Adults With Multimorbidity. **2022**, 5, e2223911

o

80 Red Blood Cell Distribution Width and Pediatric Community-Acquired Pneumonia Disease Severity.

o

79 Evaluating the ability of the NLHA2 and artificial neural network models to predict COVID-19 severity, and comparing them with the four existing scoring systems. **2022**, 105735

78 Association of Serum Albumin and Copeptin with Early Clinical Deterioration and Instability in Community-Acquired Pneumonia. **2022**, 90, 323-337

77 Effects of lymphocyte and neutrophil counts and their time courses on mortality in patients with postoperative pneumonia. **2022**, 12,

76 Predictive value of arterial blood lactate to serum albumin ratio for in-hospital mortality of patients with community-acquired pneumonia admitted to the Intensive Care Unit. 1-10

75 Point-of-care application of diaphragmatic ultrasonography in the emergency department for the prediction of development of respiratory failure in community-acquired pneumonia: A pilot study. 9,

74 Clinical features and prognostic predictors in patients with rheumatic diseases complicated by Pneumocystis pneumonia. **2022**, 122, 1018-1025

73 A Paradigm Shift in the Diagnosis of Aspiration Pneumonia in Older Adults. **2022**, 11, 5214

1

72 Analysis of changes in location before hospital admission, discharge destination and prognostic factors for the survival in hospitals with chronic-phase inpatients. **2022**, 59, 347-359

o

71	Pneumonia and Related Conditions in Critically Ill Patientsâ€”Insights from Basic and Experimental Studies. 2022 , 23, 9896	0
70	Extended-Spectrum Antibiotics for Community-Acquired Pneumonia with a Low Risk of Drug-Resistant Pathogens. 2022 ,	0
69	N-myc and STAT interactor is a novel biomarker of severity in community-acquired pneumonia: a prospective study. 2022 , 23,	0
68	Validity of the ROX index in predicting invasive mechanical ventilation requirement in pneumonia. 2022 , 9, e001320	0
67	Machine learning-derived prediction of in-hospital mortality in patients with severe acute respiratory infection: analysis of claims data from the German-wide Helios hospital network. 2022 , 23,	0
66	Utility of Differential White Cell Count and Cell Population Data for Ruling Out COVID-19 Infection in Patients With Community-Acquired Pneumonia. 2022 ,	1
65	An algorithm to predict the need for invasive mechanical ventilation in hospitalized COVID-19 patients: the experience in Sao Paulo.	0
64	Is rehabilitation effective in preventing decreased functional status after community-acquired pneumonia in elderly patients? Results from a multicentre, retrospective observational study. 2022 , 12, e051307	0
63	Protein C activity as a potential prognostic factor for nursing home-acquired pneumonia. 2022 , 17, e0274685	0
62	How and when to manage respiratory infections out of hospital. 2022 , 31, 220092	0
61	Prevalence, Incidence, and Severity Associated with Viral Respiratory Tract Infections in Colombian adults before the COVID-19 Pandemic. 2022 ,	0
60	Administration of recombinant human thrombopoietin is associated with alleviated thrombocytopenia in adult intensive care unit patients with pneumonia: A single-center retrospective study. 13,	1
59	Community-acquired pneumonia â€”An EFIM guideline critical appraisal adaptation for internists. 2022 ,	0
58	Neumonâ adquirida en la comunidad. 2022 , 13, 3876-3884	0
57	Predicting Positive Blood Cultures in Patients presenting with Pneumonia at an Emergency Department in Singapore. 2009 , 38, 508-514	2
56	Aetiology, Clinical Presentation and Outcome in Patients with Community-Acquired Pneumonia Requiring Hospitalisation: A Prospective Study. 2022 , 62, 117-125	0
55	Sospecha de infecciâ bronquial y pulmonar aguda en el paciente inmunocompetente (exceptuando la COVID-19). 2022 ,	0
54	Characteristics and local risk factors of community-acquired and health-care-associated Staphylococcus aureus pneumonia. 2022 , 12,	0

53	Using a data entry tool results in higher fidelity to a COVID-19 hospitalization risk tier assessment algorithm than provider insight alone (Preprint).	o
52	Development and validation of tools for predicting the risk of death and ICU admission of non-HIV-infected patients with <i>Pneumocystis jirovecii</i> pneumonia. 10,	o
51	Inter-expert agreement on indications for antibiotic therapy in older adults admitted to French hospital through an emergency department. 2022 , 8, e11630	o
50	Association Between Empirical Anti-Pseudomonal Antibiotics for Recurrent Lower Respiratory Tract Infections and Mortality: A Retrospective Cohort Study. Volume 17, 2919-2929	o
49	Meropenem for children with severe pneumonia: Protocol for a randomized controlled trial. 13,	o
48	Prepandemic viral community-acquired pneumonia: diagnostic sensitivity and specificity of nasopharyngeal swabs and performance of clinical severity scores..	o
47	Cardiopulmonary and hematological effects of infrared LED photobiomodulation in the treatment of SARS-COV2. 2023 , 238, 112619	o
46	A Comparison of BUN/Albumin Ratio with PSI and CURB-65 for Predicting Mortality in COVID-19 Pneumonia in the Emergency Department. 2022 , 23, 296-300	o
45	Machine learning did not beat logistic regression in time series prediction for severe asthma exacerbations. 2022 , 12,	o
44	Deep Learning Models to Predict Fatal Pneumonia Using Chest X-Ray Images. 2022 , 2022, 1-12	o
43	Aspiration pneumonia is an independent risk factor associated with long-term hospital stay: a prospective cohort study.	o
42	Systemic corticosteroid use and cardiovascular risk in patients hospitalized for pneumonia. 2022 , 109161	o
41	Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia.	1
40	Assessment of the pneumonia severity score in community-acquired and nursing and healthcare-associated pneumonia due to COVID-19. 2022 ,	o
39	Clinical and chest computed tomography features associated with severe <i>Chlamydia psittaci</i> pneumonia diagnosed by metagenomic next-generation sequencing: A multicenter, retrospective, observational study. 2022 , 101, e32117	o
38	Characteristics, Management, and Outcomes of Community-Acquired Pneumonia Due to Human RhinovirusâA Retrospective Study. 2022 , 2022, 1-8	1
37	Machine Learning To Stratify Methicillin-Resistant <i>Staphylococcus aureus</i> Risk among Hospitalized Patients with Community-Acquired Pneumonia.	o
36	Procalcitonin to reduce exposure to antibiotics and individualise treatment in hospitalised old patients with pneumonia: a randomised study. 2022 , 22,	o

- 35 Clinical Features of COVID-19 and Differentiation from Other Causes of CAP. **2023**, 44, 008-020 ○
- 34 Oral versus parenteral antibiotic therapy in adult patients with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. **2023**, ○
- 33 Guideline-Concordant Antibiotic Therapy for the Hospital Treatment of Community-Acquired Pneumonia and 1-Year All-Cause and Cardiovascular Mortality in Elderly Patients Surviving to Discharge. **2023**, ○
- 32 Systemic steroid therapy for pneumonic chronic obstructive pulmonary disease exacerbation: A retrospective cohort study. ○
- 31 Is aggressive care appropriate for patients with cancer complicated by pneumonia? A retrospective chart review in a tertiary hospital. **2023**, 22, ○
- 30 Severity of Illness Scores and Biomarkers for Prognosis of Patients with Coronavirus Disease 2019. **2023**, 44, 075-090 ○
- 29 Impact of severe lymphopenia on the early prediction of clinical outcome in hospitalized patients with pneumococcal community-acquired pneumonia. ○
- 28 Scores and Scores of Predicted Mortality Scores. **2023**, 163, 6-7 ○
- 27 Hydrocortisone in Severe Community-Acquired Pneumonia. ○
- 26 Cough. **2022**, 235-250 ○
- 25 Predictors of in-hospital mortality in adult cancer patients with COVID-19 infection presenting to the emergency department: A retrospective study. **2023**, 18, e0278898 ○
- 24 Radiographically confirmed community-acquired pneumonia in hospitalized adults due to pneumococcal vaccine serotypes in Sweden, 2016-2018. The ECAPS study. 11, ○
- 23 Cost-Impact Analysis of a Novel Diagnostic Test to Assess Community-Acquired Pneumonia Etiology in the Emergency Department Setting: A Multi-Country European Study. **2023**, 20, 3853 ○
- 22 A nomogram for predicting severe adenovirus pneumonia in children. 11, ○
- 21 Predicting Persistent Acute Respiratory Failure in Acute Pancreatitis: The Accuracy of Two Lung Injury Indices. ○
- 20 Characteristics, Management, and Outcomes of Community-Acquired Pneumonia due to Respiratory Syncytial Virus: A Retrospective Study. **2023**, 2023, 1-8 ○
- 19 Early platelet level reduction as a prognostic factor in intensive care unit patients with severe aspiration pneumonia. 14, ○
- 18 Effectiveness of low-intensity pulsed ultrasound for the treatment of viral pneumonia: study protocol for a prospective, randomized controlled trial. ○

- 17 Adherence to use of blood cultures according to current national guidelines and their impact in patients with community acquired pneumonia: A retrospective cohort. **2023**, ○
- 16 An artificial intelligence approach for predicting death or organ failure after hospitalization for COVID-19: development of a novel risk prediction tool and comparisons with ISARIC-4C, CURB-65, qSOFA, and MEWS scoring systems. **2023**, 24, ○
- 15 Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics. **2023**, 67, ○
- 14 Clinical relevance of bronchiectasis in patients with community-acquired pneumonia. **2023**, ○
- 13 Combining a Frailty Index Based on Laboratory Data and Pneumonia Severity Assessments to Predict In-Hospital Outcomes in Older Adults with Community-Acquired Pneumonia. ○
- 12 Lung Infections. **2013**, 414-422.e1 ○
- 11 Pneumonia. **2023**, 340-352 ○
- 10 Association of Different Risk Scores and 30-Day Mortality in Kidney Transplant Recipients with COVID-19. **2023**, 59, 657 ○
- 9 Serum Cystatin C within 24 hours after admission: a potential predictor for acute kidney injury in Chinese patients with community acquired pneumonia. **2023**, 45, ○
- 8 Clinical decision-making using an assessment protocol of swallowing function after aspiration pneumonia: a comparative retrospective study. **2023**, 18, 62-69 ○
- 7 In Patients Hospitalized for Community-Acquired Pneumonia, SARS-CoV-2 Is Associated with Worse Clinical Outcomes When Compared to Influenza. **2023**, 12, 571 ○
- 6 Choice of respiratory therapy for COVID-19 patients with acute hypoxemic respiratory failure: a retrospective case series study. 11, e15174 ○
- 5 Pneumonia in the Emergency Department: controversial aspects in daily clinical practice. **2023**, 12, ○
- 4 Investigation of Etiology of Community-Acquired Pneumonia in Hospitalized Patients in a tertiary hospital of São Paulo City, Brazil. ○
- 3 Extracting relevant predictive variables for COVID-19 severity prognosis: An exhaustive comparison of feature selection techniques. **2023**, 18, e0284150 ○
- 2 Updating cut-off values of severity scoring systems for community-acquired pneumonia to orchestrate more predictive accuracy. **2023**, 55, ○
- 1 Subjective and objective survival prediction in mechanically ventilated critically ill patients: a prospective cohort study. **2023**, 27, ○